<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11549733</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>18</Issue><PubDate><Year>2001</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release.</ArticleTitle><Pagination><StartPage>7226</StartPage><EndPage>7235</EndPage><MedlinePgn>7226-35</MedlinePgn></Pagination><Abstract><AbstractText>Interactions between amyloid beta-protein (Abeta) and lipids have been suggested to play important roles in the pathogenesis of Alzheimer's disease. However, the molecular mechanism underlying these interactions has not been fully understood. We examined the effect of Abeta on lipid metabolism in cultured neurons and astrocytes and found that oligomeric Abeta, but not monomeric or fibrillar Abeta, promoted lipid release from both types of cells in a dose- and time-dependent manner. The main components of lipids released after the addition of Abeta were cholesterol, phospholipids, and monosialoganglioside (GM1). Density-gradient and electron microscopic analyses of the conditioned media demonstrated that these Abeta and lipids formed particles and were recovered from the fractions at densities of approximately 1.08-1.18 g/ml, which were similar to those of high-density lipoprotein (HDL) generated by apolipoproteins. The lipid release mediated by Abeta was abolished by concomitant treatment with Congo red and the PKC inhibitor, H7, whereas it was not inhibited with N-acetyl-l-cysteine. These Abeta-lipid particles were not internalized into neurons, whereas HDL-like particles produced by apolipoprotein E were internalized. Our findings indicate that oligomeric Abeta promotes lipid release from neuronal membrane, which may lead to the disruption of neuronal lipid homeostasis and the loss of neuronal function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michikawa</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dementia Research, National Institute for Longevity Sciences, Obu, Aichi 474-8522, Japan. michi@nils.go.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Q W</ForeName><Initials>QW</Initials></Author><Author ValidYN="Y"><LastName>Sawamura</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Yanagisawa</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010713">Phosphatidylcholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>3U05FHG59S</RegistryNumber><NameOfSubstance UI="D003224">Congo Red</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002499" MajorTopicYN="N">Centrifugation, Density Gradient</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003224" MajorTopicYN="N">Congo Red</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="Y">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010713" MajorTopicYN="N">Phosphatidylcholines</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011233" MajorTopicYN="N">Precipitin Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11549733</ArticleId><ArticleId IdType="pmc">PMC6762992</ArticleId><ArticleId IdType="pii">21/18/7226</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.21-18-07226.2001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Avdulov NA, Chochina SV, Igbavboa U, Warden CS, Vassiliev AV, Wood WG. Lipid binding to amyloid &#x3b2;-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J Neurochem. 1997;69:1746&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pubmed">9326304</ArticleId></ArticleIdList></Reference><Reference><Citation>Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid &#x3b2;-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem. 1996;271:32916&#x2013;32922.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955133</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of A&#x3b2;(1&#x2013;40) peptide to ganglioside-containing membrane vesicles. J Biol Chem. 1997;272:22987&#x2013;22990.</Citation><ArticleIdList><ArticleId IdType="pubmed">9287293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, Suzuki H, Araki W, Inoue H, Shirotani K, Takahashi K, Gallyas F, Tabira T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med. 1999;5:560&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229234</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Epand RM. Lipid polymorphism and protein-lipid interactions. Biochim Biophys Acta. 1998;1376:353&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804988</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri M, Hyman B, Beyreuther K, Masters C. Aging and dementia. In: Graham D, Lantos P, editors. Greenfield's neuropathology. Arnold; London: 1997. pp. 153&#x2013;233.</Citation></Reference><Reference><Citation>Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA, LaDu MJ. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (&#x2212;/&#x2212;), and human apoE transgenic mice. J Biol Chem. 1999;274:30001&#x2013;30007.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514484</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, Younkin SG, Holtzman DM. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol. 2000;48:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">10939571</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan QW, Wei Y, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem. 2001;76:391&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">11208902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. Protofibrillar intermediates of amyloid &#x3b2;-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999;19:8876&#x2013;8884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertel C, Terzi E, Hauser N, Jakob-Rotne R, Seelig J, Kemp JA. Inhibition of the electrostatic interaction between &#x3b2;-amyloid peptide and membranes prevents &#x3b2;-amyloid-induced toxicity. Proc Natl Acad Sci USA. 1997;94:9412&#x2013;9216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23204</ArticleId><ArticleId IdType="pubmed">9256496</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM. Expression of human apolipoprotein E reduces amyloid-&#x3b2; deposition in a mouse model of Alzheimer's disease. J Clin Invest. 1999;103:R15&#x2013;R21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Isobe I, Michikawa M, Yanagisawa K. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid &#x3b2;-protein and chloroquine in cultured rat astrocytes. Neurosci Lett. 1999;266:129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">10353344</ArticleId></ArticleIdList></Reference><Reference><Citation>Isobe I, Yanagisawa K, Michikawa M. A possible model of senile plaques using synthetic amyloid &#x3b2;-protein and rat glial culture. Exp Neurol. 2000;162:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito J, Zhang LY, Asai M, Yokoyama S. Differential generation of high-density lipoprotein by endogenous and exogenous apolipoproteins in cultured fetal rat astrocytes. J Neurochem. 1999;72:2362&#x2013;2369.</Citation><ArticleIdList><ArticleId IdType="pubmed">10349845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Wen GY, Banker C, Chen CMJ, Spienza VJ, Hon H, Wisniewski HM. Detection and quantitation of amyloid &#x3b2;-peptide with 2 monoclonal antibodies. Neurosci Res Commun. 1990;7:113&#x2013;122.</Citation></Reference><Reference><Citation>Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun. 1994;205:1164&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">7802646</ArticleId></ArticleIdList></Reference><Reference><Citation>Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun. 1996;223:592&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">8687441</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70:2070&#x2013;2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572293</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., III Soluble multimeric Alzheimer beta(1&#x2013;40) pre-amyloid complexes in dilute solution. Neurobiol Aging. 1995;16:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532108</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., III Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507030</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yokoyama S. Independent regulation of cholesterol incorporation into free apolipoprotein-mediated cellular lipid efflux in rat vascular smooth muscle cells. J Biol Chem. 1995;270:26216&#x2013;26223.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592827</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Peterson DA, Schubert D. Amyloid &#x3b2; peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci USA. 1998;95:13266&#x2013;13271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23777</ArticleId><ArticleId IdType="pubmed">9789077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA. 1994;91:12243&#x2013;12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45413</ArticleId><ArticleId IdType="pubmed">7991613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark RJ, Blanc EM, Mattson MP. Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol Neurobiol. 1996;12:211&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">8884749</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason RP, Estermyer JD, Kelly JF, Mason PE. Alzheimer's disease amyloid &#x3b2;-peptide 25&#x2013;35 is localized in the membrane hydrocarbon core: x-ray diffraction analysis. Biochem Biophys Res Commun. 1996;222:78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason RP, Jacob RF, Walter MF, Mason PE, Avdulov NA, Chochina SV, Igbavboa U, Wood WG. Distribution and fluidizing action of soluble and aggregated amyloid &#x3b2;-peptide in rat synaptic plasma membranes. J Biol Chem. 1999;274:18801&#x2013;18807.</Citation><ArticleIdList><ArticleId IdType="pubmed">10373497</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol. 1999;45:537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated &#x3b2;-amyloid peptide are attenuated by basic FGF. Brain Res. 1993;621:35&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221072</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Chakrabartty A. Membrane disruption by Alzheimer &#x3b2;-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem. 1996;271:26482&#x2013;26489.</Citation><ArticleIdList><ArticleId IdType="pubmed">8900116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez AJ. Cholesterol efflux mediated by apolipoproteins is an active cellular process distinct from efflux mediated by passive diffusion. J Lipid Res. 1997;38:1807&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pubmed">9323590</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez AJ, Oram JF, Bierman EL. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem. 1991;266:10104&#x2013;10111.</Citation><ArticleIdList><ArticleId IdType="pubmed">1645339</ArticleId></ArticleIdList></Reference><Reference><Citation>Michikawa M, Yanagisawa K. Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J Neurosci Res. 1998;54:58&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778150</ArticleId></ArticleIdList></Reference><Reference><Citation>Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 2000;74:1008&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693931</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller WE, Koch S, Eckert A, Hartmann H, Scheuer K. &#x3b2;-Amyloid peptide decreases membrane fluidity. Brain Res. 1995;674:133&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">7773681</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterman D, Mora R, Kezdy FJ, Kaiser ET, Meredith SC. A synthetic amphiphilic &#x3b2;-strand tridecapeptide: a model for apolipoprotein B. J Am Chem Soc. 1984;106:6845&#x2013;6847.</Citation></Reference><Reference><Citation>Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by &#x3b2;-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993;13:1676&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576726</ArticleId><ArticleId IdType="pubmed">8463843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid &#x3b2;-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med. 1998;4:832&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662376</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270:9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Walsh DM, Amarante P, Ostaszewski BL, Stimson ER, Maggio JE, Teplow DB, Selkoe DJ. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry. 1998;37:3602&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521679</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawamura N, Gong JS, Garver WS, Heidenreich RA, Ninomiya H, Ohno K, Yanagisawa K, Michikawa M. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem. 2001;276:10314&#x2013;10319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152466</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA. 1995;92:1989&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42408</ArticleId><ArticleId IdType="pubmed">7892213</ArticleId></ArticleIdList></Reference><Reference><Citation>Scriver CR, Stanbury JB, Wyngaarden JB, Frederickson DS. Neimann-Pick disease type C: a cellular cholesterol lipidosis. McGraw-Hill; New York: 1995.</Citation></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994;53:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083687</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to &#x3b2;-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble beta 1&#x2013;40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994;145:452&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887395</ArticleId><ArticleId IdType="pubmed">8053502</ArticleId></ArticleIdList></Reference><Reference><Citation>Terzi E, Holzemann G, Seelig J. Self-association of &#x3b2;-amyloid peptide (1&#x2013;40) in solution and binding to lipid membranes. J Mol Biol. 1995;252:633&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">7563079</ArticleId></ArticleIdList></Reference><Reference><Citation>Theret N, Delbart C, Aguie G, Fruchart JC, Vassaux G, Ailhaud G. Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation. Biochem Biophys Res Commun. 1990;173:1361&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">2268337</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid &#x3b2;-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364&#x2013;22372.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, Haass C, Seubert P, Koo EH, Selkoe DJ. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997;272:7977&#x2013;7982.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065468</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid &#x3b2;-protein (A&#x3b2;): a possible form of preamyloid in Alzheimer's disease. Nat Med. 1995;1:1062&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11551913</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>276</Volume><Issue>46</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations.</ArticleTitle><Pagination><StartPage>43446</StartPage><EndPage>43454</EndPage><MedlinePgn>43446-54</MedlinePgn></Pagination><Abstract><AbstractText>Recent studies have shown independently that presenilin-1 (PS1) null mutants and familial Alzheimer's disease (FAD)-linked mutants should both down-regulate signaling of the unfolded protein response (UPR). However, it is difficult to accept that both mutants possess the same effects on the UPR. Furthermore, contrary to these observations, neither loss of PS1 and PS2 function nor expression of FAD-linked PS1 mutants were reported to have a discernable impact on the UPR. Therefore, re-examination and detailed analyses are needed to clarify the relationship between PS1 function and UPR signaling. Here, we report that PS1/PS2 null and dominant negative PS1 mutants, which are mutated at aspartate residue 257 or 385, did not affect signaling of the UPR. In contrast, FAD-linked PS1 mutants were confirmed to disturb UPR signaling by inhibiting activation of both Ire1alpha and ATF6, both of which are endoplasmic reticulum (ER) stress transducers in the UPR. Furthermore, PS1 mutants also disturbed activation of PERK (PKR-like ER kinase), which plays a crucial role in inhibiting translation during ER stress. Taken together, these observations suggested that PS1 mutations could affect signaling pathways controlled by each of the respective ER-stress transducers, possibly through a gain-of-function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katayama</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yoneda</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rozmahel</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>George-Hyslop</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Tohyama</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="Y">Stress, Physiological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="Y">Transduction, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11551913</ArticleId><ArticleId IdType="doi">10.1074/jbc.M104096200</ArticleId><ArticleId IdType="pii">S0021-9258(19)82985-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11553691</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture.</ArticleTitle><Pagination><StartPage>1168</StartPage><EndPage>1178</EndPage><MedlinePgn>1168-78</MedlinePgn></Pagination><Abstract><AbstractText>The gamma-secretase cleavage is the last step in the generation of the beta-amyloid peptide (Abeta) from the amyloid precursor protein (APP). The Abeta precipitates in the amyloid plaques in the brain of Alzheimer's disease patients. The fate of the intracellular APP carboxy-terminal stub generated together with Abeta has been, in contrast, only poorly documented. The analogies between the processing of APP and other transmembrane proteins like SREBP and Notch suggests that this intracellular fragment could have important signalling functions. We demonstrate here that APP-C59 is rapidly degraded (half-life approximately 5 min) when overexpressed in baby hamster kidney cells or primary cultures of neurones by a mechanism that is not inhibited by endosomal/lysosomal or proteasome inhibitors. Furthermore, APP-C59 binds to the DNA binding protein Fe65, although this does not increase the half-life of APP-C59. Finally, we demonstrate that a fraction of APP-C59 becomes redistributed to the nuclear detergent-insoluble pellet, in which the transcription factor SP1 is also present. Overall our results reinforce the analogy between Notch and APP processing, and suggest that the APP intracellular domain, like the Notch intracellular domain, could have a role in signalling events from the plasma membrane to the nucleus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cupers</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuronal Cell Biology Group, Center for Human Genetics, Flanders Interuniversitary Institute for Biotechnology and Catholic University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlans</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Craessaerts</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Annaert</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012672" MajorTopicYN="N">Semliki forest virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016329" MajorTopicYN="N">Sp1 Transcription Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013347" MajorTopicYN="N">Subcellular Fractions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11553691</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00516.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11554609</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0024-3205</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>13</Issue><PubDate><Year>2001</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Life sciences</Title><ISOAbbreviation>Life Sci</ISOAbbreviation></Journal><ArticleTitle>Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain.</ArticleTitle><Pagination><StartPage>1471</StartPage><EndPage>1484</EndPage><MedlinePgn>1471-84</MedlinePgn></Pagination><Abstract><AbstractText>In vivo assessment of the beta-sheet proteins deposited in amyloid plaques (A beta peptide) or neurofibrillary tangles (tau protein) presents a target for the development of biological markers for Alzheimer's disease (AD). In an effort to develop in vivo beta-sheet imaging probes, derivatives of thioflavin-T (ThT) were synthesized and evaluated. These compounds lack the positively charged quaternary heterocyclic nitrogen of ThT and are therefore uncharged at physiological pH. They are 600-fold more lipophilic than ThT. These ThT derivatives bind to A beta(1-40) fibrils with higher affinity (Ki = 20.2 nM) than ThT (Ki = 890 nM). The uncharged ThT derivatives stained both plaques and neurofibrillary tangles in post-mortem AD brain, showing some preference for plaque staining. A carbon-11 labeled compound, [N-methyl-11C]6-Me-BTA-1, was prepared, and its brain entry and clearance were studied in Swiss-Webster mice. This compound entered the brain at levels comparable to commonly used neuroreceptor imaging agents (0.223 %ID-kg/g or 7.61 %ID/g at 2 min post-injection) and showed good clearance of free and non-specifically bound radioactivity in normal rodent brain tissue (brain clearance t(1,2) = 20 min). The combination of relatively high affinity for amyloid, specificity for staining plaques and neurofibrillary tangles in post-mortem AD brain, and good brain entry and clearance makes [N-methyl-11C]6-Me-BTA-1 a promising candidate as an in vivo positron emission tomography (PET) beta-sheet imaging agent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>W E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, PA 15213, USA. Klunkwe@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>G F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Debnath</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Life Sci</MedlineTA><NlmUniqueID>0375521</NlmUniqueID><ISSNLinking>0024-3205</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055598" MajorTopicYN="N">Chemical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002627" MajorTopicYN="N">Chemistry, Physical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006651" MajorTopicYN="N">Histocytochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11554609</ArticleId><ArticleId IdType="doi">10.1016/s0024-3205(01)01232-2</ArticleId><ArticleId IdType="pii">S0024320501012322</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11559310</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>9</Issue><PubDate><Year>2001</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.</ArticleTitle><Pagination><StartPage>1395</StartPage><EndPage>1402</EndPage><MedlinePgn>1395-402</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether nondemented subjects with pathological evidence of preclinical Alzheimer disease (AD) demonstrate neuronal loss in the entorhinal cortex and hippocampus, and whether the onset of cognitive deficits in AD coincides with the onset of neuronal degeneration.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Preclinical AD cases have been defined by the absence of cognitive decline but with neuropathological evidence of AD. The hippocampus and entorhinal cortex were examined in 13 nondemented cases (Clinical Dementia Rating [CDR] 0) with healthy brains, 4 cases with preclinical AD, 8 cases with very mild symptomatic AD (CDR 0.5), and 4 cases with severe AD (CDR 3, hippocampus only). The volume and number of neurons were determined stereologically in 2 areas that are vulnerable to AD--the entorhinal cortex (as a whole and layer II alone) and hippocampal field CA1.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant decrease in neuron number or volume with age in the healthy nondemented group and little or none between the healthy and preclinical AD groups. Substantial decreases were found in the very mild AD group in neuron number (35% in the entorhinal cortex, 50% in layer II, and 46% in CA1) and volume (28% in the entorhinal cortex, 21% in layer II, and 29% in CA1). Greater decrements were observed in CA1 in the severe AD group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is little or no neuronal loss in aging or preclinical AD but substantial loss in very mild AD. The findings indicate that AD results in clinical deficits only when it produces significant neuronal loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Price</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Campus Box 8108, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA. PriceJ@Thalamus.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>A I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Tsou</LastName><ForeName>S K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>McKeel</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId><ArticleId IdType="doi">10.1001/archneur.58.9.1395</ArticleId><ArticleId IdType="pii">noc10060</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11559702</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>276</Volume><Issue>49</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Proteasome inhibition in glyoxal-treated fibroblasts and resistance of glycated glucose-6-phosphate dehydrogenase to 20 S proteasome degradation in vitro.</ArticleTitle><Pagination><StartPage>45662</StartPage><EndPage>45668</EndPage><MedlinePgn>45662-8</MedlinePgn></Pagination><Abstract><AbstractText>Glycation and glycoxidation protein products are formed upon binding of sugars to NH(2) groups of lysine and arginine residues and have been shown to accumulate during aging and in pathologies such as Alzheimer's disease and diabetes. Because the proteasome is the major intracellular proteolytic system involved in the removal of altered proteins, the effect of intracellular glycation on proteasome function has been analyzed in human dermal fibroblasts subjected to treatment with glyoxal that promotes the formation of N epsilon-carboxymethyl-lysine adducts on proteins. The three proteasome peptidase activities were decreased in glyoxal-treated cells as compared with control cells, and glyoxal was also found to inhibit these peptidase activities in vitro. In addition, the activity of glucose-6-phosphate dehydrogenase, a crucial enzyme for the regulation of the intracellular redox status, was dramatically reduced in glyoxal-treated cells. Further analysis was performed to determine whether glycated proteins are substrates for proteasome degradation. In contrast to the oxidized glucose-6-phosphate dehydrogenase, both N epsilon-carboxymethyl-lysine- and fluorescent-glycated enzymes were resistant to degradation by the 20 S proteasome in vitro, and this resistance was correlated with an increased conformational stability of the glycated proteins. These results provide one explanation for why glycated proteins build up both as a function of disease and aging. Finally, N epsilon-carboxymethyl-lysine-modified proteins were found to be ubiquitinated in glyoxal-treated cells suggesting a potential mechanism by which these modified proteins may be marked for degradation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bulteau</LastName><ForeName>A L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Laboratoire de Biologie et Biochimie Cellulaire du Vieillissement, Universit&#xe9; Denis Diderot, Paris 7, 2 Place Jussieu, CC 7128, 75251 Paris Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbeke</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Petropoulos</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Chaffotte</LastName><ForeName>A F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Friguet</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000817">Anilino Naphthalenesulfonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015853">Cysteine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017127">Glycation End Products, Advanced</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009097">Multienzyme Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>50NP6JJ975</RegistryNumber><NameOfSubstance UI="D006037">Glyoxal</NameOfSubstance></Chemical><Chemical><RegistryNumber>630I4V6051</RegistryNumber><NameOfSubstance UI="C027132">1-anilino-8-naphthalenesulfonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.49</RegistryNumber><NameOfSubstance UI="D005954">Glucosephosphate Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000817" MajorTopicYN="N">Anilino Naphthalenesulfonates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015853" MajorTopicYN="N">Cysteine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005954" MajorTopicYN="N">Glucosephosphate Dehydrogenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017127" MajorTopicYN="N">Glycation End Products, Advanced</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006037" MajorTopicYN="N">Glyoxal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009097" MajorTopicYN="N">Multienzyme Complexes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>11</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11559702</ArticleId><ArticleId IdType="doi">10.1074/jbc.M105374200</ArticleId><ArticleId IdType="pii">S0021-9258(19)37350-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11567612</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>APP processing and synaptic plasticity in presenilin-1 conditional knockout mice.</ArticleTitle><Pagination><StartPage>713</StartPage><EndPage>726</EndPage><MedlinePgn>713-26</MedlinePgn></Pagination><Abstract><AbstractText>We have developed a presenilin-1 (PS1) conditional knockout mouse (cKO), in which PS1 inactivation is restricted to the postnatal forebrain. The PS1 cKO mouse is viable and exhibits no gross abnormalities. The carboxy-terminal fragments of the amyloid precursor protein differentially accumulate in the cerebral cortex of cKO mice, while generation of beta-amyloid peptides is reduced. Expression of Notch downstream effector genes, Hes1, Hes5, and Dll1, is unaffected in the cKO cortex. Although basal synaptic transmission, long-term potentiation, and long-term depression at hippocampal area CA1 synapses are normal, the PS1 cKO mice exhibit subtle but significant deficits in long-term spatial memory. These results demonstrate that inactivation of PS1 function in the adult cerebral cortex leads to reduced Abeta generation and subtle cognitive deficits without affecting expression of Notch downstream genes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saura</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>S Y</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>L D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Handler</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kawarabayashi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fedeles</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kandel</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11567612</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(01)00417-2</ArticleId><ArticleId IdType="pii">S0896-6273(01)00417-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11578777</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-0186</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>5-6</Issue><PubDate><Year>2001</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Neurochemistry international</Title><ISOAbbreviation>Neurochem Int</ISOAbbreviation></Journal><ArticleTitle>Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice.</ArticleTitle><Pagination><StartPage>415</StartPage><EndPage>425</EndPage><MedlinePgn>415-25</MedlinePgn></Pagination><Abstract><AbstractText>The varepsilon4 allele of apolipoprotein E (apoE) is a genetic risk factor for Alzheimer's disease (AD). In order to gain a better understanding of the molecular mechanisms by which apoE and possibly other apolipoproteins produced in the central nervous system (CNS) influence AD pathogenesis, we have purified and characterized the two most abundant apolipoproteins produced in the CNS, apoE and apoJ. We purified apoE and apoJ from primary cultures of mouse astrocytes, which were derived from transgenic mice expressing human apoE isoforms in the absence of mouse apoE. Utilizing antibody affinity columns, we were able to purify both human apoE3 and apoE4, as well as mouse apoJ-containing lipoproteins. Astrocyte-secreted human apoE was present in high density-like lipoproteins of three predominant sizes ranging from 8 to 15 nm in diameter. Mouse apoJ was in particles between 10 and 17 nm in diameter with a peak size range of approximately 11 nm. ApoE and apoJ were in distinct lipoproteins. Utilization of quick-freeze, deep-etch electron microscopy revealed the apoE particles were discs while the apoJ particles were smaller and more irregular in appearance. The lipid composition of apoE particles was very different from those containing apoJ. ApoE-particles contained a similar mass of apoE and lipid, with cholesterol and phospholipid being about equal in mass per particle. ApoJ-particles were relatively lipid poor (three parts protein, one part lipid), with phospholipids being much more abundant than cholesterol. Detailed characterization of phospholipid composition by electrospray ionization mass spectrometry analysis revealed ethanolamine glycerophospholipids to be the most abundant phospholipid present in both apoE and apoJ particles. Analysis of cerebrospinal fluid from apoE3 and apoE4 transgenic mice revealed that human and mouse apoE were in particles the same size as those secreted by astrocytes. Further use of physiological preparations of CNS-derived lipoproteins may allow for a detailed understanding of the role of these molecules in the normal brain and in diseases such as AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeMattos</LastName><ForeName>R B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Center for the Study of Nervous System Injury, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendza</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Heuser</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Kierson</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00861</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM29647</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurochem Int</MedlineTA><NlmUniqueID>8006959</NlmUniqueID><ISSNLinking>0197-0186</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495243">Clu protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11578777</ArticleId><ArticleId IdType="doi">10.1016/s0197-0186(01)00049-3</ArticleId><ArticleId IdType="pii">S0197018601000493</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11580253</PMID><DateCompleted><Year>2001</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-2836</ISSN><JournalIssue CitedMedium="Print"><Volume>312</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of molecular biology</Title><ISOAbbreviation>J Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis.</ArticleTitle><Pagination><StartPage>1103</StartPage><EndPage>1119</EndPage><MedlinePgn>1103-19</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid beta-protein (Abeta) assembly into toxic oligomeric and fibrillar structures is a seminal event in Alzheimer's disease, therefore blocking this process could have significant therapeutic benefit. A rigorous mechanistic understanding of Abeta assembly would facilitate the targeting and design of fibrillogenesis inhibitors. Prior studies have shown that Abeta fibrillogenesis involves conformational changes leading to the formation of extended beta-sheets and that an alpha-helix-containing intermediate may be involved. However, the significance of this intermediate has been a matter of debate. We report here that the formation of an oligomeric, alpha-helix-containing assembly is a key step in Abeta fibrillogenesis. The generality of this phenomenon was supported by conformational studies of 18 different Abeta peptides, including wild-type Abeta(1-40) and Abeta(1-42), biologically relevant truncated and chemically modified Abeta peptides, and Abeta peptides causing familial forms of cerebral amyloid angiopathy. Without exception, fibrillogenesis of these peptides involved an oligomeric alpha-helix-containing intermediate and the kinetics of formation of the intermediate and of fibrils was temporally correlated. The kinetics varied depending on amino acid sequence and the extent of peptide N- and C-terminal truncation. The pH dependence of helix formation suggested that Asp and His exerted significant control over this process and over fibrillogenesis in general. Consistent with this idea, Abeta peptides containing Asp--&gt;Asn or His--&gt;Gln substitutions showed altered fibrillogenesis kinetics. These data emphasize the importance of the dynamic interplay between Abeta monomer conformation and oligomerization state in controlling fibrillogenesis kinetics.</AbstractText><CopyrightInformation>Copyright 2001 Academic Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirkitadze</LastName><ForeName>M D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condron</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Teplow</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG14366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS38328</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Mol Biol</MedlineTA><NlmUniqueID>2985088R</NlmUniqueID><ISSNLinking>0022-2836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QD397987E</RegistryNumber><NameOfSubstance UI="D006639">Histidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7006-34-0</RegistryNumber><NameOfSubstance UI="D001216">Asparagine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001216" MajorTopicYN="N">Asparagine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002850" MajorTopicYN="N">Chromatography, Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006639" MajorTopicYN="N">Histidine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>11</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11580253</ArticleId><ArticleId IdType="doi">10.1006/jmbi.2001.4970</ArticleId><ArticleId IdType="pii">S0022-2836(01)94970-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11580892</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>A miniature head-mounted two-photon microscope. high-resolution brain imaging in freely moving animals.</ArticleTitle><Pagination><StartPage>903</StartPage><EndPage>912</EndPage><MedlinePgn>903-12</MedlinePgn></Pagination><Abstract><AbstractText>Two-photon microscopy has enabled anatomical and functional fluorescence imaging in the intact brain of rats. Here, we extend two-photon imaging from anesthetized, head-stabilized to awake, freely moving animals by using a miniaturized head-mounted microscope. Excitation light is conducted to the microscope in a single-mode optical fiber, and images are scanned using vibrations of the fiber tip. Microscope performance was first characterized in the neocortex of anesthetized rats. We readily obtained images of vasculature filled with fluorescently labeled blood and of layer 2/3 pyramidal neurons filled with a calcium indicator. Capillary blood flow and dendritic calcium transients were measured with high time resolution using line scans. In awake, freely moving rats, stable imaging was possible except during sudden head movements.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Helmchen</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biological Computation Research Department, Bell Laboratories, Lucent Technologies, Murray Hill, NJ 07974, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fee</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Tank</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Denk</LastName><ForeName>W</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003911">Dextrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009930">Organic Chemicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C015219">fluorescein isothiocyanate dextran</NameOfSubstance></Chemical><Chemical><RegistryNumber>138067-55-7</RegistryNumber><NameOfSubstance UI="C071336">calcium green</NameOfSubstance></Chemical><Chemical><RegistryNumber>I223NX31W9</RegistryNumber><NameOfSubstance UI="D016650">Fluorescein-5-isothiocyanate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="N">Anesthesia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016477" MajorTopicYN="N">Artifacts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003911" MajorTopicYN="N">Dextrans</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005336" MajorTopicYN="N">Fiber Optic Technology</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016650" MajorTopicYN="N">Fluorescein-5-isothiocyanate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019416" MajorTopicYN="N">Head Movements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007834" MajorTopicYN="N">Lasers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008904" MajorTopicYN="N">Miniaturization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055100" MajorTopicYN="N">Optical Fibers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009930" MajorTopicYN="N">Organic Chemicals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11580892</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(01)00421-4</ArticleId><ArticleId IdType="pii">S0896-6273(01)00421-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11581097</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9262</ISSN><JournalIssue CitedMedium="Print"><Volume>154</Volume><Issue>7</Issue><PubDate><Year>2001</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>American journal of epidemiology</Title><ISOAbbreviation>Am J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort.</ArticleTitle><Pagination><StartPage>635</StartPage><EndPage>641</EndPage><MedlinePgn>635-41</MedlinePgn></Pagination><Abstract><AbstractText>Research on the relation between diabetes mellitus and dementia has produced conflicting results, and the relation has not been investigated among Blacks and Hispanics. In this study, Cox proportional hazards models were used to analyze longitudinal data from 1,262 elderly subjects without dementia at baseline (1991-1996) who were followed for an average of 4.3 years between 1992 and 1997. Outcomes were incident Alzheimer's disease and dementia associated with stroke. The prevalence of diabetes was 20% at baseline. The adjusted relative risk of Alzheimer's disease among persons with diabetes as compared with those without diabetes was 1.3 (95% confidence interval (CI): 0.8, 1.9). The adjusted relative risk for the composite outcome of Alzheimer's disease and cognitive impairment without dementia (without stroke) in subjects with diabetes was 1.6 (95% CI: 1.2, 2.1). The adjusted relative risk of stroke-associated dementia in persons with diabetes was 3.4 (95% CI: 1.7, 6.9). Among Blacks and Hispanics, approximately one third of the risk of stroke-associated dementia was attributable to diabetes (33% (95% CI: 31, 36) and 36% (95% CI: 33, 37), respectively), as compared with 17% (95% CI: 13, 22) among Whites. The finding of an association between diabetes and the composite outcome of Alzheimer's disease and cognitive impairment without dementia (without stroke) is consistent with prior reports of a modest relation between diabetes and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luchsinger</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research of Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>M X</ForeName><Initials>MX</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Epidemiol</MedlineTA><NlmUniqueID>7910653</NlmUniqueID><ISSNLinking>0002-9262</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009519" MajorTopicYN="N" Type="Geographic">New York City</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11581097</ArticleId><ArticleId IdType="doi">10.1093/aje/154.7.635</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11584272</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>10</Issue><PubDate><Year>2001</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide.</ArticleTitle><Pagination><StartPage>905</StartPage><EndPage>912</EndPage><MedlinePgn>905-12</MedlinePgn></Pagination><Abstract><AbstractText>The pathogenic event common to all forms of Alzheimer's disease is the abnormal accumulation of the amyloid beta-peptide (Abeta). Here we provide strong evidence that intracellular cholesterol compartmentation modulates the generation of Abeta. Using genetic, biochemical and metabolic approaches, we found that cholesteryl-ester levels are directly correlated with Abeta production. Acyl-coenzyme A:cholesterol acyltransferase (ACAT), the enzyme that catalyses the formation of cholesteryl esters, modulates the generation of Abeta through the tight control of the equilibrium between free cholesterol and cholesteryl esters. We also show that pharmacological inhibitors of ACAT, developed for the treatment of atherosclerosis, are potent modulators of Abeta generation, indicating their potential for use in the treatment of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puglielli</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Massachusetts General Hospital, Harvard Medical School, Building 114, 16th Street, Charlestown, Massachusetts 02129-4404, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konopka</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pack-Chung</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ingano</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Berezovska</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>T Y</ForeName><Initials>TY</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>135025-12-6</RegistryNumber><NameOfSubstance UI="C087132">CP 113818</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.26</RegistryNumber><NameOfSubstance UI="D002785">Sterol O-Acyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002785" MajorTopicYN="N">Sterol O-Acyltransferase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11584272</ArticleId><ArticleId IdType="doi">10.1038/ncb1001-905</ArticleId><ArticleId IdType="pii">ncb1001-905</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11592856</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0969-9961</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>890</StartPage><EndPage>899</EndPage><MedlinePgn>890-9</MedlinePgn></Pagination><Abstract><AbstractText>Clinical, epidemiological, and laboratory studies suggest that cholesterol may play a role in the pathogenesis of Alzheimer's disease (AD). Transgenic mice exhibiting an Alzheimer's beta-amyloid phenotype were treated with the cholesterol-lowering drug BM15.766 and tested for modulation of beta-amyloid levels. BM15.766 treatment reduced plasma cholesterol, brain Abeta peptides, and beta-amyloid load by greater than twofold. A strong, positive correlation between the amount of plasma cholesterol and Abeta was observed. Furthermore, drug treatment reduced the amyloidogenic processing of the amyloid precursor protein, suggesting alterations in processing in response to cholesterol modulation. This study demonstrates that hypocholesterolemia is associated with reduced Abeta accumulation suggesting that lowering cholesterol by pharmacological means may be an effective approach for reducing the risk of developing AD.</AbstractText><CopyrightInformation>Copyright 2001 Academic Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Refolo</LastName><ForeName>L M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA. refolo@nki.rfmh.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappolla</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>LaFrancois</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Malester</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Thomas-Bryant</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tint</LastName><ForeName>G S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Petanceska</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>K E</ForeName><Initials>KE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 146133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG1438101A2</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000683">Serum Amyloid P-Component</NameOfSubstance></Chemical><Chemical><RegistryNumber>86621-92-3</RegistryNumber><NameOfSubstance UI="C047457">BM 15766</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.-</RegistryNumber><NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.3.-</RegistryNumber><NameOfSubstance UI="D044925">Oxidoreductases Acting on CH-CH Group Donors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.3.1.21</RegistryNumber><NameOfSubstance UI="C019995">7-dehydrocholesterol reductase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044925" MajorTopicYN="Y">Oxidoreductases Acting on CH-CH Group Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000683" MajorTopicYN="N">Serum Amyloid P-Component</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>24</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11592856</ArticleId><ArticleId IdType="doi">10.1006/nbdi.2001.0422</ArticleId><ArticleId IdType="pii">S0969-9961(01)90422-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11606569</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>276</Volume><Issue>51</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure.</ArticleTitle><Pagination><StartPage>48165</StartPage><EndPage>48174</EndPage><MedlinePgn>48165-74</MedlinePgn></Pagination><Abstract><AbstractText>The microtubule-associated protein tau is a natively unfolded protein in solution, yet it is able to polymerize into the ordered paired helical filaments (PHF) of Alzheimer's disease. In the splice isoforms lacking exon 10, this process is facilitated by the formation of beta-structure around the hexapeptide motif PHF6 ((306)VQIVYK(311)) encoded by exon 11. We have investigated the structural requirements for PHF polymerization in the context of adult tau isoforms containing four repeats (including exon 10). In addition to the PHF6 motif there exists a related PHF6* motif ((275)VQIINK(280)) in the repeat encoded by the alternatively spliced exon 10. We show that this PHF6* motif also promotes aggregation by the formation of beta-structure and that there is a cross-talk between the two hexapeptide motifs during PHF aggregation. We also show that two of the tau mutations found in hereditary frontotemporal dementias, DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Bergen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, Notkestrasse 85, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barghorn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Marx</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId><ArticleId IdType="doi">10.1074/jbc.M105196200</ArticleId><ArticleId IdType="pii">S0021-9258(19)40331-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11606625</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>21</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.</ArticleTitle><Pagination><StartPage>8370</StartPage><EndPage>8377</EndPage><MedlinePgn>8370-7</MedlinePgn></Pagination><Abstract><AbstractText>Inflammation in Alzheimer's disease (AD) patients is characterized by increased cytokines and activated microglia. Epidemiological studies suggest reduced AD risk associates with long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). Whereas chronic ibuprofen suppressed inflammation and plaque-related pathology in an Alzheimer transgenic APPSw mouse model (Tg2576), excessive use of NSAIDs targeting cyclooxygenase I can cause gastrointestinal, liver, and renal toxicity. One alternative NSAID is curcumin, derived from the curry spice turmeric. Curcumin has an extensive history as a food additive and herbal medicine in India and is also a potent polyphenolic antioxidant. To evaluate whether it could affect Alzheimer-like pathology in the APPSw mice, we tested a low (160 ppm) and a high dose of dietary curcumin (5000 ppm) on inflammation, oxidative damage, and plaque pathology. Low and high doses of curcumin significantly lowered oxidized proteins and interleukin-1beta, a proinflammatory cytokine elevated in the brains of these mice. With low-dose but not high-dose curcumin treatment, the astrocytic marker GFAP was reduced, and insoluble beta-amyloid (Abeta), soluble Abeta, and plaque burden were significantly decreased by 43-50%. However, levels of amyloid precursor (APP) in the membrane fraction were not reduced. Microgliosis was also suppressed in neuronal layers but not adjacent to plaques. In view of its efficacy and apparent low toxicity, this Indian spice component shows promise for the prevention of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>G P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Departments of Medicine and Neurology, University of California, Los Angeles, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Beech</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Frautschy</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG013741</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG028583</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA091343</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13471</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017365" MajorTopicYN="N">Spices</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11606625</ArticleId><ArticleId IdType="pmc">PMC6762797</ArticleId><ArticleId IdType="pii">21/21/8370</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.21-21-08370.2001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams JD, Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol Chem Neuropathol. 1991;14:213&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">1958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksenova MV, Aksenov MY, Butterfield DA, Carney JM. Alpha-1-antichymotrypsin interaction with a beta (1&#x2013;40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci Lett. 1996;211:45&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">8809844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062949</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res Mol Brain Res. 1999;68:181&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320795</ArticleId></ArticleIdList></Reference><Reference><Citation>Began G, Sudharshan E, Appu Rao AG. Inhibition of lipoxygenase 1 by phosphatidylcholine micelles-bound curcumin. Lipids. 1998;33:1223&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930409</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid &#x3b2; protein toxicity. Cell. 1994;77:817&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">8004671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med. 1998;105:17S&#x2013;21S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996;271:4436&#x2013;4440.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626795</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and Histamine H2 blocking drugs. Neurobiol Aging. 1995;16:523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">8544901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Pettingell WH, Jr, de Paradis M, Tanzi RE, Wasco W. The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J Biol Chem. 1994;269:26618&#x2013;26621.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappell MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity. Gastroenterol Clin North Am. 2000;29:97&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">10752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan MM, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol. 1998;55:1955&#x2013;1962.</Citation><ArticleIdList><ArticleId IdType="pubmed">9714315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Hsiao K. Impaired synaptic plasticity and learning in amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN. Gamma-tocopherol traps mutagenic electrophiles such as NOx and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci USA. 1997;94:3217&#x2013;3222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20349</ArticleId><ArticleId IdType="pubmed">9096373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole GM, Bell L, Truong QB, Saitoh T. An endosomal lysosomal pathway for degradation of amyloid precursor protein. Ann NY Acad Sci. 1992;674:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">1288357</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad CC, Marshall PL, Talent JM, Malakowsky CA, Choi J, Gracy RW. Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun. 2000;275:678&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964722</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ, Paxinos G. The mouse brain in stereotaxis coordinates, Ed 1. Academic; London: 1997.</Citation></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Hu W, Miller SA, Kim P, Harris-White ME, Cole GM (2001) Phenolic anti-inflammatory antioxidant reversal of A&#x3b2;-induced cognitive deficits and neuropathology. Neurobiol Aging, in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755008</ArticleId></ArticleIdList></Reference><Reference><Citation>Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. NeuroReport. 1999;10:1699&#x2013;1705.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501560</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlich AL, Butcher LL. Involvement of free oxygen radicals in &#x3b2;-amyloidosis: an hypothesis. Neurobiol Aging. 1994;15:443&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, Pandav R, Belle SH, DeKosky ST. Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US Cross-National Dementia Study. Arch Neurol. 2000;57:824&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867779</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasson BT, Dude JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062131</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. Glial-neuronal interactions in Alzheimer's disease: the potential role of a &#x201c;cytokine cycle&#x201d; in disease progression. Brain Pathol. 1998;8:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in Alzheimer's pathogenesis: a role for specific polymorphisms in disease risk. Exp Gerontol. 2000;35:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833595</ArticleId><ArticleId IdType="pubmed">10959036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for &#x3b2;-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to alzheimer disease. Proc Natl Acad Sci USA. 1994;91:3270&#x2013;3274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43558</ArticleId><ArticleId IdType="pubmed">8159737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal-Eldin A, Frank J, Razdan A, Tengblad S, Basu S, Vessby B. Effects of dietary phenolic compounds on tocopherol, cholesterol, and fatty acids in rats. Lipids. 2000;35:427&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul S, Krishnakantha TP. Influence of retinol deficiency and curcumin/turmeric feeding on tissue microsomal membrane lipid peroxidation and fatty acids in rats. Mol Cell Biochem. 1997;175:43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">9350032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl. 1991;26:54&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000;130:467S&#x2013;471S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10721931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Hsiao Ashe K, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao Ashe K, Frautschy SA, Cole GM (2001) Ibuprofen effects of Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging, in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755007</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Aragon S, Benedi JM, Villar AM. Modifications on antioxidant capacity and lipid peroxidation in mice under fraxetin treatment. J Pharm Pharmacol. 1997;49:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9120770</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 1995;676:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">7796173</ArticleId></ArticleIdList></Reference><Reference><Citation>McGettigan P, Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des. 2000;6:1693&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pubmed">11102559</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Markesbery WR, Roberts RJI, Morrow JD. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol. 1998;44:410&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749613</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ, Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with ApoE genotype in Alzheimer's disease patients. Am J Pathol. 1999;155:863&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866881</ArticleId><ArticleId IdType="pubmed">10487843</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci. 1998;18:2974&#x2013;2981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792583</ArticleId><ArticleId IdType="pubmed">9526014</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthane U, Yasha TC, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol. 1998;43:283&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506543</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappolla MA, Chyan Y-J, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of &#x3b2;-amyloid in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 1998;152:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858256</ArticleId><ArticleId IdType="pubmed">9546346</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Smith MA. A central role for oxidative damage in the pathogenesis and therapeutics of Alzheimer's disease. Alzheimer's Res. 1997;2:319&#x2013;324.</Citation></Reference><Reference><Citation>Pratic&#xf2; D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med. 2000;109:577&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063960</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratic&#xf2; D, Lee VM-Y, Trojanowski JQ, Rokach J, FitzGerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998;12:1777&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837868</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratic&#xf2; D, Uryu K, Leight S, Trojanowski JQ, Lee VM. Increased lipid peroxidation preces amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001;21:4183&#x2013;4187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762743</ArticleId><ArticleId IdType="pubmed">11404403</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajakumar DV, Rao MN. Antioxidant properties of dehydrozingerone and curcumin in rat brain homogenates. Mol Cell Biochem. 1994;140:73&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">7877600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E, Gil A. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis. 1999;147:371&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Webster S, Lih-Fen L, Brachova L, Civin WH, Emmerling M, Brenda S, Walker D, McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging. 1996;17:681&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozemuller JM, Stam FC, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett. 1990;119:75&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">1711182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl J Med. 1997;336:1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin ST. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17:761&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886636</ArticleId><ArticleId IdType="pubmed">8892349</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji M, Hirai S, Yamaguchi H, Harigaya Y, Ishiguro K, Matsubara E. Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain. Am J Pathol. 1991;138:247&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886058</ArticleId><ArticleId IdType="pubmed">1702930</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzypczak-Jankun E, McCabe NP, Selman SH, Jankun J. Curcumin inhibits lipoxygenase by binding to its central cavity: theoretical and X-ray evidence. Int J Mol Med. 2000;6:521&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">11029517</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci USA. 1991;88:10540&#x2013;10543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52964</ArticleId><ArticleId IdType="pubmed">1683703</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997;17:2653&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573097</ArticleId><ArticleId IdType="pubmed">9092586</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlank SL, Tabaton M, Perry G. Amyloid-&#x3b2; deposition is Alzheimer transgenic mice is associated with oxidative stress. J Neurochem. 1998;70:2212&#x2013;2215.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572310</ArticleId></ArticleIdList></Reference><Reference><Citation>Soudamini KK, Unnikrishnan MC, Soni KB, Kuttan R. Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. Indian J Physiol Pharmacol. 1992;36:239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">1291474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreejayan N, Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol. 1994;46:1013&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreejayan N, Rao MNA. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol. 1997;49:105&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">9120760</ArticleId></ArticleIdList></Reference><Reference><Citation>Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol. 1972;25:447&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">4146582</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart WF, Kawas C, Corrada M, Meter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung J, Russell RI, Nyeomans, Chan FK, Chen S, Fock K, Goh KL, Kullavanijaya P, Kimura K, Lau C, Louw J, Sollano J, Triadiafalopulos G, Xiao S, Brooks P. Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol [Suppl] 2000;15:G58&#x2013;G68.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100995</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomoda T, Kurashige T, Hayashi Y, Enzan H. Primary changes in liver damage by aspirin in rats. Acta Paediatr Jpn. 1998;40:593&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">9893296</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol. 2000;130:184&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940225</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 1996;10:1485&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135:235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">1625800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci USA. 2001;98:5371&#x2013;5373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33340</ArticleId><ArticleId IdType="pubmed">11344276</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YX, Pindolia KR, Janakiraman N, Chapman RA, Gautam SC. Curcumin inhibits IL-1 alpha and TNF-alpha induction of AP-1 and NK-kB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol. 1998;11:49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9439980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto H, Hanada K, Kawasaki K, Nishijima M. Inhibitory effect on curcumin on mammalian phospholipase D activity. FEBS Lett. 1997;417:196&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis. 1999;20:445&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys. 1989;14:175&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">2472207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11683992</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>223</EndPage><MedlinePgn>213-23</MedlinePgn></Pagination><Abstract><AbstractText>We characterized beta-synuclein, the non-amyloidogenic homolog of alpha-synuclein, as an inhibitor of aggregation of alpha-synuclein, a molecule implicated in Parkinson's disease. For this, doubly transgenic mice expressing human (h) alpha- and beta-synuclein were generated. In doubly transgenic mice, beta-synuclein ameliorated motor deficits, neurodegenerative alterations, and neuronal alpha-synuclein accumulation seen in halpha-synuclein transgenic mice. Similarly, cell lines transfected with beta-synuclein were resistant to alpha-synuclein accumulation. halpha-synuclein was coimmunoprecipitated with hbeta-synuclein in the brains of doubly transgenic mice and in the double-transfected cell lines. Our results raise the possibility that beta-synuclein might be a natural negative regulator of alpha-synuclein aggregation and that a similar class of endogenous factors might regulate the aggregation state of other molecules involved in neurodegeneration. Such an anti-amyloidogenic property of beta-synuclein might also provide a novel strategy for the treatment of neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockenstein</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mante</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mallory</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497607">SNCB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497608">Sncb protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051846">beta-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007163" MajorTopicYN="N">Immunosorbent Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051846" MajorTopicYN="N">beta-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11683992</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(01)00462-7</ArticleId><ArticleId IdType="pii">S0896-6273(01)00462-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11689468</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>13</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology.</ArticleTitle><Pagination><StartPage>2433</StartPage><EndPage>2444</EndPage><MedlinePgn>2433-44</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid beta protein (AbetaP) is the major constituent of senile plaques associated with Alzheimer's disease (AD). However, its mechanistic role in AD pathogenesis is poorly understood. Globular and nonfibrillar AbetaPs are continuously released during normal metabolism. Using techniques of atomic force microscopy, laser confocal microscopy, electrical recording, and biochemical assays, we have examined the molecular conformations of reconstituted globular AbetaPs as well as their real-time and acute effects on neuritic degeneration. Atomic force microscopy (AFM) of AbetaP1-42 shows globular structures that do not form fibers in physiological-buffered solution for up to 8 h of continuous imaging. AFM of AbetaP1-42 reconstituted in a planar lipid bilayer reveals multimeric channel-like structures. Consistent with these AFM resolved channel-like structures, biochemical analysis demonstrates that predominantly monomeric AbetaPs in solution form stable tetramers and hexamers after incorporation into lipid membranes. Electrophysiological recordings demonstrate the presence of multiple single channel currents of different sizes. At the cellular level, AbetaP1-42 allows calcium uptake and induces neuritic abnormality in a dose- and time-dependent fashion. At physiological nanomolar concentrations, rapid neuritic degeneration was observed within minutes; at micromolar concentrations, neuronal death was observed within 3-4 h. These effects are prevented by zinc (an AbetaP channel blocker) and by the removal of extracellular calcium, but are not prevented by antagonists of putative AbetaP cell surface receptors. Thus, AbetaP channels may provide a direct pathway for calcium-dependent AbetaP toxicity in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, California 93016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005452">Fluoresceins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008051">Lipid Bilayers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008563">Membrane Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>148504-34-1</RegistryNumber><NameOfSubstance UI="C085925">calcein AM</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>FASEB J 2002 May;16(7):759</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005452" MajorTopicYN="N">Fluoresceins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008051" MajorTopicYN="N">Lipid Bilayers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008563" MajorTopicYN="N">Membrane Lipids</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11689468</ArticleId><ArticleId IdType="doi">10.1096/fj.01-0377com</ArticleId><ArticleId IdType="pii">15/13/2433</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11694153</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0098-7484</ISSN><JournalIssue CitedMedium="Print"><Volume>286</Volume><Issue>17</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>07</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.</ArticleTitle><Pagination><StartPage>2120</StartPage><EndPage>2127</EndPage><MedlinePgn>2120-7</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the sensitivity and specificity with which cerebral metabolic patterns at a single point in time forecast subsequent documentation of progressive dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">Positron emission tomography (PET) studies of [(18)F]fluorodeoxyglucose in 146 patients undergoing evaluation for dementia with at least 2 years' follow-up for disease progression at the University of California, Los Angeles, from 1991 to 2000, and PET studies in 138 patients undergoing evaluation for dementia at an international consortium of facilities, with histopathological diagnoses an average of 2.9 years later, conducted from 1984 to 2000.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Regional distribution of [(18)F]fluorodeoxyglucose in each patient, classified by criteria established a priori as positive or negative for presence of a progressive neurodegenerative disease in general and of Alzheimer disease (AD) specifically, compared with results of longitudinal or neuropathologic analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). Among patients with neuropathologically based diagnoses, PET identified patients with AD and patients with any neurodegenerative disease with a sensitivity of 94% and specificities of 73% and 78%, respectively. The negative likelihood ratio of experiencing a progressive vs nonprogressive course over the several years following a single negative brain PET scan was 0.10 (95% confidence interval, 0.06-0.16), and the initial pattern of cerebral metabolism was significantly associated with the subsequent course of progression overall (P&lt;.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients presenting with cognitive symptoms of dementia, regional brain metabolism was a sensitive indicator of AD and of neurodegenerative disease in general. A negative PET scan indicated that pathologic progression of cognitive impairment during the mean 3-year follow-up was unlikely to occur.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>D H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Ahmanson Biological Imaging Center, CHS AR-144, Department of Molecular and Medical Pharmacology, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095-6942, USA. dsilver@ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>C Y</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Kung De Aburto</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Czernin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rapoport</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Author><Author ValidYN="Y"><LastName>Pietrini</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Schapiro</LastName><ForeName>M B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Alavi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Kowell</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Gambhir</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>C K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05128-07</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2002 Feb 27;287(8):985-6; author reply 986-7. doi: 10.1001/jama.287.8.985.</RefSource><PMID Version="1">11866638</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2002 Feb 27;287(8):986-7.</RefSource><PMID Version="1">11866639</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="Y">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11694153</ArticleId><ArticleId IdType="doi">10.1001/jama.286.17.2120</ArticleId><ArticleId IdType="pii">joc10908</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11698669</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>98</Volume><Issue>24</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase.</ArticleTitle><Pagination><StartPage>13554</StartPage><EndPage>13559</EndPage><MedlinePgn>13554-9</MedlinePgn></Pagination><Abstract><AbstractText>The deposition of amyloid beta-peptide (A beta) in the brain is closely associated with the development of Alzheimer's disease. A beta is generated from the amyloid precursor protein (APP) by sequential action of beta-secretase (BACE1) and gamma-secretase. Although BACE1 is distributed among various other tissues, its physiological substrates other than APP have yet to be identified. ST6Gal I is a sialyltransferase that produces a sialyl alpha 2,6galactose residue, and the enzyme is secreted out of the cell after proteolytic cleavage. We report here that BACE1 is involved in the proteolytic cleavage of ST6Gal I, on the basis of the following observations. ST6Gal I was colocalized with BACE1 in the Golgi apparatus by immunofluorescence microscopy, suggesting that BACE1 acts on ST6Gal I within the same intracellular compartment. When BACE1 was overexpressed with ST6Gal I in COS cells, the secretion of ST6Gal I markedly increased. When APP(SW) (Swedish familial Alzheimer's disease mutation), a preferable substrate for BACE1, was coexpressed with ST6Gal I in COS cells, the secretion of ST6Gal I significantly decreased, suggesting that that the beta-cleavage of overexpressed APP(SW) competes with ST6Gal I processing. In addition, BACE1-Fc (Fc, the hinge and constant region of IgG) chimera cleaved protein A-ST6Gal I fusion protein in vitro. Thus, we conclude that BACE1 is responsible for the cleavage and secretion of ST6Gal I.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitazume</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Glyco-chain Functions Laboratory, Supra-biomolecular System Group, Frontier Research System, The Institute of Physical and Chemical Research (RIKEN), 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tachida</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Oka</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shirotani</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>T C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.99.-</RegistryNumber><NameOfSubstance UI="D012799">Sialyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.99.1</RegistryNumber><NameOfSubstance UI="D000094802">beta-D-Galactoside alpha 2-6-Sialyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012799" MajorTopicYN="N">Sialyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094802" MajorTopicYN="N">beta-D-Galactoside alpha 2-6-Sialyltransferase</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11698669</ArticleId><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="doi">10.1073/pnas.241509198</ArticleId><ArticleId IdType="pii">241509198</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard N P, Gerard C, Hama E, Lee H J, Saido T C. Science. 2001;292:1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Nature (London) 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T, Selkoe D J. Nature (London) 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J D, Liu K N, Luo Y, Slack J L, Stocking K L, Peschon J J, Johnson R S, Castner B J, Cerretti D P, Black R A. J Biol Chem. 1998;273:27765&#x2013;27767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F. Proc Natl Acad Sci USA. 1999;96:3922&#x2013;3927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22396</ArticleId><ArticleId IdType="pubmed">10097139</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H, Dressler D. Nat Biotechnol. 2000;18:125&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">10657070</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y M, Xu M, Lai M T, Huang Q, Castro J L, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil J G, et al. Nature (London) 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson J P, Barbour R, Basi G S, Caccavello R, Davis D, Doan M, Dovey H F, Frigon N, Hong J, et al. Nature (London) 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett B D, Babu-Khan S, Kahn S, Mendiaz E A, Denis P, Teplow D B, Ross S, Amarante P, Loeloff R, et al. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski M J, Shuck M E, Miao H, Tory M C, Pauley A M, Brashier J R, Stratman N C, Mathews W R, Buhl A E, et al. Nature (London) 1999;402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett B D, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt D R, Price D L, Wong P C. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson J C, Colley K J. J Biol Chem. 1989;264:17615&#x2013;17618.</Citation><ArticleIdList><ArticleId IdType="pubmed">2681181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan H A, Woloski B M, Hellman M, Jamieson J C. J Biol Chem. 1983;258:11505&#x2013;11509.</Citation><ArticleIdList><ArticleId IdType="pubmed">6413502</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein J, Lee E U, McEntee K, Lai P H, Paulson J C. J Biol Chem. 1987;262:17735&#x2013;17743.</Citation><ArticleIdList><ArticleId IdType="pubmed">3121604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber A C, Kozdrowski I, Wyss S R, Berger E G. Eur J Biochem. 1979;93:453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">33805</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhammer A, Kornfeld S. J Biol Chem. 1986;261:5249&#x2013;5255.</Citation><ArticleIdList><ArticleId IdType="pubmed">3082881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarnesto A, Kohlin T, Thurin J, Blaszczyk-Thurin M. J Biol Chem. 1990;265:15067&#x2013;15075.</Citation><ArticleIdList><ArticleId IdType="pubmed">2394712</ArticleId></ArticleIdList></Reference><Reference><Citation>Colley K J. Glycobiology. 1997;7:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108620</ArticleId><ArticleId IdType="pubmed">9061359</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T C, Iwatsubo T, Mann D M, Shimada H, Ihara Y, Kawashima S. Neuron. 1995;14:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume-Kawaguchi S, Dohmae N, Takio K, Tsuji S, Colley K J. Glycobiology. 1999;9:1397&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10561465</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama K, Terakado K, Usami M, Yoshikawa K. Nature (London) 1990;347:566&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1977086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume-Kawaguchi S, Kabata S, Arita M. J Biol Chem. 2001;276:15696&#x2013;15703.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278664</ArticleId></ArticleIdList></Reference><Reference><Citation>Colley K J, Lee E U, Paulson J C. J Biol Chem. 1992;267:7784&#x2013;7793.</Citation><ArticleIdList><ArticleId IdType="pubmed">1560012</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli U K. Nature (London) 1970;227:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Teplow D B, Selkoe D J. Neuron. 1995;14:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosshart H, Berger E G. Eur J Biochem. 1992;208:341&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">1521530</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody G M, Justement L B, Delibrias C C, Matthews R J, Lin J, Thomas M L, Fearon D T. Science. 1995;269:242&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">7618087</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe T L, Williams G T, Davies S L, Neuberger M S. Science. 1996;274:798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">8864124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte R J, Campbell M A, Fischer W H, Sefton B M. Science. 1992;258:1001&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">1279802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennet T, Chui D, Paulson J C, Marth J D. Proc Natl Acad Sci USA. 1998;95:4504&#x2013;4509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22519</ArticleId><ArticleId IdType="pubmed">9539767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai H, Allende M L, Wada R, Kono M, Sango K, Deng C, Miyakawa T, Crawley J N, Werth N, Bierfreund U, et al. J Biol Chem. 2000;27:27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11133999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh K A, Sun J, Liu Y, Kawai H, Crawford T O, Proia R L, Griffin J W, Schnaar R L. Proc Natl Acad Sci USA. 1999;96:7532&#x2013;7537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22120</ArticleId><ArticleId IdType="pubmed">10377449</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckhardt M, Bukalo O, Chazal G, Wang L, Goridis C, Schachner M, Gerardy-Schahn R, Cremer H, Dityatev A. J Neurosci. 2000;20:5234&#x2013;5244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772332</ArticleId><ArticleId IdType="pubmed">10884307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima S, Nagata S. Nucleic Acids Res. 1990;18:5322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC332193</ArticleId><ArticleId IdType="pubmed">1698283</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11701929</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>294</Volume><Issue>5545</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.</ArticleTitle><Pagination><StartPage>1346</StartPage><EndPage>1349</EndPage><MedlinePgn>1346-9</MedlinePgn></Pagination><Abstract><AbstractText>The substantia nigra in Parkinson's disease (PD) is depleted of dopaminergic neurons and contains fibrillar Lewy bodies comprising primarily alpha-synuclein. We screened a library to identify drug-like molecules to probe the relation between neurodegeneration and alpha-synuclein fibrilization. All but one of 15 fibril inhibitors were catecholamines related to dopamine. The inhibitory activity of dopamine depended on its oxidative ligation to alpha-synuclein and was selective for the protofibril-to-fibril conversion, causing accumulation of the alpha-synuclein protofibril. Adduct formation provides an explanation for the dopaminergic selectivity of alpha-synuclein-associated neurotoxicity in PD and has implications for current and future PD therapeutic and diagnostic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conway</LastName><ForeName>K A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochet</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Bieganski</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Lansbury</LastName><ForeName>P T</ForeName><Initials>PT</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS38375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011809">Quinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2001 Nov 9;294(5545):1257-8. doi: 10.1126/science.294.5545.1257a.</RefSource><PMID Version="1">11701896</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011809" MajorTopicYN="N">Quinones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11701929</ArticleId><ArticleId IdType="doi">10.1126/science.1063522</ArticleId><ArticleId IdType="pii">294/5545/1346</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11705634</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.</ArticleTitle><Pagination><StartPage>747</StartPage><EndPage>754</EndPage><MedlinePgn>747-54</MedlinePgn></Pagination><Abstract><AbstractText>With high resolution, quantitative magnetic resonance imaging (MRI) techniques, it is now possible to examine alterations in brain anatomy in vivo and to identify regions affected in the earliest stages of Alzheimer's disease (AD). In this study, we compared MRI-derived entorhinal and hippocampal volume in healthy elderly controls, patients who presented at the clinic with cognitive complaints, but did not meet criteria for dementia (non-demented), and patients with very mild AD. The two patient groups differed significantly from controls in entorhinal volume, but not from each other; in contrast, they differed from each other, as well as from controls, in hippocampal volume, with the mild AD cases showing the greatest atrophy. Follow-up clinical evaluations available on 23/28 non-demented patients indicated that 12/23 had converted to AD within 12-77 months from the baseline MRI examination. Converters could be best differentiated from non-converters on the basis of entorhinal, but not hippocampal volume. These data suggest that although both the EC and hippocampal formation degenerate before the onset of overt dementia, EC volume is a better predictor of conversion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>B C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goncharova</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Forchetti</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG09466</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(01)00271-8</ArticleId><ArticleId IdType="pii">S0197458001002718</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11706389</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9297</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>256</EndPage><MedlinePgn>251-6</MedlinePgn></Pagination><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an adult-onset degenerative disorder characterized by the death of motor neurons in the cortex, brain stem, and spinal cord. Despite intensive research the basic pathophysiology of ALS remains unclear. Although most cases are sporadic, approximately 10% of ALS cases are familial (FALS). Mutations in the Cu/Zn superoxide dismutase (SOD1) gene cause approximately 20% of FALS. The gene(s) responsible for the remaining 80% of FALS remain to be found. Using a large European kindred without SOD1 mutation and with classic autosomal dominant adult-onset ALS, we have identified a novel locus by performing a genome scan and linkage analysis. The maximum LOD score is 4.5 at recombination fraction 0.0, for polymorphism D18S39. Haplotype analysis has identified a 7.5-cM, 8-Mb region of chromosome 18q21, flanked by markers D18S846 and D18S1109, as a novel FALS locus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hand</LastName><ForeName>Collette K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Centre for Research in Neuroscience, McGill University and the Montr&#xe9;al General Hospital Research Institute, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoris</LastName><ForeName>Jawad</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Salachas</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gros-Louis</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Ana Am&#xe9;lia Sim&#xf5;es</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Mayeux-Portas</LastName><ForeName>Veronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>Carl G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Am J Hum Genet 2002 Oct;71(4):1007</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="Y">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002887" MajorTopicYN="N">Chromosomes, Human, Pair 18</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="N">Recombination, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2001</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2001</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11706389</ArticleId><ArticleId IdType="pmc">PMC384894</ArticleId><ArticleId IdType="doi">10.1086/337945</ArticleId><ArticleId IdType="pii">S0002-9297(07)61299-3</ArticleId></ArticleIdList><ReferenceList><Title>Electronic-Database Information</Title><Reference><Citation>Center for Medical Genetics, Marshfield Medical Research Foundation, http://research.marshfieldclinic.org/genetics/ (for genetic maps)</Citation></Reference><Reference><Citation>Cooperative Human Linkage Center, The, http://lpg.nci.nih.gov/CHLC/</Citation></Reference><Reference><Citation>Fondation Jean Dausset CEPH, www.cephb.fr</Citation></Reference><Reference><Citation>GenBank Overview, http://www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html (for TXNL gene [accession number NM_004786])</Citation></Reference><Reference><Citation>Genome Database, The, http://www.gdb.org</Citation></Reference><Reference><Citation>Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for ALS1 [MIM 105400], ALS2 [MIM 205100], ALS4 [MIM 602433], ALS5 [MIM 602099], ALS FTD [MIM 105550], and TXNL gene [MIM 603049])</Citation></Reference><Reference><Citation>UCSC Human Genome Project Working Draft, http://genome.ucsc.edu/</Citation></Reference></ReferenceList><ReferenceList><Reference><Citation>Al Chalabi A, Leigh PN (2000) Recent advances in amyotrophic lateral sclerosis. Curr Opin Neurol 13:397&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pubmed">10970056</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MA, Gusella JF (1984) Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines. In Vitro 20:856&#x2013;858</Citation><ArticleIdList><ArticleId IdType="pubmed">6519667</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Ferrante R, Klivenyi P, Klein AM, Shinobu LA, Epstin CJ, Beal MF (2000) Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Ann Neurol 47:447&#x2013;455</Citation><ArticleIdList><ArticleId IdType="pubmed">10762155</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Strittmatter WJ, Morgenlander JC (2000) Apolipoprotein E and neuromuscular disease: a critical review of the literature. Arch Neurol 57:1561&#x2013;1565</Citation><ArticleIdList><ArticleId IdType="pubmed">11074787</ArticleId></ArticleIdList></Reference><Reference><Citation>Boukaftane Y, Khoris J, Moulard B, Salachas F, Meininger V, Malafosse A, Camu W, Rouleau GA (1998) Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci 25:192&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pubmed">9706719</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH Jr (1995) Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 80:687&#x2013;692</Citation><ArticleIdList><ArticleId IdType="pubmed">7889564</ArticleId></ArticleIdList></Reference><Reference><Citation>Camu W, Khoris J, Moulard B, Salachas F, Briolotti V, Rouleau GA, Meininger V (1999) Genetics of familial ALS and consequences for diagnosis. French ALS Research Group. J Neurol Sci 165 Suppl 1:S21&#x2013;S26</Citation><ArticleIdList><ArticleId IdType="pubmed">10448977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chance PF, Rabin BA, Ryan SG, Ding Y, Scavina M, Crain B, Griffin JW, Cornblath DR (1998) Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 62:633&#x2013;640</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1376963</ArticleId><ArticleId IdType="pubmed">9497266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottingham RW Jr, Idury RM, Sch&#xe4;ffer AA (1993) Faster sequential genetic linkage computations. Am J Hum Genet 53:252&#x2013;263</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682239</ArticleId><ArticleId IdType="pubmed">8317490</ArticleId></ArticleIdList></Reference><Reference><Citation>de Belleroche J, Orrell R, King A (1995) Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments. J Med Genet 32:841&#x2013;847</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1051731</ArticleId><ArticleId IdType="pubmed">8592323</ArticleId></ArticleIdList></Reference><Reference><Citation>Flowers JM, Leigh PN, Davies AM, Ninkina NN, Buchman VL, Vaughan J, Wood NW, Powell JF (1999) Mutations in the gene encoding human persyn are not associated with amyotrophic lateral sclerosis or familial Parkinson's disease. Neurosci Lett 274:21&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">10530510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, Figlewicz DA, Kwiatkowski T, Hosler BA, Sagie T, Skaug J, Nasir J, Brown RH Jr, Scherer SW, Rouleau GA, Hayden MR, Ikeda JE (2001) A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29:166&#x2013;173</Citation><ArticleIdList><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118:707&#x2013;719</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward C, Colville S, Swingler RJ, Brock DJH (1999) Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 52:1899&#x2013;1901</Citation><ArticleIdList><ArticleId IdType="pubmed">10371543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hentati A, Bejaoui K, Pericak-Vance MA, Hentati F, Speer MC, Hung WY, Figlewicz DA, Haines J, Rimmler J, Ben Hamida C, Ben Hamida M, Brown RH Jr, Siddique T (1994) Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet 7:425&#x2013;428</Citation><ArticleIdList><ArticleId IdType="pubmed">7920663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hentati A, Ouahchi K, Pericak-Vance MA, Nijhawan D, Ahmed A, Yang Y, Rimmler J, Hung W-Y, Schlotter B, Ahmed A, Ben Hamida M, Hentati F, Siddique T (1998) Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics 2:55&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">9933301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosler BA, Siddique T, Sapp PC, Sailor W, Huang MC, Hossain A, Daube JR, Nance M, Fan C, Kaplan J, Hung W-Y, McKenna-Yasek D, Haines JL, Pericak-Vance MA, Horvitz HR, Brown RH Jr (2000) Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 284:1664&#x2013;1669</Citation><ArticleIdList><ArticleId IdType="pubmed">11015796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson AJ (1981) Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 104:217&#x2013;247</Citation><ArticleIdList><ArticleId IdType="pubmed">7016254</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien J-P, Couillard-Despr&#xe9;s S, Meier J (1998) Transgenic mice in the study of ALS: the role of neurofilaments. Brain Pathol 8:759&#x2013;769</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098559</ArticleId><ArticleId IdType="pubmed">9804382</ArticleId></ArticleIdList></Reference><Reference><Citation>King A, Houlden H, Hardy J, Lane R, Chancellor A, de Belleroche J (1993) Absence of linkage between chromosome 21 loci and familial amyotrophic lateral sclerosis. J Med Genet 30:318</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1016343</ArticleId><ArticleId IdType="pubmed">8487280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunst CB, Messer L, Gordon J, Haines J, Patterson D (2000) Genetic mapping of a mouse modifier gene that can prevent ALS onset. Genomics 70:181&#x2013;189</Citation><ArticleIdList><ArticleId IdType="pubmed">11112346</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11:376&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pubmed">7493016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AA, et al (1994) Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 44:1878&#x2013;1884</Citation><ArticleIdList><ArticleId IdType="pubmed">7936241</ArticleId></ArticleIdList></Reference><Reference><Citation>Melov S, Coskun P, Patel M, Tuinstra R, Cottrell B, Jun AS, Zastawny TH, Dizdaroglu M, Goodman SI, Huang T-T, Miziorko H, Epstein CJ, Wallace DC (1999) Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc Natl Acad Sci USA 96:846&#x2013;851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15313</ArticleId><ArticleId IdType="pubmed">9927656</ArticleId></ArticleIdList></Reference><Reference><Citation>Melov S, Schneide JA, Day BJ, Hinerfeld D, Coskun P, Mirra SS, Crapo JD, Wallace DC (1998) A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet 18:159&#x2013;163</Citation><ArticleIdList><ArticleId IdType="pubmed">9462746</ArticleId></ArticleIdList></Reference><Reference><Citation>Orrell RW, Habgood JJ, de Belleroche JS, Lane RJ (1997) The relationship of spinal muscular atrophy to motor neuron disease: investigation of SMN and NAIP gene deletions in sporadic and familial ALS. J Neurol Sci 145:55&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">9073029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott J (1989) Computer-simulation methods in human linkage analysis. Proc Natl Acad Sci USA 86:4175&#x2013;4178</Citation><ArticleIdList><ArticleId IdType="pmc">PMC287412</ArticleId><ArticleId IdType="pubmed">2726769</ArticleId></ArticleIdList></Reference><Reference><Citation>Parboosingh JS, Meininger V, McKenna-Yasek D, Brown RH Jr, Rouleau GA (1999) Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. Arch Neurol 56:710&#x2013;712</Citation><ArticleIdList><ArticleId IdType="pubmed">10369311</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin BA, Griffin JW, Crain B, Scavina M, Chance PF, Cornblath DR (1999) Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain 122:1539&#x2013;1550</Citation><ArticleIdList><ArticleId IdType="pubmed">10430837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddique T, Deng HX (1996) Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 5:1465&#x2013;1470</Citation><ArticleIdList><ArticleId IdType="pubmed">8875253</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddique T, Figlewicz DA, Pericak-Vance MA, Haines JL, Rouleau G, Jeffers AJ, Sapp P, Hung W-Y, Bebout J, McKenna-Yasek D, Deng G, Horvitz HR, Gusella JF, Brown RH Jr, Roses AD (1991) Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 324:1381&#x2013;1384</Citation><ArticleIdList><ArticleId IdType="pubmed">2020294</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddique T, Hong S, Brooks BR, Hung W-Y, Siddique NA, Rimmler J, Karplan JP, Haines JL, Brown RH Jr, Pericak-Vance MA (1998) X-linked dominant ALS. Paper presented at the annual meeting of the American Academy of Neurology, Minneapolis, April 27&#x2013;May 2</Citation></Reference><Reference><Citation>Smith RG, Appel SH (1995) Molecular approaches to amyotrophic lateral sclerosis. Annu Rev Med 46:133&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">7598450</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks DE, Ott J, Lathrop GM (1990) SLINK: a general simulation program for linkage analysis. Am J Hum Genet Suppl 47:A204</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11709151</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>08</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>401</EndPage><MedlinePgn>389-401</MedlinePgn></Pagination><Abstract><AbstractText>We tested the hypothesis that amyloid precursor protein (APP) and its relatives function as vesicular receptor proteins for kinesin-I. Deletion of the Drosophila APP-like gene (Appl) or overexpression of human APP695 or APPL constructs caused axonal transport phenotypes similar to kinesin and dynein mutants. Genetic reduction of kinesin-I expression enhanced while genetic reduction of dynein expression suppressed these phenotypes. Deletion of the C terminus of APP695 or APPL, including the kinesin binding region, disrupted axonal transport of APP695 and APPL and abolished the organelle accumulation phenotype. Neuronal apoptosis was induced only by overexpression of constructs containing both the C-terminal and Abeta regions of APP695. We discuss the possibility that axonal transport disruption may play a role in the neurodegenerative pathology of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gunawardena</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0683, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>L S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GM35252</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489697">APLP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11709151</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(01)00496-2</ArticleId><ArticleId IdType="pii">S0896-6273(01)00496-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11710888</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0098-7484</ISSN><JournalIssue CitedMedium="Print"><Volume>286</Volume><Issue>18</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Complete genomic screen in Parkinson disease: evidence for multiple genes.</ArticleTitle><Pagination><StartPage>2239</StartPage><EndPage>2244</EndPage><MedlinePgn>2239-44</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The relative contribution of genes vs environment in idiopathic Parkinson disease (PD) is controversial. Although genetic studies have identified 2 genes in which mutations cause rare single-gene variants of PD and observational studies have suggested a genetic component, twin studies have suggested that little genetic contribution exists in the common forms of PD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify genetic risk factors for idiopathic PD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Genetic linkage study conducted 1995-2000 in which a complete genomic screen (n = 344 markers) was performed in 174 families with multiple individuals diagnosed as having idiopathic PD, identified through probands in 13 clinic populations in the continental United States and Australia. A total of 870 family members were studied: 378 diagnosed as having PD, 379 unaffected by PD, and 113 with unclear status.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Logarithm of odds (lod) scores generated from parametric and nonparametric genetic linkage analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two-point parametric maximum parametric lod score (MLOD) and multipoint nonparametric lod score (LOD) linkage analysis detected significant evidence for linkage to 5 distinct chromosomal regions: chromosome 6 in the parkin gene (MLOD = 5.07; LOD = 5.47) in families with at least 1 individual with PD onset at younger than 40 years, chromosomes 17q (MLOD = 2.28; LOD = 2.62), 8p (MLOD = 2.01; LOD = 2.22), and 5q (MLOD = 2.39; LOD = 1.50) overall and in families with late-onset PD, and chromosome 9q (MLOD = 1.52; LOD = 2.59) in families with both levodopa-responsive and levodopa-nonresponsive patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data suggest that the parkin gene is important in early-onset PD and that multiple genetic factors may be important in the development of idiopathic late-onset PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>W K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Center for Human Genetics, Box 3445, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nance</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Hubble</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>W C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>M B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Colcher</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hiner</LastName><ForeName>B C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ondo</LastName><ForeName>W G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>F H</ForeName><Initials>FH</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>C G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Masterman</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mastaglia</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Laing</LastName><ForeName>N G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Stajich</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Slotterbeck</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Booze</LastName><ForeName>M W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Ribble</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Rampersaud</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>L T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Roses</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS26630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS39764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 6.-</RegistryNumber><NameOfSubstance UI="D008025">Ligases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002886" MajorTopicYN="N">Chromosomes, Human, Pair 17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002893" MajorTopicYN="N">Chromosomes, Human, Pair 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002895" MajorTopicYN="N">Chromosomes, Human, Pair 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002896" MajorTopicYN="N">Chromosomes, Human, Pair 6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002898" MajorTopicYN="N">Chromosomes, Human, Pair 8</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002899" MajorTopicYN="N">Chromosomes, Human, Pair 9</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008025" MajorTopicYN="N">Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="Y">Ubiquitin-Protein Ligases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11710888</ArticleId><ArticleId IdType="doi">10.1001/jama.286.18.2239</ArticleId><ArticleId IdType="pii">joc10904</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11715026</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>11</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts.</ArticleTitle><Pagination><StartPage>1030</StartPage><EndPage>1033</EndPage><MedlinePgn>1030-3</MedlinePgn></Pagination><Abstract><AbstractText>Genetic and biochemical evidence have led to the suggestion that presenilins could be the long-searched-for gamma-secretase, the proteolytic activity that generates the carboxy terminus of amyloid beta-peptides. This activity is also thought to be responsible for the release of the Notch intracellular domain (NICD) from Notch. Here, we report the production of endogenous secreted and intracellular 40- and 42-amino-acid Abeta peptides in mouse fibroblasts deficient in presenilin 1, presenilin 2 or both. We show that the endogenous production of Abeta40 and Abeta42 was not altered by presenilin deficiency. By contrast, inactivating presenilin genes fully abolished NICD production. These data indicate that Abeta and NICD production are distinct catabolic events. Also, even though NICD formation is indeed presenilin dependent, endogenous secreted and intracellular beta-amyloid peptides are still generated in absence of presenilins, indicating that there is a gamma-secretase activity distinct from presenilins, at least in murine fibroblasts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Armogida</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut de pharmacologie mol&#xe9;culaire et cellulaire, UMR6097 du CNRS, 660 route des Lucioles, 06560 Valbonne, France. checler@ipmc.cnrs.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petit</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Scarzello</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>da Costa</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Checler</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2002 Jul;4(7):E164-5; author reply E165-6. doi: 10.1038/ncb0702-e164b.</RefSource><PMID Version="1">12105422</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2002 Jul;4(7):E164; author reply E165-6. doi: 10.1038/ncb0702-e164a.</RefSource><PMID Version="1">12105423</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11715026</ArticleId><ArticleId IdType="doi">10.1038/ncb1101-1030</ArticleId><ArticleId IdType="pii">ncb1101-1030</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11724784</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>277</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP).</ArticleTitle><Pagination><StartPage>3767</StartPage><EndPage>3775</EndPage><MedlinePgn>3767-75</MedlinePgn></Pagination><Abstract><AbstractText>The familial Alzheimer's disease gene product amyloid beta precursor protein (APP) is sequentially processed by beta- and gamma-secretases to generate the Abeta peptide. The biochemical pathway leading to Abeta formation has been extensively studied since extracellular aggregates of Abeta peptides are considered the culprit of Alzheimer's disease. Aside from its pathological relevance, the biological role of APP processing is unknown. Cleavage of APP by gamma-secretase releases, together with Abeta, a COOH-terminal APP intracellular domain, termed AID. This peptide has recently been identified in brain tissue of normal control and patients with sporadic Alzheimer's disease. We have previously shown that AID acts as a positive regulator of apoptosis. Nevertheless, the molecular mechanism by which AID regulates this process remains unknown. Hoping to gain clues about the function of APP, we used the yeast two-hybrid system to identify interaction between the AID region of APP and JNK-interacting protein-1 (JIP1). This molecular interaction is confirmed in vitro, in vivo by fluorescence resonance energy transfer (FRET), and in mouse brain lysates. These data provide a link between APP and its processing by gamma-secretase, and stress kinase signaling pathways. These pathways are known regulators of apoptosis and may be involved in the pathogenesis of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheinfeld</LastName><ForeName>Meir H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Department of Microbiology &amp; Immunology, Bronx, New York 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roncarati</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Vito</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Abdallah</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>D'Adamio</LastName><ForeName>Luciano</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32GM07288</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490666">MAPK8IP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490665">Mapk8ip protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="Y">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11724784</ArticleId><ArticleId IdType="doi">10.1074/jbc.M108357200</ArticleId><ArticleId IdType="pii">S0021-9258(20)87672-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11726200</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-291X</ISSN><JournalIssue CitedMedium="Print"><Volume>289</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>Wild-type and mutated nicastrins do not display aminopeptidase M- and B-like activities.</ArticleTitle><Pagination><StartPage>678</StartPage><EndPage>680</EndPage><MedlinePgn>678-80</MedlinePgn></Pagination><Abstract><AbstractText>Nicastrin is a recently discovered protein interacting with presenilins and the beta-amyloid precursor protein, the proteins playing key roles in Alzheimer's disease and which, when mutated, appear responsible for early-onset familial forms of Alzheimer's disease. Nicastrin was reported to modulate beta-amyloid production, a phenotype affected differently by missense mutations or deletions of a conserved hydrophilic domain. In addition to such a function, nicastrin was recently suggested to possess putative catalytic activity based on its sequence homology with enzymes of the aminopeptidase family. We set up stably transfected human HEK293 cells expressing either wild-type or mutated nicastrins and we show that these proteins do not exhibit aminopeptidase M- and B-like activities.</AbstractText><CopyrightInformation>(c) 2001 Elsevier Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fergani</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IPMC du CNRS, UMR6097, 660 route des Lucioles, 06560 Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Checler</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.11.-</RegistryNumber><NameOfSubstance UI="D000626">Aminopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.11.2</RegistryNumber><NameOfSubstance UI="D018826">CD13 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.11.6</RegistryNumber><NameOfSubstance UI="C019721">aminopeptidase B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000626" MajorTopicYN="N">Aminopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018826" MajorTopicYN="N">CD13 Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11726200</ArticleId><ArticleId IdType="doi">10.1006/bbrc.2001.6030</ArticleId><ArticleId IdType="pii">S0006291X01960309</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11726544</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>14</Issue><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death.</ArticleTitle><Pagination><StartPage>2680</StartPage><EndPage>2688</EndPage><MedlinePgn>2680-8</MedlinePgn></Pagination><Abstract><AbstractText>Ubiquitin-B+1 (UBB+1) is a mutant ubiquitin that accumulates in the neurones of patients with Alzheimer's disease (AD). Here we report on the biochemical and functional differences between ubiquitin and UBB+1 and the effect of the mutant protein on neuronal cells. UBB+1 lacks the capacity to ubiquitinate, and although it is ubiquitinated itself, UBB+1 is not degraded by the ubiquitin-proteasomal system and is quite stable in neuronal cells. Overexpression of UBB+1 in neuroblastoma cells significantly induces nuclear fragmentation and cell death. Our results demonstrate that accumulation of UBB+1 in neurones is detrimental and may contribute to neuronal dysfunction in AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Vrij</LastName><ForeName>F M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Graduate School for Neurosciences Amsterdam, Netherlands Institute for Brain Research, Research Group Molecular Misreading, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sluijs</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Gregori</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>D F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Hermens</LastName><ForeName>W T</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Goldgaber</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Verhaagen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Van Leeuwen</LastName><ForeName>F W</ForeName><Initials>FW</Initials></Author><Author ValidYN="Y"><LastName>Hol</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009097">Multienzyme Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007763" MajorTopicYN="N">Lac Operon</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009097" MajorTopicYN="N">Multienzyme Complexes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>16</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11726544</ArticleId><ArticleId IdType="doi">10.1096/fj.01-0438com</ArticleId><ArticleId IdType="pii">15/14/2680</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11732920</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-2960</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>49</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>11</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide.</ArticleTitle><Pagination><StartPage>14995</StartPage><EndPage>15001</EndPage><MedlinePgn>14995-5001</MedlinePgn></Pagination><Abstract><AbstractText>Inheritance of apoE4 is a strong risk factor for the development of late-onset sporadic Alzheimer's disease (AD). Several lines of evidence suggest that apoE4 binds to the Alzheimer Abeta protein and, under certain experimental conditions, promotes formation of beta-sheet structures and amyloid fibrils. Deposition of amyloid fibrils is a critical step in the development of AD. We report here that addition of melatonin to Abeta in the presence of apoE resulted in a potent isoform-specific inhibition of fibril formation, the extent of which was far greater than that of the inhibition produced by melatonin alone. This effect was structure-dependent and unrelated to the antioxidant properties of melatonin, since it could be reproduced neither with the structurally related indole N-acetyl-5-hydroxytryptamine nor with the antioxidants ascorbate, alpha-tocophenol, and PBN. The enhanced inhibitory effects of melatonin and apoE were lost when bovine serum albumin was substituted for apoE. In addition, Abeta in combination with apoE was highly neurotoxic (apoE4 &gt; apoE3) to neuronal cells in culture, and this activity was also prevented by melatonin. These findings suggest that reductions in brain melatonin, which occur during aging, may contribute to a proamyloidogenic microenvironment in the aging brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poeggeler</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of South Alabama, Mobile, Alabama 36688, New York University, New York, New York 10003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miravalle</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zagorski</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chyan</LastName><ForeName>Y J</ForeName><Initials>YJ</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bryant-Thomas</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Frangione</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ghiso</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pappolla</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 15408</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 16783</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 38777</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>6</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>6</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11732920</ArticleId><ArticleId IdType="doi">10.1021/bi0114269</ArticleId><ArticleId IdType="pii">bi0114269</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11738035</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces.</ArticleTitle><Pagination><StartPage>911</StartPage><EndPage>926</EndPage><MedlinePgn>911-26</MedlinePgn></Pagination><Abstract><AbstractText>To examine the in vivo function of presenilin-1 (PS1), we selectively deleted the PS1 gene in excitatory neurons of the adult mouse forebrain. These conditional knockout mice were viable and grew normally, but they exhibited a pronounced deficiency in enrichment-induced neurogenesis in the dentate gyrus. This reduction in neurogenesis did not result in appreciable learning deficits, indicating that addition of new neurons is not required for memory formation. However, our postlearning enrichment experiments lead us to postulate that adult dentate neurogenesis may play a role in the periodic clearance of outdated hippocampal memory traces after cortical memory consolidation, thereby ensuring that the hippocampus is continuously available to process new memories. A chronic, abnormal clearance process in the hippocampus may conceivably lead to memory disorders in the mammalian brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rampon</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Y P</ForeName><Initials>YP</Initials></Author><Author ValidYN="Y"><LastName>Shrom</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kyin</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sopher</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>M W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Ware</LastName><ForeName>C B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Langdon</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Tsien</LastName><ForeName>J Z</ForeName><Initials>JZ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078201">Aplp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron 2002 Jan 17;33(2):313</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2001 Dec 6;32(5):763-5. doi: 10.1016/s0896-6273(01)00525-6.</RefSource><PMID Version="1">11738022</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(01)00523-2</ArticleId><ArticleId IdType="pii">S0896-6273(01)00523-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11740561</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>414</Volume><Issue>6864</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP.</ArticleTitle><Pagination><StartPage>643</StartPage><EndPage>648</EndPage><MedlinePgn>643-8</MedlinePgn></Pagination><Abstract><AbstractText>Proteolytic processing of amyloid precursor protein (APP) generates amyloid-beta peptide and has been implicated in the pathogenesis of Alzheimer's disease. However, the normal function of APP, whether this function is related to the proteolytic processing of APP, and where this processing takes place in neurons in vivo remain unknown. We have previously shown that the axonal transport of APP in neurons is mediated by the direct binding of APP to the kinesin light chain subunit of kinesin-I, a microtubule motor protein. Here we identify an axonal membrane compartment that contains APP, beta-secretase and presenilin-1. The fast anterograde axonal transport of this compartment is mediated by APP and kinesin-I. Proteolytic processing of APP can occur in the compartment in vitro and in vivo in axons. This proteolysis generates amyloid-beta and a carboxy-terminal fragment of APP, and liberates kinesin-I from the membrane. These results suggest that APP functions as a kinesin-I membrane receptor, mediating the axonal transport of beta-secretase and presenilin-1, and that processing of APP to amyloid-beta by secretases can occur in an axonal membrane compartment transported by kinesin-I.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamal</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute and Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093-0683, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almenar-Queralt</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>LeBlanc</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>L S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002451" MajorTopicYN="N">Cell Compartmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId><ArticleId IdType="doi">10.1038/414643a</ArticleId><ArticleId IdType="pii">414643a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11755003</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures.</ArticleTitle><Pagination><StartPage>945</StartPage><EndPage>956</EndPage><MedlinePgn>945-56</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a uniquely human disorder. Despite intense research, the lack of availability of model systems has hindered AD studies though in recent years transgenic mouse models have been produced, which develop AD-like amyloid beta peptide (Abeta) plaques. For the study of inflammatory changes in AD brains, these transgenic mice may have limitations due to differences in the innate immune system of humans and rodents. Many studies of inflammatory processes in AD have focused on the role of activated microglia. Over the last 8 years, our research has focused on the properties of human microglia cultured from brain tissues of AD and non-demented (ND) individuals. As these are the cells observed to be activated in AD tissues, they represent a useful system for modeling the inflammatory components of AD. In this review, we summarize data by our group and others on the use of microglia for AD-related inflammatory research, with emphasis on results using human postmortem brain microglia. A range of products have been shown to be produced by human postmortem microglia, both constitutively and in response to treatment with Abeta, including proinflammatory cytokines such as interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF) alpha, and macrophage colony stimulating factor (M-CSF), along with complement proteins, especially C1q, superoxide radicals and neurotoxic factors. In our studies, we have demonstrated that there was a significant difference between AD and ND microglia in terms of their secretion of M-CSF and C1q. We also discuss the role of putative Abeta microglial receptors, particular recent data showing a role for the receptor for advanced glycation endproducts (RAGE) in mediating the responses of human microglia to Abeta. Finally, our studies on the use of an Abeta spot paradigm to model microglia interactions with plaques demonstrated that many of the features of AD inflammation can be modeled with postmortem brain derived microglia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>L F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>L. J. Roberts Alzheimer's Center, Sun Health Research Institute, 10515 W. Santa Fe Dr., Sun City, AZ 85351, USA. lihfen.lue@sunhealth.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>123</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11755003</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(01)00311-6</ArticleId><ArticleId IdType="pii">S0197458001003116</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11756496</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau.</ArticleTitle><Pagination><StartPage>133</StartPage><EndPage>141</EndPage><MedlinePgn>133-41</MedlinePgn></Pagination><Abstract><AbstractText>Formation of neurofibrillary tangles (NFTs) is a common neuropathological feature found in several neurodegenerative diseases, including Alzheimer's disease. We have developed a transgenic (Tg) mouse expressing mutant human tau (V337M), derived from frontotemporal dementia parkinsonism-17. V337M Tg mice revealed tau aggregations in the hippocampus, which fulfills the histological criteria for NFTs in human neurodegenerative diseases. Concurrent with the accumulation of RNA and phosphorylated tau, neurons exhibited morphological characteristics of degenerating neurons, which include a loss of microtubules, accumulation of ribosomes, plasma and nuclear membrane ruffling, and swelling of the Golgi network. Thus, mutant tau induces neuronal degeneration associated with the accumulation of RNA and phosphorylated tau. The functional consequences of this neuronal degeneration was evidenced by the reduction of hippocampal neural activity and behavioral abnormality in Tg mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanemura</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Alzheimer's Disease, The Institute of Physical and Chemical Research (RIKEN), 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Miyuki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Akagi</LastName><ForeName>Takumi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hashikawa</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tominaga</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Michinori</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Haruyasu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>368GB5141J</RegistryNumber><NameOfSubstance UI="D012967">Sodium Dodecyl Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3U05FHG59S</RegistryNumber><NameOfSubstance UI="D003224">Congo Red</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003224" MajorTopicYN="N">Congo Red</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012967" MajorTopicYN="N">Sodium Dodecyl Sulfate</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11756496</ArticleId><ArticleId IdType="pmc">PMC6757582</ArticleId><ArticleId IdType="pii">22/1/133</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-01-00133.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barghorn S, Zheng-Fischhofer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow E, Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39:11714&#x2013;11720.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan JB, Nagle BW, Doenges KH. Inhibition of tubulin assembly by RNA and other polyanions: evidence for a required protein. Proc Natl Acad Sci USA. 1975;72:3570&#x2013;3574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC433037</ArticleId><ArticleId IdType="pubmed">1059144</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, Li D, Payami H, Awert F, Markopoulou K, Andreadis A, D'Souza I, Lee VM, Reed L, Trojanowski JQ, Zhukareva V, Bird T, Schellenberg G, Wilhelmsen KC. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA. 1998;95:13103&#x2013;13107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23724</ArticleId><ArticleId IdType="pubmed">9789048</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande J, Bergstedt K, Linden T, Kalimo H, Wieloch T. Ultrastructural changes in the hippocampal CA1 region following transient cerebral ischemia: evidence against programmed cell death. Exp Brain Res. 1992;88:91&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">1371756</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, Bird TD, Schellenberg GD. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA. 1999;96:5598&#x2013;5603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21906</ArticleId><ArticleId IdType="pubmed">10318930</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P, von Bergen M, Mandelkow EM, Davies P, Mandelkow E. A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc Natl Acad Sci USA. 1998;95:15712&#x2013;15717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28109</ArticleId><ArticleId IdType="pubmed">9861035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Crino PB, Lee VM, Eberwine JH, Trojanowski JQ. Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Ann Neurol. 1997;41:200&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029069</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996;383:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias. Neuron. 1998;21:955&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001;276:529&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">11013246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayer PE, Lyon H, Jakobsen P, Andersen PE. Standardized methyl green-pyronin Y procedures using pure dyes. Histochem J. 1986;2&#x2013;3:90&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2426223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM-Y. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914&#x2013;19147.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y. Massive somatodendritic sprouting of cortical neurons in Alzheimer's disease. Brain Res. 1988;459:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">3139259</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima M, Tabira T, Poorkaj P, Schellenberg GD, Trojanowski JQ, Lee VM, Schmidt ML, Takahashi K, Nabika T, Matsumoto T, Yamashita Y, Yoshioka S, Ishino H. A distinct familial presenile dementia with a novel missense mutation in the tau gene. NeuroReport. 1999;10:497&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">10208578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996;399:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Trojanowski JQ. Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron. 1999;24:507&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegenhorst M, Gwinn-Hardy K, Murphy MP, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin W-L, Yen S-H, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Littauer UZ, Giveon D, Thierauf M, Ginzburg I, Ponstingl H. Common and distinct tubulin binding sites for microtubule-associated proteins. Proc Natl Acad Sci USA. 1986;83:7162&#x2013;7166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC386675</ArticleId><ArticleId IdType="pubmed">3463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Loew LM, Cohen LB, Dix J, Fluhler EN, Montana V, Salama G, Wu JY. A naphthyl analog of the aminostyryl pyridinium class of potentiometric membrane dyes shows consistent sensitivity in a variety of tissue, cell, and model membrane preparations. J Membr Biol. 1992;130:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">1469705</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel G, Mercken M, Murayama M, Noguchi K, Ishiguro K, Imahori K, Takashima A. Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells. Biochim Biophys Acta. 1998;1380:177&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9565682</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998;21:428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">9786340</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA. 1998;95:7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu N, Mercken M, Yamaguchi H, Sugihara S, Wolozin B. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci USA. 1998;95:9637&#x2013;9641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21391</ArticleId><ArticleId IdType="pubmed">9689133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tominaga T, Tominaga Y, Yamada H, Matsumoto G, Ichikawa M. Quantification of optical signals with electrophysiological signals in neural activities of Di-4-ANEPPS stained rat hippocampal slices. J Neurosci Methods. 2000;102:11&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11000407</ArticleId></ArticleIdList></Reference><Reference><Citation>Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA. 2000;97:8093&#x2013;8097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16675</ArticleId><ArticleId IdType="pubmed">10869421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin BL, Pruchnicki A, Dickson DW, Davies P. A neuronal antigen in the brains of Alzheimer patients. Science. 1986;232:648&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">3083509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen SH, Hutton M, DeTure M, Ko LW, Nacharaju P. Fibrillogenesis of tau: insights from tau missense mutations in FTDP-17. Brain Pathol. 1999;9:695&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098577</ArticleId><ArticleId IdType="pubmed">10517508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11756667</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Functional MRI detection of pharmacologically induced memory impairment.</ArticleTitle><Pagination><StartPage>455</StartPage><EndPage>460</EndPage><MedlinePgn>455-60</MedlinePgn></Pagination><Abstract><AbstractText>To examine alterations in brain activation associated with pharmacologically induced memory impairment, we used functional MRI (fMRI) to study the effects of lorazepam and scopolamine on a face-name associative encoding paradigm. Ten healthy young subjects were scanned on four occasions, 2 weeks apart; they were administered i.v. saline during two placebo-scanning sessions and then alternately administered i.v. lorazepam (1 mg) or scopolamine (0.4 mg) in a double-blind, randomized, cross-over design. Both the extent and magnitude of activation within anatomic regions of interest (ROIs) were examined to determine the reproducibility of activation in the placebo sessions and the regional specificity of the pharmacologic effects. Activation within all ROIs was consistent across the two placebo scans during the encoding of novel face-name pairs (compared with visual fixation). With the administration of either lorazepam or scopolamine, significant decreases were observed in both the extent and magnitude of activation within the hippocampal, fusiform, and inferior prefrontal ROIs, but no significant alterations in activation in the striate cortex were found. Both medications impaired performance on postscan memory measures, and significant correlations between memory performance and extent of activation were found in hippocampal and fusiform ROIs. These findings suggest that pharmacologic effects can be detected with fMRI by using a reproducible experimental paradigm and that medications that impair memory also diminish activation in specific brain regions thought to subserve complex memory processes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA 02129, USA. reisa@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greve</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>H Diana</ForeName><Initials>HD</Initials></Author><Author ValidYN="Y"><LastName>Cocchiarella</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Firth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lake</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Routledge</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS002189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG004953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-NS02189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG04953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>DL48G20X8X</RegistryNumber><NameOfSubstance UI="D012601">Scopolamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O26FZP769L</RegistryNumber><NameOfSubstance UI="D008140">Lorazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="Y">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008140" MajorTopicYN="N">Lorazepam</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012601" MajorTopicYN="N">Scopolamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="N">Visual Cortex</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>16</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11756667</ArticleId><ArticleId IdType="pmc">PMC117581</ArticleId><ArticleId IdType="doi">10.1073/pnas.012467899</ArticleId><ArticleId IdType="pii">012467899</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bunsey M, Eichenbaum H. Behav Neurosci. 1993;107:740&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">8280384</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood E R, Dudchenko P A, Eichenbaum H. Nature (London) 1999;397:613&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">10050854</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki W A, Eichenbaum H. Ann NY Acad Sci. 2000;911:175&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">10911874</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire L R. Psychol Rev. 1992;99:195&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1594723</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacter D L, Church B. J Int Neuropsychol Soc. 1995;1:434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9375229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalfonte B L, Verfaellie M, Johnson M K, Reiss L. Memory. 1996;4:591&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">8934456</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke K, Buck A, Weber B, Wieser H G. Hippocampus. 1997;7:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9228523</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacter D L, Wagner A D. Hippocampus. 1999;9:7&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088896</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R A, Bates J F, Cocchiarella A J, Schacter D L, Rosen B R, Albert M S. Hum Brain Mapp. 2001;14:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871827</ArticleId><ArticleId IdType="pubmed">11559958</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardman J G, Limbird L E, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw&#x2013;Hill; 1996. pp. 149&#x2013;150.</Citation></Reference><Reference><Citation>Hasselmo M E, Wyble B P, Wallenstein G V. Hippocampus. 1996;6:693&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">9034856</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T W, Semple J, Kumar R, Truman M I, Shorter J, Ferraro A, Fox B, McKay G, Matthews K. Psychopharmacology. 1997;134:95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9399372</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran H V, Pooviboonsuk P, Dalton J A, Lader M H. Psychopharmacology (Berlin) 1998;135:27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9489931</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop K I, Curran H V. Psychopharmacology (Berlin) 1998;140:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">9877014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagemans J, Notebaert W, Boucart M. Psychopharmacology (Berlin) 1998;138:326&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">9725755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoneim M M, Mewaldt S P. Psychopharmacologia. 1975;44:257&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">1208760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoneim M M, Mewaldt S P. Psychopharmacology (Berlin) 1977;52:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">403551</ArticleId></ArticleIdList></Reference><Reference><Citation>Molchan S E, Matochik J A, Zametkin A J, Szymanski H V, Cantillon M, Cohen R M, Sunderland T. Neuropsychopharmacology. 1994;10:191&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosier A M, Cornette L, Dupont P, Bormans G, Mortelmans L, Orban G A. Eur J Neurosci. 1999;11:3701&#x2013;3714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10564377</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasby P M, Frith C D, Paulesu E, Friston K J, Frackowiak R S, Dolan R J. Exp Brain Res. 1995;104:337&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">7672026</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel C M, Henson R N, Morris J S, Friston K J, Dolan R J. J Neurosci. 2001;21:6846&#x2013;6852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763113</ArticleId><ArticleId IdType="pubmed">11517272</ArticleId></ArticleIdList></Reference><Reference><Citation>Machielsen W C, Rombouts S A, Barkhof F, Scheltens P, Witter M P. Hum Brain Mapp. 2000;9:156&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871840</ArticleId><ArticleId IdType="pubmed">10739366</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonigle D J, Howseman A M, Athwal B S, Friston K J, Frackowiak R S, Holmes A P. NeuroImage. 2000;11:708&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860798</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins D L, Neelin P, Peters T M, Evans A C. J Comput Assist Tomogr. 1994;18:192&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126267</ArticleId></ArticleIdList></Reference><Reference><Citation>Burock M A, Dale A M. Hum Brain Mapp. 2000;11:249&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6872094</ArticleId><ArticleId IdType="pubmed">11144754</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany R J, Moss M B, Albert M S, Sandor T, Tieman J, Jolesz F. Arch Neurol. 1993;50:949&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">8363449</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany R J, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman B T, Albert M S. Ann Neurol. 2000;47:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange N, Laird N M. J Am Stat Assoc. 1989;84:241&#x2013;247.</Citation></Reference><Reference><Citation>Laird N M, Ware J H. Biometrics. 1982;38:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange N, Ryan L. Ann Stat. 1989;17:624&#x2013;642.</Citation></Reference><Reference><Citation>Pinheiro J C, Bates D M. Mixed-Effects Models in S and S-PLUS. New York: Springer; 2000.</Citation></Reference><Reference><Citation>Wang G J, Volkow N D, Levy A V, Felder C A, Fowler J S, Pappas N R, Hitzemann R J, Wong C T. J Nucl Med. 1999;40:715&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319741</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosier A, Cornette L, Dupont P, Bormans G, Michiels J, Mortelmans L, Orban G A. Proc Natl Acad Sci USA. 1997;94:7627&#x2013;7632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23873</ArticleId><ArticleId IdType="pubmed">9207143</ArticleId></ArticleIdList></Reference><Reference><Citation>Furey M L, Pietrini P, Haxby J V. Science. 2000;290:2315&#x2013;2319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125148</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11780111</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>415</Volume><Issue>6867</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>p53 mutant mice that display early ageing-associated phenotypes.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>53</EndPage><MedlinePgn>45-53</MedlinePgn></Pagination><Abstract><AbstractText>The p53 tumour suppressor is activated by numerous stressors to induce apoptosis, cell cycle arrest, or senescence. To study the biological effects of altered p53 function, we generated mice with a deletion mutation in the first six exons of the p53 gene that express a truncated RNA capable of encoding a carboxy-terminal p53 fragment. This mutation confers phenotypes consistent with activated p53 rather than inactivated p53. Mutant (p53+/m) mice exhibit enhanced resistance to spontaneous tumours compared with wild-type (p53+/+) littermates. As p53+/m mice age, they display an early onset of phenotypes associated with ageing. These include reduced longevity, osteoporosis, generalized organ atrophy and a diminished stress tolerance. A second line of transgenic mice containing a temperature-sensitive mutant allele of p53 also exhibits early ageing phenotypes. These data suggest that p53 has a role in regulating organismal ageing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tyner</LastName><ForeName>Stuart D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Cell and Molecular Biology Program, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatachalam</LastName><ForeName>Sundaresan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jene</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ghebranious</LastName><ForeName>Nader</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Igelmann</LastName><ForeName>Herbert</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Xiongbin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Soron</LastName><ForeName>Gabrielle</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Brayton</LastName><ForeName>Cory</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang Hee</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Karsenty</LastName><ForeName>Gerard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Donehower</LastName><ForeName>Lawrence A</ForeName><Initials>LA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 Jan 3;415(6867):26-7. doi: 10.1038/415026a.</RefSource><PMID Version="1">11780097</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019588" MajorTopicYN="N">Aging, Premature</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016158" MajorTopicYN="N">Genes, p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006197" MajorTopicYN="N">Hair</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>30</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11780111</ArticleId><ArticleId IdType="doi">10.1038/415045a</ArticleId><ArticleId IdType="pii">415045a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11784794</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6.</ArticleTitle><Pagination><StartPage>486</StartPage><EndPage>492</EndPage><MedlinePgn>486-92</MedlinePgn></Pagination><Abstract><AbstractText>Postnatal neurogenesis can be modulated after brain injury, but the role of the attendant expression of inflammatory mediators in such responses remains to be determined. Here we report that transgenically directed production of interleukin-6 (IL-6) by astroglia decreased overall neurogenesis by 63% in the hippocampal dentate gyrus of young adult transgenic mice. The proliferation, survival, and differentiation of neural progenitor cells labeled with the thymidine analog bromodeoxyuridine were all reduced in the granule cell layer of these mice, whereas their distribution and gliogenesis appeared normal. These effects were not a consequence of general toxicity of the IL-6 transgene, because they were manifested in the absence of neuronal death and of major changes in glial cell number and morphology. These findings suggest that long-term exposure of the brain to proinflammatory mediators such as IL-6, as is seen in certain degenerative disorders and infections, can interfere with adult neurogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valli&#xe8;res</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratories of Neuronal Structure and Function, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Iain L</ForeName><Initials>IL</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author><Author ValidYN="Y"><LastName>Sawchenko</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS21182</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AGO6088</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AGO5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS021182</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH50426</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS021182</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005452">Fluoresceins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009930">Organic Chemicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C435731">fluoro jade</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005452" MajorTopicYN="N">Fluoresceins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="Y">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009930" MajorTopicYN="N">Organic Chemicals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>31</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11784794</ArticleId><ArticleId IdType="pmc">PMC6758670</ArticleId><ArticleId IdType="pii">22/2/486</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-02-00486.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec. 1946;94:239&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">21015608</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, Oksenberg JR. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol. 2000;165:6576&#x2013;6582.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengzon J, Kokaia Z, Elmer E, Nanobashvili A, Kokaia M, Lindvall O. Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures. Proc Natl Acad Sci USA. 1997;94:10432&#x2013;10437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23380</ArticleId><ArticleId IdType="pubmed">9294228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonni A, Sun Y, Nadal-Vicens M, Bhatt A, Frank DA, Rozovsky I, Stahl N, Yancopoulos GD, Greenberg ME. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science. 1997;278:477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334309</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochu S, Olivier M, Rivest S. Neuronal activity and transcription of proinflammatory cytokines, IkappaBalpha, and iNOS in the mouse brain during acute endotoxemia and chronic infection with Trypanosoma brucei brucei. J Neurosci Res. 1999;57:801&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">10467251</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron HA, Gould E. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience. 1994;61:203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron HA, Woolley CS, McEwen BS, Gould E. Differentiation of newly born neurons and glia in the dentate gyrus of the adult rat. Neuroscience. 1993;56:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247264</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA. 1993;90:10061&#x2013;10065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47713</ArticleId><ArticleId IdType="pubmed">7694279</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CS, Stalder A, Samimi A, Campbell IL. Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev Neurosci. 1994;16:212&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">7535683</ArticleId></ArticleIdList></Reference><Reference><Citation>Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999;97:703&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">10380923</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA. 1997;94:4080&#x2013;4085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20571</ArticleId><ArticleId IdType="pubmed">9108108</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisch AJ, Barrot M, Schad CA, Self DW, Nestler EJ. Opiates inhibit neurogenesis in the adult rat hippocampus. Proc Natl Acad Sci USA. 2000;97:7579&#x2013;7584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16588</ArticleId><ArticleId IdType="pubmed">10840056</ArticleId></ArticleIdList></Reference><Reference><Citation>Fee D, Grzybicki D, Dobbs M, Ihyer S, Clotfelter J, Macvilay S, Hart MN, Sandor M, Fabry Z. Interleukin 6 promotes vasculogenesis of murine brain microvessel endothelial cells. Cytokine. 2000;12:655&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">10843741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage FH, Coates PW, Palmer TD, Kuhn HG, Fisher LJ, Suhonen JO, Peterson DA, Suhr ST, Ray J. Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain. Proc Natl Acad Sci USA. 1995;92:11879&#x2013;11883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40506</ArticleId><ArticleId IdType="pubmed">8524867</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli R, Pagano SF, Gritti A, Vescovi AL. Regulation of neuronal differentiation in human CNS stem cell progeny by leukemia inhibitory factor. Dev Neurosci. 2000;22:86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">10657701</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Tanapat P. Lesion-induced proliferation of neuronal progenitors in the dentate gyrus of the adult rat. Neuroscience. 1997;80:427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">9284346</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Cameron HA, Daniels DC, Woolley CS, McEwen BS. Adrenal hormones suppress cell division in the adult rat dentate gyrus. J Neurosci. 1992;12:3642&#x2013;3650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575731</ArticleId><ArticleId IdType="pubmed">1527603</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci. 1997;17:2492&#x2013;2498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573503</ArticleId><ArticleId IdType="pubmed">9065509</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ. Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci. 1999;2:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray WP, Sundstrom LE. Kainic acid increases the proliferation of granule cell progenitors in the dentate gyrus of the adult rat. Brain Res. 1998;790:52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">9593820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross CG. Neurogenesis in the adult brain: death of a dogma. Nat Rev Neurosci. 2000;1:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252770</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA. 1997;94:1500&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19820</ArticleId><ArticleId IdType="pubmed">9037082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. 1998;57:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalman M, Hajos F. Distribution of glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes in the rat brain. I. Forebrain. Exp Brain Res. 1989;78:147&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">2591509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MS, Bell DH. Mitotic neuroblasts in the 9-day-old and 11-month-old rodent hippocampus. J Neurosci. 1984;4:1429&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564978</ArticleId><ArticleId IdType="pubmed">6726341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MS, Hinds JW. Neurogenesis in the adult rat: electron microscopic analysis of light radioautographs. Science. 1977;197:1092&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">887941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature. 1997;386:493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. Experience-induced neurogenesis in the senescent dentate gyrus. J Neurosci. 1998;18:3206&#x2013;3212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792643</ArticleId><ArticleId IdType="pubmed">9547229</ArticleId></ArticleIdList></Reference><Reference><Citation>Koblar SA, Turnley AM, Classon BJ, Reid KL, Ware CB, Cheema SS, Murphy M, Bartlett PF. Neural precursor differentiation into astrocytes requires signaling through the leukemia inhibitory factor receptor. Proc Natl Acad Sci USA. 1998;95:3178&#x2013;3181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19715</ArticleId><ArticleId IdType="pubmed">9501236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci. 1996;16:2027&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurenzi MA, Siden A, Persson MA, Norkrans G, Hagberg L, Chiodi F. Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and noninflammatory diseases of the nervous system. Clin Immunol Immunopathol. 1990;57:233&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">2208805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire V, Koehl M, Le Moal M, Abrous DN. Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proc Natl Acad Sci USA. 2000;97:11032&#x2013;11037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27143</ArticleId><ArticleId IdType="pubmed">11005874</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Solway K, Messing RO, Sharp FR. Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J Neurosci. 1998;18:7768&#x2013;7778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793017</ArticleId><ArticleId IdType="pubmed">9742147</ArticleId></ArticleIdList></Reference><Reference><Citation>Markakis EA, Gage FH. Adult-generated neurons in the dentate gyrus send axonal projections to field CA3 and are surrounded by synaptic vesicles. J Comp Neurol. 1999;406:449&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">10205022</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M, Fernandez-Vivancos E, Frank A, De la Fuente M, Hernanz A. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentrations. Brain Res. 2000;869:216&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">10865077</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Fernandez MA, Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol. 1998;56:307&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9770242</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa E, Aimi Y, Yasuhara O, Tooyama I, Shimada M, McGeer PL, Kimura H. Enhancement of progenitor cell division in the dentate gyrus triggered by initial limbic seizures in rat models of epilepsy. Epilepsia. 2000;41:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">10643917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson M, Perfilieva E, Johansson U, Orwar O, Eriksson PS. Enriched environment increases neurogenesis in the adult rat dentate gyrus and improves spatial memory. J Neurobiol. 1999;39:569&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">10380078</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano HJ, Pfaff DW, Gibbs RB. RB and Cdc2 expression in brain: correlations with 3H-thymidine incorporation and neurogenesis. J Neurosci. 1993;13:2930&#x2013;2938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576668</ArticleId><ArticleId IdType="pubmed">8331381</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol. 2000;425:479&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">10975875</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH. Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J Neurosci. 1997;17:3727&#x2013;3738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573703</ArticleId><ArticleId IdType="pubmed">9133393</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters M, Muller AM, Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood. 1998;92:3495&#x2013;3504.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808540</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, O'Shea RD, Bloom FE, Campbell IL. Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci. 1997;17:9473&#x2013;9480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573407</ArticleId><ArticleId IdType="pubmed">9391003</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosell DR, McEwen BS. Interleukin-6 (Il-6), Il-6 receptor expression in the rat hippocampus in response to status epilepticus: time-course, distribution, correlation with neuronal degeneration. Soc Neurosci Abstr. 2000;26:1617.</Citation></Reference><Reference><Citation>Scheffler B, Horn M, Blumcke I, Laywell ED, Coomes D, Kukekov VG, Steindler DA. Marrow-mindedness: a perspective on neuropoiesis. Trends Neurosci. 1999;22:348&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">10407420</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmued LC, Albertson C, Slikker W., Jr Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997;751:37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9098566</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott BW, Wang S, Burnham WM, De Boni U, Wojtowicz JM. Kindling-induced neurogenesis in the dentate gyrus of the rat. Neurosci Lett. 1998;248:73&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9654345</ArticleId></ArticleIdList></Reference><Reference><Citation>Seri B, Garcia-Verdugo JM, Alvarez-Buylla A. Identification of the neural stem cells in the adult hippocampus. Soc Neurosci Abstr. 2000;26:825.</Citation></Reference><Reference><Citation>Shimazaki T, Shingo T, Weiss S. The ciliary neurotrophic factor/leukemia inhibitory factor/gp130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells. J Neurosci. 2001;21:7642&#x2013;7653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762896</ArticleId><ArticleId IdType="pubmed">11567054</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature. 2001;410:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268214</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanfield BB, Trice JE. Evidence that granule cells generated in the dentate gyrus of adult rats extend axonal projections. Exp Brain Res. 1988;72:399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">2465172</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev. 1999;79:1&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9922367</ArticleId></ArticleIdList></Reference><Reference><Citation>Turski WA, Cavalheiro EA, Bortolotto ZA, Mello LM, Schwarz M, Turski L. Seizures produced by pilocarpine in mice: a behavioral, electroencephalographic and morphological analysis. Brain Res. 1984;321:237&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">6498517</ArticleId></ArticleIdList></Reference><Reference><Citation>Valli&#xe8;res L, Rivest S. Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1beta. J Neurochem. 1997;69:1668&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">9326296</ArticleId></ArticleIdList></Reference><Reference><Citation>Valli&#xe8;res L, Rivest S. Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Endocrinology. 1999;140:3890&#x2013;3903.</Citation><ArticleIdList><ArticleId IdType="pubmed">10465257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11786404</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils.</ArticleTitle><Pagination><StartPage>101</StartPage><EndPage>112</EndPage><MedlinePgn>101-12</MedlinePgn></Pagination><Abstract><AbstractText>A pathological hallmark of Alzheimer's disease is the senile plaque, composed of beta-amyloid fibrils, microglia, astrocytes, and dystrophic neurites. We reported previously that class A scavenger receptors mediate adhesion of microglia and macrophages to beta-amyloid fibrils and oxidized low-density lipoprotein (oxLDL)-coated surfaces. We also showed that CD36, a class B scavenger receptor and an oxLDL receptor, promotes H(2)O(2) secretion by macrophages adherent to oxLDL-coated surfaces. Whether CD36 is expressed on microglia, and whether it plays a role in secretion of H(2)O(2) by microglia interacting with fibrillar beta-amyloid is not known. Using fluorescence-activated cell sorting analysis and immunohistochemistry, we found that CD36 is expressed on human fetal microglia, and N9-immortalized mouse microglia. We also found that CD36 is expressed on microglia and on vascular endothelial cells in the brains of Alzheimer's disease patients. Bowes human melanoma cells, which normally do not express CD36, gained the ability to specifically bind to surfaces coated with fibrillar beta-amyloid when transfected with a cDNA encoding human CD36, suggesting that CD36 is a receptor for fibrillar beta-amyloid. Furthermore, two different monoclonal antibodies to CD36 inhibited H(2)O(2) production by N9 microglia and human macrophages adherent to fibrillar beta-amyloid by approximately 50%. Our data identify a role for CD36 in fibrillar beta-amyloid-induced H(2)O(2) production by microglia, and imply that CD36 can mediate binding to fibrillar beta-amyloid. We propose that similar to their role in the interaction of macrophages with oxLDL, class A scavenger receptors and CD36 play complimentary roles in the interactions of microglia with fibrillar beta-amyloid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coraci</LastName><ForeName>Indra Sethy</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cellular Biophysics, Columbia University College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husemann</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Joan W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dufour</LastName><ForeName>Jennifer H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Campanella</LastName><ForeName>Gabriele K</ForeName><Initials>GK</Initials></Author><Author ValidYN="Y"><LastName>Luster</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Silverstein</LastName><ForeName>Samuel C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>El-Khoury</LastName><ForeName>Joseph B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 AI020516</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37-AI 20516</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS041330</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 HL010196</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041330</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018955">CD36 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010545">Peroxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018110">Receptors, Lipoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051116">Receptors, Scavenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495124">SCARB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C454739">Scarb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495125">Scarb1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051117">Scavenger Receptors, Class A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051122">Scavenger Receptors, Class B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018955" MajorTopicYN="N">CD36 Antigens</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="Y">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010545" MajorTopicYN="N">Peroxides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018110" MajorTopicYN="Y">Receptors, Lipoprotein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051116" MajorTopicYN="N">Receptors, Scavenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051117" MajorTopicYN="N">Scavenger Receptors, Class A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051122" MajorTopicYN="N">Scavenger Receptors, Class B</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11786404</ArticleId><ArticleId IdType="pmc">PMC1867121</ArticleId><ArticleId IdType="doi">10.1016/s0002-9440(10)64354-4</ArticleId><ArticleId IdType="pii">S0002-9440(10)64354-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ: The origins of Alzheimer disease: a is for amyloid. JAMA 2000, 283:1615-1617</Citation><ArticleIdList><ArticleId IdType="pubmed">10735401</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Robe A, Zigman W, Silverman W: Neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1989, 48:606-609</Citation><ArticleIdList><ArticleId IdType="pubmed">2477504</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC: Microglia, scavenger receptors, and the pathogenesis of Alzheimer&#x2019;s disease. Neurobiol Aging 1998, 19:S81-S84</Citation><ArticleIdList><ArticleId IdType="pubmed">9562474</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H: Inflammatory response in Alzheimer&#x2019;s disease. Tohoku J Exp Med 1994, 174:295-303</Citation><ArticleIdList><ArticleId IdType="pubmed">7539162</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Cassatella MA, Szendrei GI, Otvos Jr L, Baron P, Villalba M, Ferrari D, Rossi F: Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647&#x2013;650</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD: Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996, 382:716-719</Citation><ArticleIdList><ArticleId IdType="pubmed">8751442</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianca VD, Dusi S, Bianchini E, Dal Pra I, Rossi F: Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer&#x2019;s disease. J Biol Chem 1999, 274:15493-15499</Citation><ArticleIdList><ArticleId IdType="pubmed">10336441</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo LM, Roher AE: Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 1996, 16:6021-6037</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579176</ArticleId><ArticleId IdType="pubmed">8815885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell MD, Lopez-Gonzalez R, Lawson L, Hughes D, Fraser I, Gordon S, Perry VH: Upregulation of the macrophage scavenger receptor in response to different forms of injury in the CNS. J Neurocytol 1994, 23:605-613</Citation><ArticleIdList><ArticleId IdType="pubmed">7836955</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Ghosh RN, Maxfield FR: Microglial cells internalize aggregates of the Alzheimer&#x2019;s disease amyloid beta-protein via a scavenger receptor. Neuron 1996, 17:553-565</Citation><ArticleIdList><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie RH, Freeman M, Hyman BT: Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer&#x2019;s disease. Am J Pathol 1996, 148:399-403</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861668</ArticleId><ArticleId IdType="pubmed">8579103</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda M, Akiyama H, Yamada Y, Kondo H, Kawabe Y, Takeya M, Takahashi K, Suzuki H, Doi T, Sakamoto A, Ookawara S, Mato M, Gough PJ, Greaves DR, Gordon S, Kodama T, Matsushita M: Immunohistochemical evidence for a macrophage scavenger receptor in Mato cells and reactive microglia of ischemia and Alzheimer&#x2019;s disease. Biochem Biophys Res Commun 1998, 245:734-740</Citation><ArticleIdList><ArticleId IdType="pubmed">9588184</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M: A&#x3b2;-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 2001, 158:63-73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850262</ArticleId><ArticleId IdType="pubmed">11141480</ArticleId></ArticleIdList></Reference><Reference><Citation>Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA: CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993, 268:11811-11816</Citation><ArticleIdList><ArticleId IdType="pubmed">7685021</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxeiner H, Husemann J, Thomas CA, Loike JD, El Khoury J, Silverstein SC: Complementary roles for scavenger receptor A and CD36 of human monocyte-derived macrophages in adhesion to surfaces coated with oxidized low-density lipoproteins and in secretion of H2O2. J Exp Med 1998, 188:2257-2265</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212435</ArticleId><ArticleId IdType="pubmed">9858512</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JE, Chiu FC: Growth kinetics, cell shape, and the cytoskeleton of primary astrocyte cultures. J Neurochemistry 1984, 42:175-184</Citation><ArticleIdList><ArticleId IdType="pubmed">6537788</ArticleId></ArticleIdList></Reference><Reference><Citation>Righi M, Sassano M, Valsasnini P, Shammah S, Ricciardi-Castagnoli P: Activation of the M-CSF gene in mouse macrophages immortalized by retroviruses carrying a v-myc oncogene. Oncogene 1991, 6:103-111</Citation><ArticleIdList><ArticleId IdType="pubmed">1825138</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus CM, Brosnan CF, Berman JW: Cytokine induction of MIP-1 alpha and MIP-1 beta in human fetal microglia. J Immunol 1998, 160:1449-1455</Citation><ArticleIdList><ArticleId IdType="pubmed">9570566</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Thomas CA, Loike JD, Hickman SE, Cao L, Silverstein SC: Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 1994, 269:10197-10200</Citation><ArticleIdList><ArticleId IdType="pubmed">8144597</ArticleId></ArticleIdList></Reference><Reference><Citation>Oquendo P, Hundt E, Lawler J, Seed B: CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell 1989, 58:95-101</Citation><ArticleIdList><ArticleId IdType="pubmed">2473841</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Hartley DM, Condron MM, Selkoe DJ, Teplow DB: In vitro studies of &#x3b2;-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692&#x2192;Gly) Alzheimer&#x2019;s disease. Biochem J 2001, 355:869-877</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221805</ArticleId><ArticleId IdType="pubmed">11311152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rook GA, Steele J, Umar S, Dockrell HM: A simple method for the solubilisation of reduced NBT, and its use as a calorimetric assay for activation of human macrophages by gamma-interferon. J Immunol Methods 1985, 82:161-167</Citation><ArticleIdList><ArticleId IdType="pubmed">3928762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ault KA, Springer TA: Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells. J Immunol 1981, 126:359-364</Citation><ArticleIdList><ArticleId IdType="pubmed">7451976</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Vaca K: Inflammatory glia mediate delayed neuronal damage after ischemia in the central nervous system. Stroke 1993, 24(Suppl 12):184-190</Citation><ArticleIdList><ArticleId IdType="pubmed">8249026</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S: Ultrastructural localization of monosaccharide residues on cerebral endothelium. Lab Invest 1985, 52:553-558</Citation><ArticleIdList><ArticleId IdType="pubmed">3990246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannoji H, Yeger H, Becker LE: A specific histochemical marker (lectin Ricinus communis agglutinin-1) for normal human microglia, and application to routine histopathology. Acta Neuropathol 1986, 71:341-343</Citation><ArticleIdList><ArticleId IdType="pubmed">3541481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yankner BA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994, 91:12243-12247</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45413</ArticleId><ArticleId IdType="pubmed">7991613</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputo CB, Fraser PE, Sobel IE, Kirschner DA: Amyloid-like properties of a synthetic peptide corresponding to the carboxy terminus of beta-amyloid protein precursor. Arch Biochem Biophys 1992, 292:199-205</Citation><ArticleIdList><ArticleId IdType="pubmed">1727636</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL: Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 1996, 87:2020-2028</Citation><ArticleIdList><ArticleId IdType="pubmed">8634453</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawara A, DeSantis NM, Nogueira N, Nathan CF: Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates. J Clin Invest 1982, 70:1042-1048</Citation><ArticleIdList><ArticleId IdType="pmc">PMC370316</ArticleId><ArticleId IdType="pubmed">7130393</ArticleId></ArticleIdList></Reference><Reference><Citation>Asch AS, Barnwell J, Silverstein RL, Nachman RL: Isolation of the thrombospondin membrane receptor. J Clin Invest 1987, 79:1054-1061</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424283</ArticleId><ArticleId IdType="pubmed">2435757</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein P: Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995, 130:503-506</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120533</ArticleId><ArticleId IdType="pubmed">7542656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V: Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA 1991, 88:7438-7442</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52311</ArticleId><ArticleId IdType="pubmed">1651506</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, McGeer PL: Brain microglia constitutively express beta-2 integrins. J Neuroimmunol 1990, 30:81-93</Citation><ArticleIdList><ArticleId IdType="pubmed">1977769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancardi GL, Liwnicz BH, Mandybur TI: Fibrous astrocytes in Alzheimer&#x2019;s disease and senile dementia of Alzheimer&#x2019;s type. Acta Neuropathol 1983, 61:76-80</Citation><ArticleIdList><ArticleId IdType="pubmed">6353837</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesner LM, Huh HY, Pearce SF, Silverstein RL: Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler Thromb Vasc Biol 1996, 16:1019-1025</Citation><ArticleIdList><ArticleId IdType="pubmed">8696941</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy GM, Zhao F, Yang L, Cordell B: Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer&#x2019;s disease. Am J Pathol 2000, 157:895-904</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885684</ArticleId><ArticleId IdType="pubmed">10980129</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy Jr GM, Yang L, Cordell B: Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J Biol Chem 1998, 273:20967&#x2013;20971</Citation><ArticleIdList><ArticleId IdType="pubmed">9694846</ArticleId></ArticleIdList></Reference><Reference><Citation>Trezzini C, Jungi TW, Spycher MO, Maly FE, Rao P: Human monocytes CD36 and CD16 are signaling molecules. Evidence from studies using antibody-induced chemiluminescence as a tool to probe signal transduction. Immunology 1990, 71:29-37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1384217</ArticleId><ArticleId IdType="pubmed">1698715</ArticleId></ArticleIdList></Reference><Reference><Citation>Husemann J, Loike JD, Kodama T, Silverstein SC: Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J Neuroimmunol 2001, 114:142-150</Citation><ArticleIdList><ArticleId IdType="pubmed">11240025</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR: Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. Neuroreport 2001, 12:1151-1154</Citation><ArticleIdList><ArticleId IdType="pubmed">11338182</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ: Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer&#x2019;s disease. An immunoelectron microscopic study. Am J Pathol 1992, 141:249-252</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886563</ArticleId><ArticleId IdType="pubmed">1632466</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM, Wilcock GK: Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry 1986, 49:1221-1226</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1029068</ArticleId><ArticleId IdType="pubmed">3794727</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnwell JW, Asch AS, Nachman RL, Yamaya M, Aikawa M, Ingravallo P: A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. J Clin Invest 1989, 84:765-772</Citation><ArticleIdList><ArticleId IdType="pmc">PMC329717</ArticleId><ArticleId IdType="pubmed">2474574</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown H, Hien TT, Day N, Mai NT, Chuong LV, Chau TT, Loc PP, Phu NH, Bethell D, Farrar J, Gatter K, White N, Turner G: Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999, 25:331-340</Citation><ArticleIdList><ArticleId IdType="pubmed">10476050</ArticleId></ArticleIdList></Reference><Reference><Citation>Claudio L: Ultrastructural features of the blood brain barrier in biopsy tissue from Alzheimer&#x2019;s disease patients. Acta Neuropathol 1996, 91:6-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8773140</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Thomas G, McLendon C, Sutton T, Mullan M: Beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168-171</Citation><ArticleIdList><ArticleId IdType="pubmed">8600393</ArticleId></ArticleIdList></Reference><Reference><Citation>De Winther MP, Gijbels MJ, van Dijk KW, van Gorp PJ, Suzuki H, Kodama T, Frants RR, Havekes LM, Hofker MH: Scavenger receptor deficiency leads to more complex atherosclerotic lesions in A-POE3 Leiden transgenic mice. Atherosclerosis 1999, 144:315-321</Citation><ArticleIdList><ArticleId IdType="pubmed">10407492</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386:292-296</Citation><ArticleIdList><ArticleId IdType="pubmed">9069289</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Buttini M, Wyss-Coray T, McConlogue L, Kodama T, Pitas RE, Mucke L: Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am J Pathol 1999, 155:1741-1747</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866996</ArticleId><ArticleId IdType="pubmed">10550330</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM: Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 1998, 152:307-317</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein and Alzheimer&#x2019;s disease. J Neurosci 1996, 16:5795-5811</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000, 105:1049-1056</Citation><ArticleIdList><ArticleId IdType="pmc">PMC300837</ArticleId><ArticleId IdType="pubmed">10772649</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11786607</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>295</Volume><Issue>5556</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors.</ArticleTitle><Pagination><StartPage>868</StartPage><EndPage>872</EndPage><MedlinePgn>868-72</MedlinePgn></Pagination><Abstract><AbstractText>Single-cell mouse embryos were infected in vitro with recombinant lentiviral vectors to generate transgenic mice carrying the green fluorescent protein (GFP) gene driven by a ubiquitously expressing promoter. Eighty percent of founder mice carried at least one copy of the transgene, and 90% of these expressed GFP at high levels. Progeny inherited the transgene(s) and displayed green fluorescence. Mice generated using lentiviral vectors with muscle-specific and T lymphocyte-specific promoters expressed high levels of GFP only in the appropriate cell types. We have also generated transgenic rats that express GFP at high levels, suggesting that this technique can be used to produce other transgenic animal species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lois</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Pease</LastName><ForeName>Shirley</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Baltimore</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004274">DNA, Recombinant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="Y">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015139" MajorTopicYN="N">Blotting, Southern</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004274" MajorTopicYN="N">DNA, Recombinant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004624" MajorTopicYN="N">Embryo Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="Y">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="Y">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017919" MajorTopicYN="N">Hepatitis B Virus, Woodchuck</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011533" MajorTopicYN="N">Proviruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="Y">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016662" MajorTopicYN="N">Virus Integration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>21</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11786607</ArticleId><ArticleId IdType="doi">10.1126/science.1067081</ArticleId><ArticleId IdType="pii">1067081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11788820</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi.</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>105</EndPage><MedlinePgn>95-105</MedlinePgn></Pagination><Abstract><AbstractText>In Huntington disease, polyglutamine expansion of the protein huntingtin (Htt) leads to selective neurodegenerative loss of medium spiny neurons throughout the striatum by an unknown apoptotic mechanism. Binding of Hip-1, a protein normally associated with Htt, is reduced by polyglutamine expansion. Free Hip-1 binds to a hitherto unknown polypeptide, Hippi (Hip-1 protein interactor), which has partial sequence homology to Hip-1 and similar tissue and subcellular distribution. The availability of free Hip-1 is modulated by polyglutamine length within Htt, with disease-associated polyglutamine expansion favouring the formation of pro-apoptotic Hippi-Hip-1 heterodimers. This heterodimer can recruit procaspase-8 into a complex of Hippi, Hip-1 and procaspase-8, and launch apoptosis through components of the 'extrinsic' cell-death pathway. We propose that Htt polyglutamine expansion liberates Hip-1 so that it can form a caspase-8 recruitment complex with Hippi. This novel non-receptor-mediated pathway for activating caspase-8 might contribute to neuronal death in Huntington disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gervais</LastName><ForeName>Fran&#xe7;ois G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Quebec, Canada H9R 4P8.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singaraja</LastName><ForeName>Roshni</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Xanthoudakis</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gutekunst</LastName><ForeName>Claire-Anne</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Leavitt</LastName><ForeName>Blair R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Metzler</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hackam</LastName><ForeName>Abigail S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vaillancourt</LastName><ForeName>John P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Houtzager</LastName><ForeName>Vicky</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Rasper</LastName><ForeName>Dita M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hayden</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Donald W</ForeName><Initials>DW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C449279">Esrrbl1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C073368">HIP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489536">Hip1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506812">Htt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499524">Htt protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499179">IFT57 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505530">CASP8 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506433">CASP9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505526">Casp8 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505528">Casp8 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506434">Casp9 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506435">Casp9 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053181">Caspase 8</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2002 Feb;4(2):E30. doi: 10.1038/ncb0202-e30.</RefSource><PMID Version="1">11835052</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053181" MajorTopicYN="N">Caspase 8</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053453" MajorTopicYN="N">Caspase 9</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020798" MajorTopicYN="N">Two-Hybrid System Techniques</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>9</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11788820</ArticleId><ArticleId IdType="doi">10.1038/ncb735</ArticleId><ArticleId IdType="pii">ncb735</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11790115</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-2960</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>22</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.</ArticleTitle><Pagination><StartPage>922</StartPage><EndPage>928</EndPage><MedlinePgn>922-8</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid (Abeta) peptides generated in Hsiao's APP Tg2576 transgenic (Tg) mice are physically and chemically distinct from those characteristic of Alzheimer's disease (AD). Transgenic mouse Abeta peptides were purified using sequential size-exclusion and reverse-phase chromatographic systems and subjected to amino acid sequencing and mass spectrometry analyses. The mouse Abeta peptides lacked the extensive N-terminal degradations, posttranslational modifications, and cross-linkages abundant in the stable Abeta peptide deposits observed in AD. Truncated Abeta molecules appear to be generated in vivo by hydrolysis at multiple sites rather than by post-mortem C-terminal degradation. In contrast to AD amyloid cores, the Tg mice peptides were soluble in Tris-SDS-EDTA solutions, revealing both monomeric and SDS-stable oligomeric species of Abeta. In contrast to our report on Novartis Pharma APP23 Tg mice [Kuo et al. (2001) J. Biol. Chem. 276, 12991], which maintain high levels of soluble Abeta early on with later development of extensive vascular amyloid, Tg2576 mice exhibited an age-related elevation of soluble Abeta with relatively limited vascular amyloid deposition. The transgenic mouse levels of carboxy-terminal (CT) APP fragments were nearly 10-fold greater than those of human brains, and this condition may contribute to the unique pathology observed in these animals. Immunization of transgenic mice may act to prevent the pathological effects of betaAPP overproduction by binding CT molecules or halting their processing to toxic forms, in addition to having any effects on Abeta itself. Thus, differences in disease evolution and biochemistry must be considered when using transgenic animals to evaluate drugs or therapeutic interventions intended to reduce the Abeta burden in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalback</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Longtine Center for Molecular Biology and Genetics, Sun Health Research Institute, Sun City, Arizona 85351, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>M Desiree</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Kokjohn</LastName><ForeName>Tyler A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Yu-Min</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Luehrs</LastName><ForeName>Dean C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brune</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Emmerling</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Roher</LastName><ForeName>Alex E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-17490</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11790115</ArticleId><ArticleId IdType="doi">10.1021/bi015685+</ArticleId><ArticleId IdType="pii">bi015685+</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11790632</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>35</EndPage><MedlinePgn>24-35</MedlinePgn></Pagination><Abstract><AbstractText>The authors used 2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([18F]FDDNP), a hydrophobic radiofluorinated derivative of 2-(1-[6-(dimethylamino)-2-naphthyl]ethylidene)malononitrile (DDNP), in conjunction with positron emission tomography to determine the localization and load of neurofibrillary tangles (NFTs) and beta-amyloid senile plaques (APs) in the brains of living Alzheimer disease (AD) patients. Previous work illustrated the in vitro binding characteristics of [18F]FDDNP to synthetic beta-amyloid(1-40) fibrils and to NFTs and APs in human AD brain specimens. In the present study, greater accumulation and slower clearance was observed in AP- and NFT-dense brain areas and correlated with lower memory performance scores. The relative residence time of the probe in brain regions affected by AD was significantly greater in patients with AD (n=9) than in control subjects (n=7; p=0.0007). This noninvasive technique for monitoring AP and NFT development is expected to facilitate diagnostic assessment of patients with AD and assist in response-monitoring during experimental treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shoghi-Jadid</LastName><ForeName>Kooresh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, UCLA School of Medicine, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Agdeppa</LastName><ForeName>Eric D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Kepe</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ercoli</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Siddarth</LastName><ForeName>Prabha</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Read</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Satyamurthy</LastName><ForeName>Nagichettiar</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Petric</LastName><ForeName>Andrej</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Sung-Cheng</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Barrio</LastName><ForeName>Jorge R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C444522">1-(6-((2-fluoroethyl)(methyl)amino)naphthalen-2-yl)ethanone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C444520">2-(1-(6-((2-fluoroethyl)(methyl)amino)-2-naphthyl)ethylidene)malononitrile</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009281">Naphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009281" MajorTopicYN="N">Naphthalenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="Y">Tomography, Emission-Computed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11790632</ArticleId><ArticleId IdType="pii">S1064-7481(12)61324-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11792857</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.</ArticleTitle><Pagination><StartPage>727</StartPage><EndPage>732</EndPage><MedlinePgn>727-32</MedlinePgn></Pagination><Abstract><AbstractText>Huntington's disease is caused by the expansion of CAG repeats coding for a polyglutamine tract in the huntingtin protein. The major pathological feature found in Huntington's disease neurons is the presence of detergent-insoluble ubiquitinated inclusion bodies composed of the huntingtin protein. However, the mechanisms that underlie inclusion body formation, and the precise relationship between inclusion bodies and events that initiate toxicity, remain unclear. Here, we analyzed the effects of drugs or genetic mutations that disrupt the microtubule cytoskeleton in a Saccharomyces cerevisiae model of the aggregation of an amino-terminal polyglutamine-containing fragment of huntingtin exon 1 (HtEx1). Treatment of yeast with drugs that disrupt microtubules resulted in less than 2% of the detergent-insoluble HtEx1 observed in mock-treated cells and prevented the formation of large juxtanuclear inclusion bodies. Disruption of microtubules also unmasked a potent glutamine length-dependent toxicity of HtEx1 under conditions where HtEx1 exists in an entirely detergent-soluble nonaggregated form. Results from the yeast model paralleled those from neuronal pheochromocytoma cells, where disruption of microtubules eliminated the formation of juxtanuclear and intranuclear inclusion bodies by HtEx1. Our results suggest that active transport along microtubules may be required for inclusion body formation by HtEx1 and that inclusion body formation may have evolved as a cellular mechanism to promote the sequestration or clearance of soluble species of HtEx1 that are otherwise toxic to cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muchowski</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences University of Washington, Box 357730, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Ke</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>D'Souza-Schorey</LastName><ForeName>Crislyn</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>Stanley</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11792857</ArticleId><ArticleId IdType="pmc">PMC117373</ArticleId><ArticleId IdType="doi">10.1073/pnas.022628699</ArticleId><ArticleId IdType="pii">022628699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zoghbi H Y, Orr H T. Annu Rev Neurosci. 2000;23:217&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845064</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou F, Finkbeiner S, Devys D, Greenberg M E. Cell. 1998;95:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778247</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh D P, Figueroa K, Hoang N, Pulst S M. Nat Genet. 2000;26:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10973246</ArticleId></ArticleIdList></Reference><Reference><Citation>Warrick J M, Chan H Y, Gray-Board G L, Chai Y, Paulson H L, Bonini N M. Nat Genet. 1999;23:425&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">10581028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi-Esfarjani P, Benzer S. Science. 2000;287:1837&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pubmed">10710314</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutekunst C A, Levey A I, Heilman C J, Whaley W L, Yi H, Nash N R, Rees H D, Madden J J, Hersch S M. Proc Natl Acad Sci USA. 1995;92:8710&#x2013;8714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41036</ArticleId><ArticleId IdType="pubmed">7568002</ArticleId></ArticleIdList></Reference><Reference><Citation>Velier J, Kim M, Schwarz C, Kim T W, Sapp E, Chase K, Aronin N, DiFiglia M. Exp Neurol. 1998;152:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682010</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukamoto T, Nukina N, Ide K, Kanazawa I. Brain Res Mol Brain Res. 1997;51:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427501</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X J, Li S H, Sharp A H, Nucifora F C, Jr, Schilling G, Lanahan A, Worley P, Snyder S H, Ross C A. Nature (London) 1995;378:398&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477378</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelender S, Sharp A H, Colomer V, Tokito M K, Lanahan A, Worley P, Holzbaur E L, Ross C A. Hum Mol Genet. 1997;6:2205&#x2013;2212.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361024</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S H, Gutekunst C A, Hersch S M, Li X J. J Neurosci. 1998;18:1261&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792727</ArticleId><ArticleId IdType="pubmed">9454836</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R J, Ziegelhoffer T, Nicolet C, Werner-Washburne M, Craig E A. Cell. 1992;71:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">1394434</ArticleId></ArticleIdList></Reference><Reference><Citation>Huffaker T C, Thomas J H, Botstein D. J Cell Biol. 1988;106:1997&#x2013;2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115142</ArticleId><ArticleId IdType="pubmed">3290223</ArticleId></ArticleIdList></Reference><Reference><Citation>Spang A, Geissler S, Grein K, Schiebel E. J Cell Biol. 1996;134:429&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120879</ArticleId><ArticleId IdType="pubmed">8707827</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschall L G, Jeng R L, Mulholland J, Stearns T. J Cell Biol. 1996;134:443&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120884</ArticleId><ArticleId IdType="pubmed">8707828</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchowski P J, Schaffar G, Sittler A, Wanker E E, Hayer-Hartl M K, Hartl F U. Proc Natl Acad Sci USA. 2000;97:7841&#x2013;7846. . (First Published June 20, 2000; 10.1073/pnas.140202897)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16632</ArticleId><ArticleId IdType="pubmed">10859365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanker E E, Scherzinger E, Heiser V, Sittler A, Eickhoff H, Lehrach H. Methods Enzymol. 1999;309:375&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D. Proc Natl Acad Sci USA. 1999;96:11404&#x2013;11409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18046</ArticleId><ArticleId IdType="pubmed">10500189</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza-Schorey C, Li G, Colombo M I, Stahl P D. Science. 1995;267:1175&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">7855600</ArticleId></ArticleIdList></Reference><Reference><Citation>Krobitsch S, Lindquist S. Proc Natl Acad Sci USA. 2000;97:1589&#x2013;1594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26479</ArticleId><ArticleId IdType="pubmed">10677504</ArticleId></ArticleIdList></Reference><Reference><Citation>Straight A F, Murray A W. Methods Enzymol. 1997;283:425&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">9251039</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin A J, Signer E R. Trends Cell Biol. 2000;10:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuemmerle S, Gutekunst C A, Klein A M, Li X J, Li S H, Beal M F, Hersch S M, Ferrante R J. Ann Neurol. 1999;46:842&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589536</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutekunst C A, Li S H, Yi H, Mulroy J S, Kuemmerle S, Jones R, Rye D, Ferrante R J, Hersch S M, Li X J. J Neurosci. 1999;19:2522&#x2013;2534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786077</ArticleId><ArticleId IdType="pubmed">10087066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker E E, Doherty P, Davies S W, Bates G P. Hum Mol Genet. 1999;8:813&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196370</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston J A, Ward C L, Kopito R R. J Cell Biol. 1998;143:1883&#x2013;1898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175217</ArticleId><ArticleId IdType="pubmed">9864362</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston J A, Dalton M J, Gurney M E, Kopito R R. Proc Natl Acad Sci USA. 2000;97:12571&#x2013;12576. . (First Published October 24, 2000; 10.1073/pnas.220417997)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18805</ArticleId><ArticleId IdType="pubmed">11050163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigley W C, Fabunmi R P, Lee M G, Marino C R, Muallem S, DeMartino G N, Thomas P J. J Cell Biol. 1999;145:481&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2185077</ArticleId><ArticleId IdType="pubmed">10225950</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Mata R, Bebok Z, Sorscher E J, Sztul E S. J Cell Biol. 1999;146:1239&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2156127</ArticleId><ArticleId IdType="pubmed">10491388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence N F, Sampat R M, Kopito R R. Science. 2001;292:1552&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375494</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P H, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell W O, Jr, Miller G, Tagle D A. Nat Genet. 1998;20:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771716</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgson J G, Agopyan N, Gutekunst C A, Leavitt B R, LePiane F, Singaraja R, Smith D J, Bissada N, McCutcheon K, Nasir J, et al. Neuron. 1999;23:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">10402204</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti P, Reddy P H, Tagle D A, Schwarcz R. Neurosci Lett. 2000;283:233&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">10754231</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11792860</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.</ArticleTitle><Pagination><StartPage>1002</StartPage><EndPage>1007</EndPage><MedlinePgn>1002-7</MedlinePgn></Pagination><Abstract><AbstractText>We have generated eight mAbs (MW1-8) that bind the epitopes polyglutamine (polyQ), polyproline (polyP), or the C terminus of exon 1 in huntingtin (htt) protein. In the brains of Huntington's disease (HD) mouse models, the anti-polyQ mAbs bind to various cytoplasmic compartments, whereas the anti-polyP and anti-C terminus mAbs bind nuclear inclusions containing htt. To use these mAbs as intracellular perturbation agents, we have cloned and expressed the antigen-binding domains of three of the mAbs as single-chain variable region fragment Abs (scFvs). In 293 cells cotransfected with htt exon 1 containing an expanded polyQ domain, MW1, MW2, and MW7 scFvs colocalize with htt exon 1. Moreover, these scFvs coimmunoprecipitate with htt exon 1 in cell extracts. In perturbation experiments, MW7 scFv, recognizing the polyP domains of htt, significantly inhibits aggregation as well as the cell death induced by mutant htt protein. In contrast, MW1 and MW2 scFvs, recognizing the polyQ stretch, stimulate htt aggregation and apoptosis. Therefore, these anti-htt scFvs can be used to investigate the role of the polyP and polyQ domains in HD pathogenesis, and antibody binding to the polyP domain has potential therapeutic value in HD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khoshnan</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biology Division, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Paul H</ForeName><Initials>PH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007135">Immunoglobulin Variable Region</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057127">Single-Chain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114805">scFv fragment SW1</NameOfSubstance></Chemical><Chemical><RegistryNumber>25191-13-3</RegistryNumber><NameOfSubstance UI="C011083">polyproline</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001666" MajorTopicYN="N">Binding Sites, Antibody</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007135" MajorTopicYN="N">Immunoglobulin Variable Region</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057127" MajorTopicYN="N">Single-Chain Antibodies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11792860</ArticleId><ArticleId IdType="pmc">PMC117420</ArticleId><ArticleId IdType="doi">10.1073/pnas.022631799</ArticleId><ArticleId IdType="pii">022631799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huntington's Disease Collaborative Research Group. Cell. 1993;72:971&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P H, Williams M, Tangle D A. Trends Neurosci. 1999;22:248&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">10354600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi H Y, Orr H T. Annu Rev Neurosci. 2000;23:217&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin A J, Signer E R. Trends Cell Biol. 2000;10:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C A. Neuron. 1997;19:1147&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427237</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanker E E. Biol Chem. 2000;81:937&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">11076024</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper J K, Schilling G, Peters M F, Herring W J, Sharp A H, Kaminsky Z, Masone J, Khan F A, Delanoy M, Borchelt D R, et al. Hum Mol Genet. 1998;7:783&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">9536081</ArticleId></ArticleIdList></Reference><Reference><Citation>Mende-Mueller L M, Toneff T, Hwang S R, Chesselet M F, Hook V Y. J Neurosci. 2001;21:1830&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762596</ArticleId><ArticleId IdType="pubmed">11245667</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies S W, Turmaine M, Cozens B A, DiFiglia M, Sharp A H, Ross C A, Scherzinger E, Wanker E E, Mangiarini L, Bates G P. Cell. 1997;90:537&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267033</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies S W, Bates G P. Philos Trans R Soc London B. 1999;354:963&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692600</ArticleId><ArticleId IdType="pubmed">10434294</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillet E, Conde F, Beal M F, Hantraye P. Prog Neurobiol. 1999;59:427&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington C L, Leavitt B R, Hayden M R. J Neural Transm Suppl. 2000;58:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">11128600</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X J. Mol Neurobiol. 1999;20:111&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">10966117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Trends Neurosci. 2001;24:182&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182459</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Ona V O, Li M, Ferrante R J, Fink K B, Zhu S, Bian J, Guo L, Farrell L A, Hersch S M, et al. Nat Med. 2000;6:797&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888929</ArticleId></ArticleIdList></Reference><Reference><Citation>Leavitt B R, Guttman J A, Hodgson J G, Kimel G H, Singaraja R, Vogl A W, Hayden M R. Am J Hum Genet. 2001;68:313&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235265</ArticleId><ArticleId IdType="pubmed">11133364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez I, Xu C J, Juo P, Kakizaka A, Blenis J, Yuan J. Neuron. 1999;22:623&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197541</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffan J S, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu Y Z, Gohler H, Wanker E E, Bates G P, Housman D E, Thompson L M. Proc Natl Acad Sci USA. 2000;97:6763&#x2013;6768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18731</ArticleId><ArticleId IdType="pubmed">10823891</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucifora F C, Jr, Sasaki M, Peters M F, Huang H, Cooper J K, Yamada M, Takahashi H, Tsuji S, Troncoso J, Dawson V L, et al. Science. 2001;291:2423&#x2013;2428.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264541</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber P W, Barnes G T, Srinidhi J, Chen J, Gusella J F, MacDonald M E. Hum Mol Genet. 1998;7:1463&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700202</ArticleId></ArticleIdList></Reference><Reference><Citation>Passani L A, Bedford M T, Faber P W, McGinnis K M, Sharp A H, Gusella J F, Vonsattel J P, MacDonald M E. Hum Mol Genet. 2000;9:2175&#x2013;2182.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958656</ArticleId></ArticleIdList></Reference><Reference><Citation>Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden M R, Margolis R L, Ross C A, Dausset J, Ferrante R J, Neri C. Proc Natl Acad Sci USA. 2001;98:1811&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC29339</ArticleId><ArticleId IdType="pubmed">11172033</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutell J M, Thomas P, Neal J W, Weston V J, Duce J, Harper P S, Jones A L. Hum Mol Gen. 1999;8:1647&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">10441327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha J H. Trends Neurosci. 2000;23:387&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">10941183</ArticleId></ArticleIdList></Reference><Reference><Citation>Worn A, Pluckthun A. J Mol Biol. 2001;305:989&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecerf J M, Shirley T L, Zhu Q, Kazantsev A, Amersdorfer P, Housman D E, Messer A, Huston J S. Proc Natl Acad Sci USA. 2001;98:4764&#x2013;4769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31908</ArticleId><ArticleId IdType="pubmed">11296304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko J, Ou S, Patterson P H. Brain Res Bull. 2001;56:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C M, Roeder R G. Pept Res. 1993;6:62&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">7683509</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh J L, Walker H, Theisen H, Zhu Y Z, Fielder T, Purcell J, Thompson L M. Hum Mol Genet. 2000;9:13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10587574</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz M F. Mol Med. 1995;1:718&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230022</ArticleId><ArticleId IdType="pubmed">8612194</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman M Y, Goldberg A L. Neuron. 2001;29:15&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182078</ArticleId></ArticleIdList></Reference><Reference><Citation>Persichetti F, Carlee L, Faber P W, McNeil S M, Ambrose C M, Srinidhi J, Anderson M, Barnes G T, Gusella J F, MacDonald M E. Neurobiol Dis. 1996;3:183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980018</ArticleId></ArticleIdList></Reference><Reference><Citation>Staub O, Rotin D. Structure (London) 1996;15:495&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">8736547</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Li X-J. Hum Mol Genet. 1998;7:777&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">9536080</ArticleId></ArticleIdList></Reference><Reference><Citation>Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker E E. Mol Biol Cell. 2001;12:1393&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34592</ArticleId><ArticleId IdType="pubmed">11359930</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11794217</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-4793</ISSN><JournalIssue CitedMedium="Print"><Volume>345</Volume><Issue>21</Issue><PubDate><Year>2001</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1515</StartPage><EndPage>1521</EndPage><MedlinePgn>1515-21</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, are inconsistent.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line, in 1991. To detect new cases of dementia, follow-up screening was performed in 1993 and 1994 and again in 1997 through 1999. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine Hz-receptor antagonists, antihypertensive agents, and hypoglycemic agents.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>in t' Veld</LastName><ForeName>B A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Eramus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruitenberg</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Stijnen</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Stricker</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012459">Salicylates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2001 Nov 22;345(21):1567-8. doi: 10.1056/NEJM200111223452110.</RefSource><PMID Version="1">11794225</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2002 Apr 11;346(15):1171-3. doi: 10.1056/NEJM200204113461515.</RefSource><PMID Version="1">11948281</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2002 Apr 11;346(15):1171-3.</RefSource><PMID Version="1">11951858</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2002 Apr 11;346(15):1171-3.</RefSource><PMID Version="1">11951859</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2002 Apr 11;346(15):1171-3.</RefSource><PMID Version="1">11951860</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012459" MajorTopicYN="N">Salicylates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>17</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11794217</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa010178</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11809755</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>277</Volume><Issue>16</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD).</ArticleTitle><Pagination><StartPage>13389</StartPage><EndPage>13393</EndPage><MedlinePgn>13389-93</MedlinePgn></Pagination><Abstract><AbstractText>The intramembranous gamma-secretase cleavage of the beta-amyloid precursor protein (APP) is dependent on biologically active presenilins (PS). Notch also undergoes a similar PS-dependent gamma-secretase-like cleavage, resulting in the liberation of the Notch intracellular domain (NICD), which is critically required for developmental signal transduction. gamma-Secretase processing of APP results in the production of a similar fragment called AICD (APP intracellular domain), which may function in nuclear signaling as well. AICD, like NICD, is rapidly removed. By using a battery of protease inhibitors we demonstrate that AICD, in contrast to NICD, is degraded by a cytoplasmic metalloprotease. In vitro degradation of AICD can be reconstituted with cytoplasmic fractions obtained from neuronal and non-neuronal cells. Taking into account the inhibition profile and the cytoplasmic localization, we identified three candidate enzymes (neurolysin, thimet oligopeptidase, and insulin-degrading enzyme (IDE), also known as insulysin), which all are involved in the degradation of bioactive peptides in the brain. When insulin, a well characterized substrate of IDE, was added to the in vitro degradation assay, removal of AICD was efficiently blocked. Moreover, overexpression of IDE resulted in enhanced degradation of AICD, whereas overexpression of the inactive IDE E111Q mutant did not affect AICD degradation. Finally, immunodepletion of IDE significantly reduced the AICD degrading activity. Therefore our data demonstrate that IDE, which is one of the proteases implicated in the removal of extracellular Abeta, also removes the cytoplasmic product of gamma-secretase cleaved APP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Laboratory for Alzheimer's and Parkinson's Disease Research, Adolf-Butenandt-Institute, Ludwig-Maximilians-University, Schillerstrasse 44, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lammich</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>12</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11809755</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111571200</ArticleId><ArticleId IdType="pii">S0021-9258(19)60924-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11810277</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0340-6717</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Human genetics</Title><ISOAbbreviation>Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>646</StartPage><EndPage>652</EndPage><MedlinePgn>646-52</MedlinePgn></Pagination><Abstract><AbstractText>Insulin-degrading enzyme (IDE; insulysin; EC 3.4.24.56) is a 110-kDa neutral metallopeptidase that can degrade a number of peptides including beta-amyloid. The gene encoding IDE is located on chromosome 10 close to a region of linkage for late-onset Alzheimer's disease (LOAD) and thus is a functional and positional candidate for this disorder. We analysed all of the coding exons, untranslated regions and 1000 bp of 5'-flanking sequence of IDE by using denaturing high-performance liquid chromatography and sequencing. We detected eight single nucleotide polymorphisms (SNPs), three in the 5' flanking sequence and five in the coding sequence, of which three were found at lower than 5% frequency. None of them changed the amino acid sequence. We genotyped the five SNPs with allele frequencies of more than 5% in 133 Caucasian LOAD cases and 135 controls collected in the UK and 95 cases and 117 controls collected at the Mayo Clinic, Rochester, USA. Two of the SNPs were analysed in a further independent case-control sample (Washington University, St. Louis: 86 cases, 94 controls). No significant association was found with any individual SNP in any of the samples or with any haplotypes. Analysis of the marker D10S583, which maps 36 kb upstream of IDE, also failed to show association in 134 cases and 111 matched controls from the UK ( P=0.63). Strong linkage disequilibrium was detected between the five SNPs that spanned the whole of the 120-kb genomic region of IDE and one major and a number of minor haplotypes were detected in the populations studied. We conclude that IDE does not make a substantial contribution to the aetiology of LOAD and therefore cannot account for the linkage between LOAD and 10q.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Wales College of Medicine, Cardiff CF14 4XN, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wavrant-DeVrieze</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hamshere</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>H V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Compton</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Spurlock</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Turic</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hoogendoorn</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Tangalos</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Liolitsa</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH 46281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH 46373</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Hum Genet</MedlineTA><NlmUniqueID>7613873</NlmUniqueID><ISSNLinking>0340-6717</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="Y">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2001</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2001</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>16</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11810277</ArticleId><ArticleId IdType="doi">10.1007/s00439-001-0614-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11814781</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-894X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Bioorganic &amp; medicinal chemistry letters</Title><ISOAbbreviation>Bioorg Med Chem Lett</ISOAbbreviation></Journal><ArticleTitle>A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.</ArticleTitle><Pagination><StartPage>295</StartPage><EndPage>298</EndPage><MedlinePgn>295-8</MedlinePgn></Pagination><Abstract><AbstractText>The synthesis of a new lipophilic thioflavin-T analogue (2-[4' -(methylamino)phenyl]benzothiazole, 6) with high affinity for amyloid is reported. Intravenous injection of [(11)C]-labeled 6 in control mice resulted in high brain uptake. Amyloid deposits were imaged with multiphoton microscopy in the brains of living transgenic mice following the systemic injection of unlabeled 6. [(11)C]6 is a promising amyloid imaging agent for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>PET Facility, Department of Radiology, University of Pittsburgh, PA 15213, USA. mathisca@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Kajdasz</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>McLellan</LastName><ForeName>Megan E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanming</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Guo-Feng</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Debnath</LastName><ForeName>Manik L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG08487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18402</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioorg Med Chem Lett</MedlineTA><NlmUniqueID>9107377</NlmUniqueID><ISSNLinking>0960-894X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055598" MajorTopicYN="N">Chemical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002627" MajorTopicYN="N">Chemistry, Physical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008853" MajorTopicYN="N">Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11814781</ArticleId><ArticleId IdType="doi">10.1016/s0960-894x(01)00734-x</ArticleId><ArticleId IdType="pii">S0960894X0100734X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11818564</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation.</ArticleTitle><Pagination><StartPage>1610</StartPage><EndPage>1615</EndPage><MedlinePgn>1610-5</MedlinePgn></Pagination><Abstract><AbstractText>beta-amyloid (A beta), derived form the beta-amyloid precursor protein (APP), is important for the pathogenesis of Alzheimer's disease (AD), which is characterized by progressive decline of cognitive functions, formation of A beta plaques and neurofibrillary tangles, and loss of neurons. However, introducing a human wild-type or mutant APP gene to rodent models of AD does not result in clear neurodegeneration, suggesting that contributory factors lowering the threshold of neuronal death may be present in AD. Because brain ischemia has recently been recognized to contribute to the pathogenesis of AD, we studied the effect of focal brain ischemia in 8- and 20-month-old mice overexpressing the 751-amino acid isoform of human APP. We found that APP751 mice have higher activity of p38 mitogen-activated protein kinase (p38 MAPK) in microglia, the main immune effector cells within the brain, and increased vulnerability to brain ischemia when compared with age-matched wild-type mice. These characteristics are associated with enhanced microglial activation and inflammation but not with altered regulation of cerebral blood flow, as assessed by MRI and laser Doppler flowmetry. Suppression of inflammation with aspirin or inhibition of p38 MAPK with a selective inhibitor, SD-282, abolishes the increased neuronal vulnerability in APP751 transgenic mice. SD-282 also suppresses the expression of inducible nitric-oxide synthase and the binding activity of activator protein 1. These findings elucidate molecular mechanisms of neuronal injury in AD and suggest that antiinflammatory compounds preventing activation of p38 MAPK in microglia may reduce neuronal vulnerability in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koistinaho</LastName><ForeName>Milla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettunen</LastName><ForeName>Mikko I</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Goldsteins</LastName><ForeName>Gundars</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kein&#xe4;nen</LastName><ForeName>Riitta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Salminen</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ort</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bures</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kauppinen</LastName><ForeName>Risto A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Linda S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Koistinaho</LastName><ForeName>Jari</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514526">indole-5-carboxamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>142M471B3J</RegistryNumber><NameOfSubstance UI="D002245">Carbon Dioxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C084025">MAP-kinase-activated kinase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002245" MajorTopicYN="N">Carbon Dioxide</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010313" MajorTopicYN="N">Partial Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018808" MajorTopicYN="N">Transcription Factor AP-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11818564</ArticleId><ArticleId IdType="pmc">PMC122238</ArticleId><ArticleId IdType="doi">10.1073/pnas.032670899</ArticleId><ArticleId IdType="pii">032670899</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price D L, Tanzi R E, Borchelt D R, Sisodia S S. Annu Rev Genet. 1998;32:461&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">9928488</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D J. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M R. Am J Health Syst Pharm. 1998;55:S5&#x2013;S10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray W J, Ashall F, Goate A M. Mol Med Today. 1998;4:151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572056</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen F W, Hol E M. J Neural Transm Suppl. 1999;57:137&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10666673</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters C L. Ann NY Acad Sci. 1993;695:91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239320</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P L, Schulzer M, McGeer E G. Neurology. 1996;47:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757015</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Veerhuis R. Neurobiol Aging. 1996;17:673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria R. Curr Opin Hematol. 1999;6:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9915549</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P L, McGeer E G. J Leukocyte Biol. 1999;65:409&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10204568</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G M, Cooper N R, Eikelenboom P, Emmerling M, Fiebich B L, et al. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger S W, Harmon A D. Nature (London) 1997;388:878&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278049</ArticleId></ArticleIdList></Reference><Reference><Citation>London J A, Biegel D, Pachter J S. Proc Natl Acad Sci USA. 1996;93:4147&#x2013;4152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39502</ArticleId><ArticleId IdType="pubmed">8633031</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Cassatella M A, Szendrei G I, Otvos L, Jr, Baron P, Villalba M, Ferrari D, Rossi F. Nature (London) 1995;374:647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Neve R L, Robakis N K. Trends Neurosci. 1998;21:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">9464679</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature (London) 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb B T, Bardel K A, Kulnane L S, Anderson J J, Holtz G, Wagner S L, Sisodia S S, Hoeger E J. Nat Neurosci. 1999;2:695&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412057</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon M N, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, et al. Nat Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler M M. Neurobiol Aging. 2000;21:153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria R N. Neurobiol Aging. 2000;21:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867217</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon D A, Greiner L H, Mortimer J A, Riley K P, Greiner P A, Markesbery W R. JAMA. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri M M, Jobst K A, Morris J H, King E M, McDonald B, Joachim C, Litchfield S, Barnetson L, Smith A D. J Neuropathol Exp Neurol. 1997;56:165&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">9034370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirnagl U, Iadecola C, Moskowitz M A. Trends Neurosci. 1999;22:391&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">10441299</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone F C, Feuerstein G Z. J Cereb Blood Flow Metab. 1999;19:819&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">10458589</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Alexander M. Curr Opin Neurol. 2001;14:89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176223</ArticleId></ArticleIdList></Reference><Reference><Citation>del Zoppo G J, Becker K J, Hallenbeck J M. Arch Neurol. 2001;58:669&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">11296002</ArticleId></ArticleIdList></Reference><Reference><Citation>Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Proc Natl Acad Sci USA. 1998;95:15769&#x2013;15774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28119</ArticleId><ArticleId IdType="pubmed">9861045</ArticleId></ArticleIdList></Reference><Reference><Citation>Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan P H, Koistinaho J. Proc Natl Acad Sci USA. 1999;96:13496&#x2013;13500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23976</ArticleId><ArticleId IdType="pubmed">10557349</ArticleId></ArticleIdList></Reference><Reference><Citation>del Zoppo G, Ginis I, Hallenbeck J M, Iadecola C, Wang X, Feuerstein G Z. Brain Pathol. 2000;10:95&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098633</ArticleId><ArticleId IdType="pubmed">10668900</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Ross M E. Ann NY Acad Sci. 1997;835:203&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">9616775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G P, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe K H, Frautschy S A, et al. J Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Quon D, Wang Y, Catalano R, Scardina J M, Murakami K, Cordell B. Nature (London) 1991;352:239&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">1906990</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Ort M, Cimadevilla J M, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins L S. Proc Natl Acad Sci USA. 2001;98:14675&#x2013;14680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64740</ArticleId><ArticleId IdType="pubmed">11724968</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins L S, Rodems J M, Catalano R, Quon D, Cordell B. Proc Natl Acad Sci USA. 1995;92:4402&#x2013;4406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41952</ArticleId><ArticleId IdType="pubmed">7753818</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins L S, Holtzman D M, Rabin J, Mobley W C, Cordell B. Ann Neurol. 1994;35:598&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">7513982</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh F A, Sakamoto T, McKee A E, Sims R E. J Neurochem. 1987;49:846&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">3612129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Eckman C, Younkin S, Hsiao K K, Iadecola C. J Neurosci. 1997;17:7655&#x2013;7661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793926</ArticleId><ArticleId IdType="pubmed">9315887</ArticleId></ArticleIdList></Reference><Reference><Citation>Dignam J D, Lebovitz R M, Roeder R G. Nucleic Acids Res. 1983;11:1475&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC325809</ArticleId><ArticleId IdType="pubmed">6828386</ArticleId></ArticleIdList></Reference><Reference><Citation>Helenius M, H&#xe4;nninen M, Lehtinen S, Salminen A. J Mol Cell Cardiol. 1996;28:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">9011632</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson S, Korchak H, Ludewig R, Edelson H, Haines K, Levin R I, Herman R, Rider L, Kimmel S, Weissmann G. Proc Natl Acad Sci USA. 1985;82:7227&#x2013;7231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390822</ArticleId><ArticleId IdType="pubmed">2997778</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin A R, Vyas P, Attur M, Leszczynska-Piziak J, Patel I R, Weissmann G, Abramson S B. Proc Natl Acad Sci USA. 1995;92:7926&#x2013;7930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41259</ArticleId><ArticleId IdType="pubmed">7544010</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Ma W-Y, Hanenberger D, Cleary M P, Bowden T, Dong Z. J Biol Chem. 1997;272:26325&#x2013;26331.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334204</ArticleId></ArticleIdList></Reference><Reference><Citation>Grilli M, Pizzi M, Memo M, Spano P F. Science. 1996;274:1383&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910280</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Carlson G A, Iadecola C. J Cereb Blood Flow Metab. 2000;20:1659&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pubmed">11129782</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Zhang F, Niwa K, Eckman C, Turner S K, Fischer E, Younkin S, Borchelt D R, Hsiao K K, Carlson G A. Nat Neurosci. 1999;2:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Herlaar E, Brown Z. Mol Med Today. 1999;5:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498912</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper S J, LoGrasso P. Cell Signal. 2001;13:299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11369511</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin B, Pal S, Tran M P, Parsons A A, Barone F C, Erhardt J A, Aizenman E. J Neurosci. 2001;21:3303&#x2013;3311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746747</ArticleId><ArticleId IdType="pubmed">11331359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Zwiller J, Revel M O, Aunis D, Bader M F. J Biol Chem. 2001;276:13113&#x2013;13120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124958</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone F C, Irving E A, Ray A M, Lee J C, Kassis S, Kumar S, Badger A M, White R F, McVey M J, Legos J J, et al. J Pharmacol Exp Ther. 2001;296:312&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey J, Kelly J S, Butcher S P. In: Clinical Pharmacology of Cerebral Ischemia. Ter Horst G J, Korf J, editors. Totowa, NJ: Humana; 1997. pp. 253&#x2013;263.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11823645</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>295</Volume><Issue>5556</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.</ArticleTitle><Pagination><StartPage>865</StartPage><EndPage>868</EndPage><MedlinePgn>865-8</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease is a movement disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta. Dopaminergic neuronal loss also occurs in Drosophila melanogaster upon directed expression of alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease and a major component of proteinaceous Lewy bodies. We report that directed expression of the molecular chaperone Hsp70 prevented dopaminergic neuronal loss associated with alpha-synuclein in Drosophila and that interference with endogenous chaperone activity accelerated alpha-synuclein toxicity. Furthermore, Lewy bodies in human postmortem tissue immunostained for molecular chaperones, also suggesting that chaperones may play a role in Parkinson's disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Auluck</LastName><ForeName>Pavan K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Pennsylvania and University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>H Y Edwin</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Bonini</LastName><ForeName>Nancy M</ForeName><Initials>NM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050883">HSC70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C424447">Hsc70-4 protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2002 Feb 1;295(5556):809-10. doi: 10.1126/science.1069544.</RefSource><PMID Version="1">11823628</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="Y">Drosophila Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="Y">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050883" MajorTopicYN="N">HSC70 Heat-Shock Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="Y">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>21</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId><ArticleId IdType="doi">10.1126/science.1067389</ArticleId><ArticleId IdType="pii">1067389</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11830193</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>359</Volume><Issue>9303</Issue><PubDate><Year>2002</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Alcohol consumption and risk of dementia: the Rotterdam Study.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>286</EndPage><MedlinePgn>281-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Light-to-moderate alcohol consumption reduces the risk of coronary heart disease and stroke. Because vascular disease is associated with cognitive impairment and dementia, we hypothesised that alcohol consumption might also affect the risk of dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined the relation between alcohol consumption and risk of dementia in individuals taking part in the Rotterdam Study--a prospective population-based study of 7983 individuals aged 55 years and older. We studied all participants who did not have dementia at baseline (1990-93) and who had complete data on alcohol consumption (n=5395). Through follow-up examinations in 1993-94 and 1997-99 and an extensive monitoring system, we obtained nearly complete follow-up (99.7%) until the end of 1999. We used proportional hazards regression analysis, adjusted for age, sex, systolic blood pressure, education, smoking, and body-mass index, to compare the risk of developing dementia between individuals who regularly consumed alcohol and individuals who did not consume alcohol.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The average follow-up was 6.0 years. During this period, 197 individuals developed dementia (146 Alzheimer's disease, 29 vascular dementia, 22 other dementia). The median alcohol consumption was 0.29 drinks per day. Light-to-moderate drinking (one to three drinks per day) was significantly associated with a lower risk of any dementia (hazard ratio 0.58 [95% CI 0.38-0.90]) and vascular dementia (hazard ratio 0.29 [0.09-0.93]). We found no evidence that the relation between alcohol and dementia varied by type of alcoholic beverage.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These findings suggest that light-to-moderate alcohol consumption is associated with a reduced risk of dementia in individuals aged 55 years or older. The effect seems to be unchanged by the source of alcohol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruitenberg</LastName><ForeName>Annemieke</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Erasmus Medical Centre, PO Box 1738, 3000 DR Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Witteman</LastName><ForeName>Jacqueline C M</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Kala M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique M B</ForeName><Initials>MM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2002 Aug 10;360(9331):489; author reply 490-1. doi: 10.1016/S0140-6736(02)09650-2.</RefSource><PMID Version="1">12241746</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2002 Aug 10;360(9331):489-90; author reply 490-1. doi: 10.1016/S0140-6736(02)09651-4.</RefSource><PMID Version="1">12241747</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2002 Aug 10;360(9331):490; author reply 490-1. doi: 10.1016/S0140-6736(02)09652-6.</RefSource><PMID Version="1">12241748</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2002 Aug 10;360(9331):490; author reply 490-1. doi: 10.1016/S0140-6736(02)09653-8.</RefSource><PMID Version="1">12241749</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2002 Aug 10;360(9331):491. doi: 10.1016/S0140-6736(02)09655-1.</RefSource><PMID Version="1">12241751</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11830193</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(02)07493-7</ArticleId><ArticleId IdType="pii">S0140-6736(02)07493-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11831465</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0966-0844</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3-4</Issue><PubDate><Year>2001</Year><Season>Sep-Dec</Season></PubDate></JournalIssue><Title>Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine</Title><ISOAbbreviation>Biometals</ISOAbbreviation></Journal><ArticleTitle>Synaptically released zinc: physiological functions and pathological effects.</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>366</EndPage><MedlinePgn>353-66</MedlinePgn></Pagination><Abstract><AbstractText>In addition to its familiar role as a component of metalloproteins, zinc is also sequestered in the presynaptic vesicles of a specialized type of neurons called 'zinc-containing' neurons. Here we review the physiological and pathological effects of the release of zinc from these zinc-containing synaptic terminals. The best-established physiological role of synaptically released zinc is the tonic modulation of brain excitability through modulation of amino acid receptors; prominent pathological effects include acceleration of plaque deposition in Alzheimer's disease and exacerbation of excitotoxic neuron injury. Synaptically released zinc functions as a conventional synaptic neurotransmitter or neuromodulator, being released into the cleft, then recycled into the presynaptic terminal. Beyond this, zinc also has the highly unconventional property that it passes into postsynaptic neurons during synaptic events, functioning analogously to calcium in this regard, as a transmembrane neural signal. To stimulate comparisons of zinc signals with calcium signals, we have compiled a list of the important parameters of calcium signals and zinc signals. More speculatively, we hypothesize that zinc signals may loosely mimic phosphate 'signals' in the sense that signal zinc ions may commonly bind to proteins in a lasting manner (i.e., 'zincylating' the proteins) with consequential changes in protein structure and function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frederickson</LastName><ForeName>C J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>NeuroBioTex, Inc., Biomedical Engineering and Anatomy and Neuroscience, The University of Texas Medical Branch, Galveston, USA. cjfrederickson@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>A I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS 38585</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 46668</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS42015</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Biometals</MedlineTA><NlmUniqueID>9208478</NlmUniqueID><ISSNLinking>0966-0844</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013226" MajorTopicYN="N">Status Epilepticus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>105</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>30</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11831465</ArticleId><ArticleId IdType="doi">10.1023/a:1012934207456</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11835370</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.</ArticleTitle><Pagination><StartPage>145</StartPage><EndPage>155</EndPage><MedlinePgn>145-55</MedlinePgn></Pagination><Abstract><AbstractText>In Alzheimer's disease (AD), loss of cortical and hippocampal choline acetyltransferase (ChAT) activity has been correlated with dementia severity and disease duration, and it forms the basis for current therapies. However, the extent to which reductions in ChAT activity are associated with early cognitive decline has not been well established. We quantified ChAT activity in the hippocampus and four cortical regions (superior frontal, inferior parietal, superior temporal, and anterior cingulate) of 58 individuals diagnosed with no cognitive impairment (NCI; n = 26; mean age 81.4 +/- 7.3 years), mild cognitive impairment (MCI; n = 18; mean age 84.5 +/- 5.7), or mild AD (n =14; mean age 86.3 +/- 6.6). Inferior parietal cortex ChAT activity was also assessed in 12 subjects with end-stage AD (mean age 81.4 +/- 4.3 years) and compared to inferior parietal cortex ChAT levels of the other three groups. Only the end-stage AD group had ChAT levels reduced below normal. In individuals with MCI and mild AD, ChAT activity was unchanged in the inferior parietal, superior temporal, and anterior cingulate cortices compared to NCI. In contrast, ChAT activity in the superior frontal cortex was significantly elevated above normal controls in MCI subjects, whereas the mild AD group was not different from NCI or MCI. Hippocampal ChAT activity was significantly higher in MCI subjects than in either NCI or AD. Our results suggest that cognitive deficits in MCI and early AD are not associated with the loss of ChAT and occur despite regionally specific upregulation. Thus, the earliest cognitive deficits in AD involve brain changes other than simply cholinergic system loss. Of importance, the cholinergic system is capable of compensatory responses during the early stage of dementia. The upregulation in frontal cortex and hippocampal ChAT activity could be an important factor in preventing the transition of MCI subjects to AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dekoskyst@msx.upm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Milos D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Styren</LastName><ForeName>Scot D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Cochran</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Kordower</LastName><ForeName>Jeffrey H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Mufson</LastName><ForeName>Elliott J</ForeName><Initials>EJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2002 Feb;51(2):143-4. doi: 10.1002/ana.10135.</RefSource><PMID Version="1">11835369</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002799" MajorTopicYN="N">Cholinergic Fibers</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>2</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11835370</ArticleId><ArticleId IdType="doi">10.1002/ana.10069</ArticleId><ArticleId IdType="pii">10.1002/ana.10069</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11842206</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Adeno-associated virus effectively mediates conditional gene modification in the brain.</ArticleTitle><Pagination><StartPage>2320</StartPage><EndPage>2325</EndPage><MedlinePgn>2320-5</MedlinePgn></Pagination><Abstract><AbstractText>The Cre/loxP system is increasingly showing promise for investigating genes involved in neural function. Here, we demonstrate that in vivo modification of genes in the mouse brain can be accomplished in a spatial- and temporal-specific manner by targeted delivery of an adeno-associated virus (AAV) encoding a green fluorescent protein/Cre recombinase (GFP/Cre) fusion protein. By using a reporter mouse, in which Cre recombinase activates beta-galactosidase expression, we demonstrate long-term recombination of neurons in the hippocampus, striatum, and septum as early as 7 days after stereotaxic injection of virus. Recombined cells were observed for at least 6 months postinjection without evidence of cell loss or neural damage. AAV-mediated delivery of GFP/Cre provides a valuable approach to alter the mouse genome, as AAV delivers genes efficiently to neurons with low toxicity. This approach will greatly facilitate the study of genetic modifications in the mouse brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaspar</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Molecular Neurobiology Laboratory, and Peptide Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vissel</LastName><ForeName>Bryce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bengoechea</LastName><ForeName>Tasha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Crone</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Randolph-Moore</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Rolf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Brandon</LastName><ForeName>Eugene P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Schaffer</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Inder M</ForeName><Initials>IM</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kuo-Fen</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Heinemann</LastName><ForeName>Stephen F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32 AG00216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG10435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="C045073">Cre recombinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D019426">Integrases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.23</RegistryNumber><NameOfSubstance UI="D001616">beta-Galactosidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019426" MajorTopicYN="N">Integrases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="N">Recombination, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020665" MajorTopicYN="N">Septum of Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001616" MajorTopicYN="N">beta-Galactosidase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11842206</ArticleId><ArticleId IdType="pmc">PMC122363</ArticleId><ArticleId IdType="doi">10.1073/pnas.042678699</ArticleId><ArticleId IdType="pii">042678699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Capecchi M R. Science. 1989;244:1288&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">2660260</ArticleId></ArticleIdList></Reference><Reference><Citation>Price D L, Sisodia S S, Borchelt D R. Science. 1998;282:1079&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804539</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Romero M I, Ghosh P, Ye Z, Charnay P, Rushing E J, Marth J D, Parada L F. Genes Dev. 2001;15:859&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312666</ArticleId><ArticleId IdType="pubmed">11297510</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragatsis I, Levine M S, Zeitlin S. Nat Genet. 2000;26:300&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062468</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Tonegawa S. Annu Rev Neurosci. 1997;20:157&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">9056711</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks A I, Muhkerjee B, Panahian N, Cory-Slechta D, Federoff H J. Nat Biotechnol. 1997;15:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9035107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien J Z, Chen D F, Gerber D, Tom C, Mercer E H, Anderson D J, Mayford M, Kandel E R, Tonegawa S. Cell. 1996;87:1317&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980237</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer B, Henderson N. Proc Natl Acad Sci USA. 1988;85:5166&#x2013;5170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281709</ArticleId><ArticleId IdType="pubmed">2839833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberg N, Hamilton D, Hoess R. J Mol Biol. 1981;150:487&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">6276558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberg N, Hamilton D. J Mol Biol. 1981;150:467&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">6276557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer B. Methods Enzymol. 1993;225:890&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">8231893</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien J Z, Huerta P T, Tonegawa S. Cell. 1996;87:1327&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer B. Methods. 1998;14:381&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">9608509</ArticleId></ArticleIdList></Reference><Reference><Citation>Vooijs M, Jonkers J, Berns A. EMBO Rep. 2001;2:292&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1083861</ArticleId><ArticleId IdType="pubmed">11306549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn R, Schwenk F, Aguet M, Rajewsky K. Science. 1995;269:1427&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pubmed">7660125</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton M, Graham F L. J Virol. 1995;69:4600&#x2013;4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189258</ArticleId><ArticleId IdType="pubmed">7609024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohlmann A, Gotthardt M, Willnow T E, Hammer R E, Herz J. Nat Biotechnol. 1996;14:1562&#x2013;1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">9634821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Krushel L A, Edelman G M. Proc Natl Acad Sci USA. 1996;93:3932&#x2013;3936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39462</ArticleId><ArticleId IdType="pubmed">8632992</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks A I, Cory-Slechta D A, Federoff H J. Proc Natl Acad Sci USA. 2000;97:13378&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27232</ArticleId><ArticleId IdType="pubmed">11078505</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomer U, Naldini L, Kafri T, Trono D, Verma I M, Gage F H. J Virol. 1997;71:6641&#x2013;6649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191942</ArticleId><ArticleId IdType="pubmed">9261386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplitt M G, Leone P, Samulski R J, Xiao X, Pfaff D W, O'Malley K L, During M J. Nat Genet. 1994;8:148&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">7842013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar B, Erickson D, Schafer D, Hinh L, Gage F, Peterson D. Mol Ther. 2002;5:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786045</ArticleId></ArticleIdList></Reference><Reference><Citation>McCown T J, Xiao X, Li J, Breese G R, Samulski R J. Brain Res. 1996;713:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">8724980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo W D, Qu G, Sferra T J, Clark R, Chen R, Johnson P R. Hum Gene Ther. 1999;10:201&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">10022545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel R J. Brain Res. 2000;886:82&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11119690</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham F L, Smiley J, Russell W C, Nairn R. J Gen Virol. 1977;36:59&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">886304</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X, Li J, Samulski R J. J Virol. 1998;72:2224&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109519</ArticleId><ArticleId IdType="pubmed">9499080</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder R O S S, Lagarde C, Bohl D, Kaspar B, Sloan B, Cohen L K, Danos O. Hum Gene Ther. 1997;8:1891&#x2013;1900.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382955</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson D A, Lucidi-Phillipi C A, Eagle K L, Gage F H. J Neurosci. 1994;14:6872&#x2013;6885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577234</ArticleId><ArticleId IdType="pubmed">7965084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterio D C. J Microsc. 1984;134:127&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">6737468</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano P. Nat Genet. 1999;21:70&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari F K, Samulski T, Shenk T, Samulski R J. J Virol. 1996;70:3227&#x2013;3234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190186</ArticleId><ArticleId IdType="pubmed">8627803</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher K J, Gao G P, Weitzman M D, DeMatteo R, Burda J F, Wilson J M. J Virol. 1996;70:520&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189840</ArticleId><ArticleId IdType="pubmed">8523565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett J S, Samulski R J, McCown T J. Hum Gene Ther. 1998;9:1181&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">9625257</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher L J, Raymon H K, Gage F H. Ann NY Acad Sci. 1993;695:278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239296</ArticleId></ArticleIdList></Reference><Reference><Citation>Loonstra A, Vooijs M, Beverloo H B, Allak B A, van Drunen E, Kanaar R, Berns A, Jonkers J. Proc Natl Acad Sci USA. 2001;98:9209&#x2013;9214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55399</ArticleId><ArticleId IdType="pubmed">11481484</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver D P, Livingston D M. Mol Cell. 2001;8:233&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11511376</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt E E, Taylor D S, Prigge J R, Barnett S, Capecchi M R. Proc Natl Acad Sci USA. 2000;97:13702&#x2013;13707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17639</ArticleId><ArticleId IdType="pubmed">11087830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer A, Brandon E P, Kootstra N, Gage F H, Verma I M. Proc Natl Acad Sci USA. 2001;98:11450&#x2013;11455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58750</ArticleId><ArticleId IdType="pubmed">11553794</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11843691</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>216</EndPage><MedlinePgn>213-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies have shown that patients with early onset of Alzheimer disease and vascular dementia have higher levels of circulating brain-derived 24S-hydroxycholesterol (cerebrosterol). Two recent epidemiological studies indicated that treatment with inhibitors of cholesterol synthesis (statins) reduces the incidence of Alzheimer disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that treatment with high-dosage simvastatin reduces circulating levels of 24S-hydroxycholesterol.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, 24-week treatment trial for lowering of cholesterol levels. We conducted assessments at baseline, week 6, and week 24.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">An academic outpatient clinical study.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Eighteen patients who met the criteria for hypercholesterolemia.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Treatment with 80 mg/d of simvastatin at night.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Plasma lipoprotein levels were measured enzymatically; lathosterol, by means of gas chromatography; and 24S-hydroxycholesterol, by means of gas chromatography-mass spectrometry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Simvastatin reduced total plasma cholesterol levels by 36% and 35% after 6 and 24 weeks, respectively (P&lt;.001). Lathosterol levels were reduced by 74% and 72%, respectively, and the ratio of lathosterol to cholesterol, an indicator of whole-body cholesterol synthesis, was reduced by 60% and 61%, respectively (P&lt;.001). Plasma 24S-hydroxycholesterol levels were lowered by 45% and 53%, respectively (P&lt;.001). The ratio of 24S-hydroxycholesterol to cholesterol also decreased significantly (-12% [P=.01] and -23% [P&lt;.002], respectively). The further reduction of 24S-hydroxycholesterol levels and its ratio to cholesterol from weeks 6 to 24 was also significant (P=.02 for both).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The greater reduction of plasma concentrations of 24S-hydroxycholesterol compared with cholesterol indicates that simvastatin in a dosage of 80 mg/d reduces cholesterol turnover in the brain. The present results might describe a possible mechanism of how long-term treatment with statins could reduce the incidence of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Universit&#xe4;tsklinikum, University of Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;tjohann</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Hartmut H J</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Beisiegel</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>von Bergmann</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006888">Hydroxycholesterols</NameOfSubstance></Chemical><Chemical><RegistryNumber>47IMW63S3F</RegistryNumber><NameOfSubstance UI="C044563">24-hydroxycholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>AGG2FN16EV</RegistryNumber><NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006888" MajorTopicYN="N">Hydroxycholesterols</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11843691</ArticleId><ArticleId IdType="doi">10.1001/archneur.59.2.213</ArticleId><ArticleId IdType="pii">noc10221</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11844848</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>346</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>476</StartPage><EndPage>483</EndPage><MedlinePgn>476-83</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In cross-sectional studies, elevated plasma homocysteine levels have been associated with poor cognition and dementia. Studies of newly diagnosed dementia are required in order to establish whether the elevated homocysteine levels precede the onset of dementia or result from dementia-related nutritional and vitamin deficiencies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 1092 subjects without dementia (667 women and 425 men; mean age, 76 years) from the Framingham Study constituted our study sample. We examined the relation of the plasma total homocysteine level measured at base line and that measured eight years earlier to the risk of newly diagnosed dementia on follow-up. We used multivariable proportional-hazards regression to adjust for age, sex, apolipoprotein E genotype, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B12 and B6.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over a median follow-up period of eight years, dementia developed in 111 subjects, including 83 given a diagnosis of Alzheimer's disease. The multivariable-adjusted relative risk of dementia was 1.4 (95 percent confidence interval, 1.1 to 1.9) for each increase of 1 SD in the log-transformed homocysteine value either at base line or eight years earlier. The relative risk of Alzheimer's disease was 1.8 (95 percent confidence interval, 1.3 to 2.5) per increase of 1 SD at base line and 1.6 (95 percent confidence interval, 1.2 to 2.1) per increase of 1 SD eight years before base line. With a plasma homocysteine level greater than 14 micromol per liter, the risk of Alzheimer's disease nearly doubled.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An increased plasma homocysteine level is a strong, independent risk factor for the development of dementia and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, MA 02118-2526, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Selhub</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jacques</LastName><ForeName>Paul F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Irwin H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Ralph B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Peter W F</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5R01-AG16495-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01-AG08122-11</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-38038</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01-NS17950-19</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2002 Feb 14;346(7):466-8. doi: 10.1056/NEJM200202143460702.</RefSource><PMID Version="1">11844846</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>CMAJ. 2002 Apr 16;166(8):1068.</RefSource><PMID Version="1">12030205</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2002 Jun 20;346(25):2007; author reply 2008. doi: 10.1056/NEJM200206203462514.</RefSource><PMID Version="1">12075065</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2002 Jun 20;346(25):2007; author reply 2008.</RefSource><PMID Version="1">12078704</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>ACP J Club. 2002 Sep-Oct;137(2):76.</RefSource><PMID Version="1">12207454</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2002 Nov;5(4):126. doi: 10.1136/ebmh.5.4.126.</RefSource><PMID Version="1">12440468</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020138" MajorTopicYN="N">Hyperhomocysteinemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11844848</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa011613</ArticleId><ArticleId IdType="pii">346/7/476</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11847218</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>277</Volume><Issue>18</Issue><PubDate><Year>2002</Year><Month>May</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain.</ArticleTitle><Pagination><StartPage>16278</StartPage><EndPage>16284</EndPage><MedlinePgn>16278-84</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid beta (A beta) peptide that accumulates in Alzheimer's disease brain is derived from the proteolytic processing of the amyloid precursor protein by beta- and gamma-secretase activities. The beta-secretase enzyme beta-site amyloid precursor protein-cleaving enzyme (BACE) generates the N terminus of A beta by cleavage at either Asp(1) (beta-site) or Glu(11) (beta'-site), ultimately leading to the production of full-length A beta 1-40/42 or truncated A beta 11-40/42. The functional significance of this variable cleavage site specificity as well as the relative pathological impact of full-length versus N-terminally truncated A beta remains largely unknown. In our analysis of BACE reactivity in cell culture, we found that the preference of the protease for either beta- or beta'-cleavage was strongly dependent on intracellular localization. Within the endoplasmic reticulum, beta-site proteolysis predominated, whereas in the trans-Golgi network, beta'-cleavage was favored. Furthermore, the contrasting cleavage site specificities of BACE were not simply due to differences in organelle pH or the oligosaccharide composition of the glycoproteins involved. Examination of post-mortem brain specimens revealed significant levels of A beta 11-40/42 within insoluble amyloid pools. Taken together, these data support an important role for beta'-cleavage in the process of cerebral amyloid deposition and localize the processing event to the trans-Golgi network.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huse</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kangning</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pijak</LastName><ForeName>Donald S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Carlin</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Doms</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG11542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021601" MajorTopicYN="N">trans-Golgi Network</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11847218</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111141200</ArticleId><ArticleId IdType="pii">S0021-9258(19)35790-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11851430</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-2960</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing.</ArticleTitle><Pagination><StartPage>2825</StartPage><EndPage>2835</EndPage><MedlinePgn>2825-35</MedlinePgn></Pagination><Abstract><AbstractText>Proteolytic processing of the transmembrane domain of the amyloid precursor protein (APP) is a key component of Alzheimer's disease pathogenesis. Using C-terminally tagged APP derivatives, we have identified by amino-terminal sequencing a novel cleavage site of APP, at Leu-49, distal to the gamma-secretase site. This was termed -cleavage. Brefeldin A treatment and pulse-chase experiments indicate that this cleavage occurs late in the secretory pathway. The level of -cleavage is decreased by expression of presenilin-1 mutants known to impair Abeta formation, and it is sensitive to the gamma-secretase inhibitors MDL28170 and L-685,458. Remarkably, it shares similarities with site 3 cleavage of Notch-1: membrane topology, cleavage before a valine, dependence on presenilins, and inhibition profile.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weidemann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Zentrum f&#xfc;r Molekulare Biologie Heidelberg, INF 282, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggert</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Reinhard</LastName><ForeName>Friedrich B M</ForeName><Initials>FB</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Paliga</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Baier</LastName><ForeName>Gottfried</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>Konrad</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Evin</LastName><ForeName>Genevi&#xe8;ve</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11851430</ArticleId><ArticleId IdType="doi">10.1021/bi015794o</ArticleId><ArticleId IdType="pii">bi015794o</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11851541</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0098-7484</ISSN><JournalIssue CitedMedium="Print"><Volume>287</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Participation in cognitively stimulating activities and risk of incident Alzheimer disease.</ArticleTitle><Pagination><StartPage>742</StartPage><EndPage>748</EndPage><MedlinePgn>742-8</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Frequent participation in cognitively stimulating activities has been hypothesized to reduce risk of Alzheimer disease (AD), but prospective data regarding an association are lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that frequent participation in cognitive activities is associated with a reduced risk of AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Longitudinal cohort study with baseline evaluations performed between January 1994 and July 2001 and mean follow-up of 4.5 years.</AbstractText><AbstractText Label="PARTICIPANTS AND SETTING" NlmCategory="METHODS">A total of 801 older Catholic nuns, priests, and brothers without dementia at enrollment, recruited from 40 groups across the United States. At baseline, they rated frequency of participation in common cognitive activities (eg, reading a newspaper), from which a previously validated composite measure of cognitive activity frequency was derived.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Clinical diagnosis of AD by a board-certified neurologist using National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria and change in global and specific measures of cognitive function, compared by cognitive activity score at baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline scores on the composite measure of cognitive activity ranged from 1.57 to 4.71 (mean, 3.57; SD, 0.55), with higher scores indicating more frequent activity. During an average of 4.5 years of follow-up, 111 persons developed AD. In a proportional hazards model that controlled for age, sex, and education, a 1-point increase in cognitive activity score was associated with a 33% reduction in risk of AD (hazard ratio, 0.67; 95% confidence interval, 0.49-0.92). Results were comparable when persons with memory impairment at baseline were excluded and when terms for the apolipoprotein E epsilon4 allele and other medical conditions were added. In random-effects models that controlled for age, sex, education, and baseline level of cognitive function, a 1-point increase in cognitive activity was associated with reduced decline in global cognition (by 47%), working memory (by 60%), and perceptual speed (by 30%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggest that frequent participation in cognitively stimulating activities is associated with reduced risk of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, 1645 W Jackson Blvd, Suite 675, Chicago, IL 60612, USA. rwilson@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendes De Leon</LastName><ForeName>Carlos F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Bienias</LastName><ForeName>Julia L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KO8 AG00849</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012653" MajorTopicYN="Y">Self Stimulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11851541</ArticleId><ArticleId IdType="doi">10.1001/jama.287.6.742</ArticleId><ArticleId IdType="pii">joc11682</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11854752</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Arfaptin 2 regulates the aggregation of mutant huntingtin protein.</ArticleTitle><Pagination><StartPage>240</StartPage><EndPage>245</EndPage><MedlinePgn>240-5</MedlinePgn></Pagination><Abstract><AbstractText>Huntington's disease (HD) is an inherited neurodegenerative disorder. Here we demonstrate that expression of arfaptin 2/POR1 (partner of Rac1) in cultured cells induces the formation of pericentriolar and nuclear aggregates, which morphologically resemble mutant huntingtin aggregates characteristic of HD. Endogenous arfaptin 2 localizes to aggregates induced by expression of an abnormal amino-terminal fragment of huntingtin that contains polyglutamine (polyQ) expansions. A dominant inhibitory mutant of arfaptin 2 inhibits aggregation of mutant huntingtin, but not in the presence of proteasome inhibitors. Using cell-free biochemical assays, we show that arfaptin 2 inhibits proteasome activity. Finally, we show that expression of arfaptin 2 is increased at sites of neurodegeneration and the protein localizes to huntingtin aggregates in HD transgenic mouse brains. Our data suggest that arfaptin 2 is involved in regulating huntingtin protein aggregation, possibly by impairing proteasome function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Division of Tumor Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Ke</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Palacios</LastName><ForeName>Felipe</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Boshans</LastName><ForeName>Rita L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Kazantsev</LastName><ForeName>Aleksey</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Woodman</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>Gillian P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>D'Souza-Schorey</LastName><ForeName>Crislyn</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101158">ARFIP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506812">Htt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499524">Htt protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="Y">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>12</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11854752</ArticleId><ArticleId IdType="doi">10.1038/ncb761</ArticleId><ArticleId IdType="pii">ncb761</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11867728</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate.</ArticleTitle><Pagination><StartPage>2720</StartPage><EndPage>2725</EndPage><MedlinePgn>2720-5</MedlinePgn></Pagination><Abstract><AbstractText>Presenilin heterodimers apparently contain the active site of gamma-secretase, a polytopic aspartyl protease involved in the transmembrane processing of both the Notch receptor and the amyloid-beta precursor protein. Although critical to embryonic development and the pathogenesis of Alzheimer's disease, this protease is difficult to characterize, primarily because it is a multicomponent complex of integral membrane proteins. Here the functional gamma-secretase complex was isolated by using an immobilized active site-directed inhibitor of the protease. Presenilin heterodimers and nicastrin bound specifically to this inhibitor under conditions tightly correlating with protease activity, whereas several other presenilin-interacting proteins (beta-catenin, calsenilin, and presenilin-associated protein) did not bind. Moreover, anti-nicastrin antibodies immunoprecipitated gamma-secretase activity from detergent-solubilized microsomes. Unexpectedly, C83, the major endogenous amyloid-beta precursor protein substrate of gamma-secretase, was also quantitatively associated with the complex. These results provide direct biochemical evidence that nicastrin is a member of the active gamma-secretase complex, indicate that beta-catenin, calsenilin, and presenilin-associated protein are not required for gamma activity, and suggest an unprecedented mechanism of substrate-protease interaction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esler</LastName><ForeName>William P</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Program in Neuroscience, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimberly</LastName><ForeName>W Taylor</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>Beth L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Diehl</LastName><ForeName>Thekla S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 41355</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 12749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 17574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041355</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008956" MajorTopicYN="N">Models, Chemical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>27</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11867728</ArticleId><ArticleId IdType="pmc">PMC122414</ArticleId><ArticleId IdType="doi">10.1073/pnas.052436599</ArticleId><ArticleId IdType="pii">052436599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Nature (London) 1999;399:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Proc Natl Acad Sci USA. 1997;94:2095&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33655</ArticleId><ArticleId IdType="pubmed">9122152</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S. J Med Chem. 2001;44:2039&#x2013;2060.</Citation><ArticleIdList><ArticleId IdType="pubmed">11405641</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett D R, Simmons D L, Dingwall C, Christie G. Trends Neurosci. 2000;23:565&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11074266</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Chen F, Levesque G, Nishimura M, Zhang D M, Levesque L, Rogaeva E, Xu D, Liang Y, Duthie M, et al. J Biol Chem. 1998;273:16470&#x2013;16475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632714</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, Beyreuther K, Selkoe D J, Haass C. J Biol Chem. 1998;273:3205&#x2013;3211.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452432</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y M, Lai M T, Xu M, Huang Q, DiMuzio-Mower J, Sardana M K, Shi X P, Yin K C, Shafer J A, Gardell S J. Proc Natl Acad Sci USA. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Nat Cell Biol. 2000;2:461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner B A. Nat Cell Biol. 2000;2:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878814</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt D R, Lee M K, Slunt H H, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, et al. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratovitski T, Slunt H H, Thinakaran G, Price D L, Sisodia S S, Borchelt D R. J Biol Chem. 1997;272:24536&#x2013;24541.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305918</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny M B, Citron M, Amarante P, Sherrington R, Xia W, Zhang J, Diehl T, Levesque G, Fraser P, Haass C, et al. Neurobiol Dis. 1997;3:325&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173929</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Harris C L, Ratovitski T, Davenport F, Slunt H H, Price D L, Borchelt D R, Sisodia S S. J Biol Chem. 1997;272:28415&#x2013;28422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T, Selkoe D J. Nature (London) 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Duff K, Capell A, Romig H, Grim M G, Lincoln S, Hardy J, Yu X, Picciano M, Fechteler K, et al. J Biol Chem. 1999;274:28669&#x2013;28673.</Citation><ArticleIdList><ArticleId IdType="pubmed">10497236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly W T, Xia W, Rahmati T, Wolfe M S, Selkoe D J. J Biol Chem. 2000;275:3173&#x2013;3178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10652302</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y M, Xu M, Lai M T, Huang Q, Castro J L, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil J G, et al. Nature (London) 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler W P, Kimberly W T, Ostaszewski B L, Diehl T S, Moore C L, Tsai J-Y, Rahmati T, Xia W, Selkoe D J, Wolfe M S. Nat Cell Biol. 2000;2:428&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878808</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown M S, Ye J, Rawson R B, Goldstein J L. Cell. 2000;100:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm J S, Schroeter E H, Schrijvers V, Wolfe M S, Ray W J, et al. Nature (London) 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter E H, Kisslinger J A, Kopan R. Nature (London) 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert S S, Le A, Schroeter E H, Mumm J S, Saxena M T, Milner L A, Kopan R. Nature (London) 2000;405:966&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879540</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P C, Zheng H, Chen H, Becher M W, Sirinathsinghji D J, Trumbauer M E, Chen H Y, Price D L, Van der Ploeg L H, Sisodia S S. Nature (London) 1997;387:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson R T, Chen D F, Xia W, Selkoe D J, Tonegawa S. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray W J, Yao M, Mumm J, Schroeter E H, Saftig P, Wolfe M, Selkoe D J, Kopan R, Goate A M. J Biol Chem. 1999;274:36801&#x2013;36807.</Citation><ArticleIdList><ArticleId IdType="pubmed">10593990</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, Jack C, McLean P, Aster J C, Hicks C, Xia W, Wolfe M S, Kimberly W T, Weinmaster G, Selkoe D J, et al. J Neurochem. 2000;75:583&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899933</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, Jack C, Deng A, Gastineau N, Rebeck G W, Hyman B T. J Biol Chem. 2001;276:30018&#x2013;30023.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408475</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song Y Q, Rogaeva E, Chen F, Kawarai T, et al. Nature (London) 2000;407:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Getman D P, DeCrescenzo G A, Heintz R M, Reed K L, Talley J J, Bryant M L, Clare M, Houseman K A, Marr J J, Mueller R A, et al. J Med Chem. 1993;36:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423599</ArticleId></ArticleIdList></Reference><Reference><Citation>McLendon C, Xin T, Ziani-Cherif C, Murphy M P, Findlay K A, Lewis P A, Pinnix I, Sambamurti K, Wang R, Fauq A, et al. FASEB J. 2000;14:2383&#x2013;2386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11024004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev E I, Sherrington R, Rogaeva E A, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Nature (London) 1995;376:775&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano D M, Oshima J, Pettingell W H, Yu C E, Jondro P D, Schmidt S D, Wang K, et al. Science. 1995;269:973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Ray W J, Ostaszewski B L, Rahmati T, Kimberly W T, Wolfe M S, Zhang J, Goate A M, Selkoe D J. Proc Natl Acad Sci USA. 2000;97:9299&#x2013;9304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16862</ArticleId><ArticleId IdType="pubmed">10922078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11875571</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>415</Volume><Issue>6875</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Functional neurogenesis in the adult hippocampus.</ArticleTitle><Pagination><StartPage>1030</StartPage><EndPage>1034</EndPage><MedlinePgn>1030-4</MedlinePgn></Pagination><Abstract><AbstractText>There is extensive evidence indicating that new neurons are generated in the dentate gyrus of the adult mammalian hippocampus, a region of the brain that is important for learning and memory. However, it is not known whether these new neurons become functional, as the methods used to study adult neurogenesis are limited to fixed tissue. We use here a retroviral vector expressing green fluorescent protein that only labels dividing cells, and that can be visualized in live hippocampal slices. We report that newly generated cells in the adult mouse hippocampus have neuronal morphology and can display passive membrane properties, action potentials and functional synaptic inputs similar to those found in mature dentate granule cells. Our findings demonstrate that newly generated cells mature into functional neurons in the adult mammalian brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Praag</LastName><ForeName>Henriette</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA. vanpraag@salk.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schinder</LastName><ForeName>Alejandro F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Christie</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Toni</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Theo D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH090258</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Gompeting interests statement. The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>30</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11875571</ArticleId><ArticleId IdType="mid">NIHMS1672553</ArticleId><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="doi">10.1038/4151030a</ArticleId><ArticleId IdType="pii">4151030a</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altman J &amp; Das GD Autoradiographic and histological evidence of postnatal neurogenesis in rats. J. Comp. Neurol l24, 319&#x2013;335 (1965).</Citation><ArticleIdList><ArticleId IdType="pubmed">5861717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MS &amp; Hinds JW Neurogenesis in the adult rat: electron microscopic analysis of light radioautographs. Science l97, 1092&#x2013;1094 (1977).</Citation><ArticleIdList><ArticleId IdType="pubmed">887941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H &amp; Gage FH Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J. Neurosci l6, 2027&#x2013;2033 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornack DR &amp; Rakic P Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Proc. Natl Acad. Sci. USA 96, 5768&#x2013;5773 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21935</ArticleId><ArticleId IdType="pubmed">10318959</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS et al. Neurogenesis in the adult human hippocampus. Nature Med 4, 1313&#x2013;1317 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnea A &amp; Nottebohm F Seasonal recruitment of hippocampal neurons in adult free-ranging black-capped chickadees. Proc. Natl Acad. Sci. USA 9l, 11217&#x2013;11221 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45198</ArticleId><ArticleId IdType="pubmed">7972037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG &amp; Gage FH More hippocampal neurons in adult mice living in an enriched environment. Nature 386, 493&#x2013;495 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G &amp; Gage FH Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nature Neurosci 2, 266&#x2013;270 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Christie BR, Sejnowski TJ &amp; Gage FH Running enhances neurogenesis, learning and long-term potentiation in mice. Proc. Natl Acad. Sci. USA 96, 13427&#x2013;13431 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23964</ArticleId><ArticleId IdType="pubmed">10557337</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Solway K, Messing RO &amp; Sharp FR Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J. Neurosci l8, 7768&#x2013;7778 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793017</ArticleId><ArticleId IdType="pubmed">9742147</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent JM et al. Dentate granule neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult hippocampus. J. Neurosci l7, 3727&#x2013;3738 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573703</ArticleId><ArticleId IdType="pubmed">9133393</ArticleId></ArticleIdList></Reference><Reference><Citation>Magavi SS, Leavitt BR &amp; Macklis JD Induction of neurogenesis in the neocortex of adult mice. Nature 405, 951&#x2013;955 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10879536</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Cameron HA, Daniels DC, Wooley CS &amp; McEwen BS Adrenal hormones suppress cell division in the adult rat dentate gyrus. J. Neurosci l2, 3642&#x2013;3650 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575731</ArticleId><ArticleId IdType="pubmed">1527603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire V, Koehl M, Le Moal M &amp; Abrous DN Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proc. Natl Acad. Sci. USA 97, 11032&#x2013;11037 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27143</ArticleId><ArticleId IdType="pubmed">11005874</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicario-Abejon C, Collin C, Tsoulfas P &amp; McKay RD Hippocampal stem cells differentiate into excitatory and inhibitory neurons. Bur. J. Neurosci l2, 677&#x2013;688 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10712648</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah DW, Ray J &amp; Gage FH Regulation of voltage- and ligand-gated currents in rat hippocampal progenitor cells in vitro. J. Neurobiol 32, 95&#x2013;110 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">8989666</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy NS et al. In vitro neurogenesis by progenitor cells isolated from the adult hippocampus. Nature Med 6, 271&#x2013;277 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10700228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis PF &amp; Emerman M Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol 68, 510&#x2013;516 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236313</ArticleId><ArticleId IdType="pubmed">8254763</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TD, Willhoite AR &amp; Gage FH Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol 425, 479&#x2013;494 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10975875</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Yee JK, Wolff JA &amp; Friedmann T Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology l7l, 331&#x2013;341 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2503932</ArticleId></ArticleIdList></Reference><Reference><Citation>Markakis EA &amp; Gage FH Adult-generated neurons in the dentate gyrus send axonal projections to field CA3 and are surrounded by synaptic vesicles. J. Comp. Neurol 406, 449&#x2013;460 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10205022</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards FA Anatomy and electrophysiology of fast central synapses lead to a structural model for long-term potentiation. Physiol. Rev 75, 759&#x2013;787 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7480162</ArticleId></ArticleIdList></Reference><Reference><Citation>Crain B, Cotman C, Taylor D &amp; Lynch G A quantitative electron microscopic study of synaptogenesis in the dentate gyrus of the rat. Brain Res 63, 195&#x2013;204 (1973).</Citation><ArticleIdList><ArticleId IdType="pubmed">4764297</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki F, Makiura Y, Guilhem D, Sorensen JC &amp; Onteniente B Correlated axonal sprouting and dendritic spine formation during kainate-induced neuronal morphogenesis in the dentate gyrus of adult mice. Bxp. Neurol l45, 203&#x2013;213 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9184122</ArticleId></ArticleIdList></Reference><Reference><Citation>Staley KJ, Otis TS &amp; Mody I Membrane properties of dentate gyrus granule cells: comparison of sharp microelectrode and whole-cell recordings. J. Neurophysiol 67, 1346&#x2013;1358 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1597717</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;bke J, Frotscher M &amp; Spruston N Specialized electrophysiological properties of anatomically identified neurons in the hilar region of the rat fascia dentate. J. Neurophysiol 79, 1518&#x2013;1534 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9497429</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PA &amp; Miller RF Measurement of passive membrane parameters with whole-cell recording from neurons in the intact amphibian retina. J. Neurophysiol 6l, 218&#x2013;230 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2918347</ArticleId></ArticleIdList></Reference><Reference><Citation>Biebl M, Cooper CM, Winkler J &amp; Kuhn HG Analysis of neurogenesis and programmed cell death reveals a self-renewing capacity in the adult rat brain. Neurosci. Lett 29l, 17&#x2013;20 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10962143</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman LA &amp; Friedlander MJ Intracellular injections of permanent tracers in the fixed slice: a comparison of HRP and biocytin. J. Neurosci. Methods 44, 167&#x2013;177 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1474850</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TD, Markakis EA, Willhoite AR, Safar F &amp; Gage FH Fibroblast growth factor-2 activates a latent neurogenic progam in neural stem cells from diverse regions of the adult CNS. J. Neurosci l9, 8487&#x2013;8497 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783019</ArticleId><ArticleId IdType="pubmed">10493749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11875758</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9297</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Age at onset in two common neurodegenerative diseases is genetically controlled.</ArticleTitle><Pagination><StartPage>985</StartPage><EndPage>993</EndPage><MedlinePgn>985-93</MedlinePgn></Pagination><Abstract><AbstractText>To identify genes influencing age at onset (AAO) in two common neurodegenerative diseases, a genomic screen was performed for AAO in families with Alzheimer disease (AD; n=449) and Parkinson disease (PD; n=174). Heritabilities between 40%--60% were found in both the AD and PD data sets. For PD, significant evidence for linkage to AAO was found on chromosome 1p (LOD = 3.41). For AD, the AAO effect of APOE (LOD = 3.28) was confirmed. In addition, evidence for AAO linkage on chromosomes 6 and 10 was identified independently in both the AD and PD data sets. Subsequent unified analyses of these regions identified a single peak on chromosome 10q between D10S1239 and D10S1237, with a maximum LOD score of 2.62. These data suggest that a common gene affects AAO in these two common complex neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi-Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Center for Human Genetics, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>William K</ForeName><Initials>WK</Initials></Author><Author ValidYN="Y"><LastName>Hedges</LastName><ForeName>Dale J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fengyu</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gaskell</LastName><ForeName>P Craig</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Nance</LastName><ForeName>Martha A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ray L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Hubble</LastName><ForeName>Jean P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>William C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Hiner</LastName><ForeName>Bradley C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Fred A</ForeName><Initials>FA</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Mastaglia</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Stajich</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Lefkos T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Burton L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Nicodemus</LastName><ForeName>Kristin K</ForeName><Initials>KK</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Allison D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Schmechel</LastName><ForeName>Donald E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Conneally</LastName><ForeName>P Michael</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Roses</LastName><ForeName>Allen D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>OMIM</DataBankName><AccessionNumberList><AccessionNumber>MIM104300</AccessionNumber><AccessionNumber>MIM168600</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG 05128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS 26630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 10123</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS 39764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS026630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 11268</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010123</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS031153</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS039764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 31153</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013308</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH052453</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 AG011268</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR 00865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 52453</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 13308</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002878" MajorTopicYN="N">Chromosomes, Human, Pair 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002879" MajorTopicYN="N">Chromosomes, Human, Pair 10</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002896" MajorTopicYN="N">Chromosomes, Human, Pair 6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2001</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2002</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11875758</ArticleId><ArticleId IdType="pmc">PMC379130</ArticleId><ArticleId IdType="doi">10.1086/339815</ArticleId><ArticleId IdType="pii">S0002-9297(07)60305-X</ArticleId></ArticleIdList><ReferenceList><Title>Electronic-Database Information</Title><Reference><Citation>Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for AD [MIM 104300] and PD [MIM 168600])</Citation></Reference><Reference><Citation>Map-O-Mat, http://compgen.rutgers.edu/mapomat/</Citation></Reference></ReferenceList><ReferenceList><Reference><Citation>Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R, Brousolle E, Brefel-Courbon C, Harhangi S, Oostra B, Fabrizio E, Bohme GA, Pradier L, Wood NW, Filla A, Meco G, Denefle P, Agid Y, Brice A, The French Parkinson's Disease Study Group, The European Consortium on Genetic Susceptibility in Parknson's Disease (1999) A wide variety of mutations in the Parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 8:567&#x2013;574</Citation><ArticleIdList><ArticleId IdType="pubmed">10072423</ArticleId></ArticleIdList></Reference><Reference><Citation>Almasy L, Blangero J (1998) Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 62:1198&#x2013;1211</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377101</ArticleId><ArticleId IdType="pubmed">9545414</ArticleId></ArticleIdList></Reference><Reference><Citation>Amos CI (1994) Robust variance-components approach for assessing genetic linkage in pedigrees. Am J Hum Genet 54:535&#x2013;543</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1918121</ArticleId><ArticleId IdType="pubmed">8116623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis M, Go RCP, Vekrellis K, Selkoe DJ, Saunders A, Tanzi R (2000) Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290:2302&#x2013;2305</Citation><ArticleIdList><ArticleId IdType="pubmed">11125142</ArticleId></ArticleIdList></Reference><Reference><Citation>Blangero J, Almasy L (1997) Multipoint oligogenic linkage analysis of quantitative traits. Genet Epidemiol 14:959&#x2013;964</Citation><ArticleIdList><ArticleId IdType="pubmed">9433607</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Daw EW, Heath SC, Wijsman EM (1999) Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer disease pedigrees. Am J Hum Genet 64:839&#x2013;851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377802</ArticleId><ArticleId IdType="pubmed">10053019</ArticleId></ArticleIdList></Reference><Reference><Citation>Daw EW, Payami H, Nemens E, Nochlin D, Bird TD (2000) The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 66:196&#x2013;204</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288326</ArticleId><ArticleId IdType="pubmed">10631151</ArticleId></ArticleIdList></Reference><Reference><Citation>Destefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, et al (2001) Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology 57:1124&#x2013;1126</Citation><ArticleIdList><ArticleId IdType="pubmed">11571351</ArticleId></ArticleIdList></Reference><Reference><Citation>Duggirala R, Blangero J, Almasy L, Dyer TD, Williams KL, Leach RJ, O'Connell P, Stern MP (1999) Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans. Am J Hum Genet 64:1127&#x2013;1140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377837</ArticleId><ArticleId IdType="pubmed">10090898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG (2000) Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290:2303&#x2013;2304</Citation><ArticleIdList><ArticleId IdType="pubmed">11125143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulker DW, Cherny SS, Cardon LR (1995) Multipoint interval mapping of quantitative trait loci. Am J Hum Genet 56:1224&#x2013;1233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1801470</ArticleId><ArticleId IdType="pubmed">7726180</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance MA, Roses A, Williamson R, Rossor M, Owen M, Hardy J (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704&#x2013;706</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgar DE (1990) Multipoint analysis of human quantitative genetic variation. Am J Hum Genet 47:957&#x2013;967</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683895</ArticleId><ArticleId IdType="pubmed">2239972</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines JL, Pericak-Vance MA (2001) A genomic search for Alzheimer's disease genes. In: Iqbal K, Sisodia SS, Winblad B (eds) Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. John Wiley &amp; Sons, London, pp 33&#x2013;43</Citation></Reference><Reference><Citation>Harhangi BS, de Rijk MC, Van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM (2000) APOE and the risk of PD with or without dementia in a population-based study. Neurology 54:1272&#x2013;1276</Citation><ArticleIdList><ArticleId IdType="pubmed">10746597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992a) What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologica study. Neurology 42:1142&#x2013;1146</Citation><ArticleIdList><ArticleId IdType="pubmed">1603339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992b) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181&#x2013;184</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Rosenberg CR, Gaskell CP, Ervin JF, Saunders AM, Scott WK, Vance JM, Schmechel DE, Pericak-Vance MA (2000) Familial dementia with Lewy bodies. Paper presented at the Society for Neuroscience 30th Annual Meeting, New Orleans, November 4&#x2013;9</Citation></Reference><Reference><Citation>Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ (1999) A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 8:237&#x2013;245</Citation><ArticleIdList><ArticleId IdType="pubmed">9931331</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, Graham E, Dixon P, Morris C, Mander A, Clayton D, Vaughan J, Quinn N, Lees A, Daniel S, Wood N, de Silva R (2001) Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype. Ann Neurol 49:665&#x2013;668</Citation><ArticleIdList><ArticleId IdType="pubmed">11357958</ArticleId></ArticleIdList></Reference><Reference><Citation>Korczyn AD (2001) Dementia in Parkinson's disease. J Neurol Suppl 248:III1&#x2013;III4</Citation><ArticleIdList><ArticleId IdType="pubmed">11697682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, Green P (1987) Construction of multilocus genetic linkage maps in humans. Proc Natl Acad Sci USA 84:2363&#x2013;2367</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304651</ArticleId><ArticleId IdType="pubmed">3470801</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley AC, Fu YH, Guenette SY, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD, Tanzi RE (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973&#x2013;977</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (2001) Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol 58:1817&#x2013;1820</Citation><ArticleIdList><ArticleId IdType="pubmed">11708989</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al (2001) Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 286:2245&#x2013;2250</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973175</ArticleId><ArticleId IdType="pubmed">11710889</ArticleId></ArticleIdList></Reference><Reference><Citation>Matise TC, Gitlin JA (1999) MAP-O-MAT: marker-based linkage mapping on the World Wide Web. Am J Hum Genet Suppl 65:A435</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58:1803&#x2013;1809</Citation><ArticleIdList><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillysstone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM (2000) Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290:2304&#x2013;2305</Citation><ArticleIdList><ArticleId IdType="pubmed">11125144</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott WK, Conneally PM, Vance JM, Haines JL (2000) Identification of novel genes in late-onset Alzheimer disease. Exp Gerontol 35:1343&#x2013;1352</Citation><ArticleIdList><ArticleId IdType="pubmed">11113612</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroose ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274:1197&#x2013;1199</Citation><ArticleIdList><ArticleId IdType="pubmed">8895469</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775&#x2013;778</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott WK, Grubber JM, Conneally PM, Small GW, Hulette CM, Rosenberg CK, Saunders AM, Roses AD, Haines JL, Pericak-Vance MA (2000) Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J Hum Genet 66:922&#x2013;932</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288173</ArticleId><ArticleId IdType="pubmed">10712207</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, et al (2001) Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286:2239&#x2013;2244</Citation><ArticleIdList><ArticleId IdType="pubmed">11710888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754&#x2013;760</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 68:895&#x2013;900</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275643</ArticleId><ArticleId IdType="pubmed">11254447</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, Van Swieten JC, Oostra BA, Heutink P (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69:629&#x2013;634</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235491</ArticleId><ArticleId IdType="pubmed">11462174</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance JM, Ben Othmane K (1998) Methods of genotyping. In: Haines JL, Pericak-Vance MA (eds) Approaches to gene mapping in complex human diseases. Wiley-Liss, New York, pp 213&#x2013;228</Citation></Reference><Reference><Citation>Ward CD, Gibb WR (1990) Research diagnostic criteria for Parkinson's disease. Adv Neurol 53:245&#x2013;249</Citation><ArticleIdList><ArticleId IdType="pubmed">2239463</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks DE, Conley YP, Mah TS, Paul TO, Morse L, Ngo-Chang J, Dailey JP, Ferrell RE, Gorin MB (2000) A full genome scan for age-related maculopathy. Hum Mol Genet 9:1329&#x2013;1349</Citation><ArticleIdList><ArticleId IdType="pubmed">10814715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA (2000) Progression of parkinsonism and loss of cognitive function in Alzheimer disease. Arch Neurol 57:855&#x2013;860</Citation><ArticleIdList><ArticleId IdType="pubmed">10867783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11879646</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome.</ArticleTitle><Pagination><StartPage>677</StartPage><EndPage>688</EndPage><MedlinePgn>677-88</MedlinePgn></Pagination><Abstract><AbstractText>Most Down's syndrome (DS) patients develop Alzheimer's disease (AD) neuropathology. Astrocyte and neuronal cultures derived from fetal DS brain show alterations in the processing of amyloid beta precursor protein (AbetaPP), including increased levels of AbetaPP and C99, reduced levels of secreted AbetaPP (AbetaPPs) and C83, and intracellular accumulation of insoluble Abeta42. This pattern of AbetaPP processing is recapitulated in normal astrocytes by inhibition of mitochondrial metabolism, consistent with impaired mitochondrial function in DS astrocytes. Intracellular Abeta42 and reduced AbetaPPs are also detected in DS and AD brains. The survival of DS neurons is markedly increased by recombinant or astrocyte-produced AbetaPPs, suggesting that AbetaPPs may be a neuronal survival factor. Thus, mitochondrial dysfunction in DS may lead to intracellular deposition of Abeta42, reduced levels of AbetaPPs, and a chronic state of increased neuronal vulnerability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Busciglio</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA. busciglio@nso1.uchc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelsman</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Caine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pigino</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Menglan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HD38466</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS30352</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS33325</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002232">Carbocyanines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014475">Uncoupling Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>21527-78-6</RegistryNumber><NameOfSubstance UI="C068624">5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>555-60-2</RegistryNumber><NameOfSubstance UI="D002258">Carbonyl Cyanide m-Chlorophenyl Hydrazone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002232" MajorTopicYN="N">Carbocyanines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002258" MajorTopicYN="N">Carbonyl Cyanide m-Chlorophenyl Hydrazone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014475" MajorTopicYN="N">Uncoupling Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>30</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11879646</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(02)00604-9</ArticleId><ArticleId IdType="pii">S0896627302006049</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11880497</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells.</ArticleTitle><Pagination><StartPage>1679</StartPage><EndPage>1689</EndPage><MedlinePgn>1679-89</MedlinePgn></Pagination><Abstract><AbstractText>Generation of amyloid-beta (Abeta) from the amyloid precursor protein (APP) requires proteolytic cleavage by two proteases, beta- and gamma-secretase. Several lines of evidence suggest a role for cholesterol on secretase activities, although the responsible cellular mechanisms remain unclear. Here we show that alterations in cholesterol transport from late endocytic organelles to the endoplasmic reticulum have important consequences for both APP processing and the localization of gamma-secretase-associated presenilins (PS). Exposure of neuronal cells to cholesterol transport-inhibiting agents resulted in a marked decrease in beta-cleavage of full-length APP. In contrast, gamma-secretase activity on APP C-terminal fragments was enhanced, increasing the production of both Abeta40 and Abeta42. Remarkably, retention of cholesterol in endosomal/lysosomal compartments induced PS1 and PS2 to accumulate in Rab7-positive vesicular organelles implicated in cholesterol sorting. Accumulation of PS in vesicular compartments was prominent in both Chinese hamster ovary cells deficient in Niemann-Pick C1 protein as well as in neuronal cells exposed to the cholesterol transport-inhibiting agent U18666A. Because Abeta42 also localized to PS1-containing vesicular compartments, organelles involved in cholesterol transport might represent an important site for gamma-secretase activity. Our results suggest that the subcellular distribution of cholesterol may be an important factor in how cholesterol alters Abeta production and the risk of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Runz</LastName><ForeName>Heiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Molecular Biology, University of Heidelberg, 69120 Heidelberg, Germany. hrunz@ix.urz.uni-heidelberg.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rietdorf</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tomic</LastName><ForeName>Inge</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>de Bernard</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>Konrad</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pepperkok</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090802">rab7 GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000716463">rab7 GTP-binding proteins, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000716465">rab7 GTP-binding proteins, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000716466">rab7 GTP-binding proteins, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002451" MajorTopicYN="N">Cell Compartmentation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022162" MajorTopicYN="N">Cytoplasmic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007424" MajorTopicYN="N">Intracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090802" MajorTopicYN="N">rab7 GTP-Binding Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11880497</ArticleId><ArticleId IdType="pmc">PMC6758870</ArticleId><ArticleId IdType="pii">22/5/1679</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-05-01679.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, St. George-Hyslop P, Cordell B, Fraser P, De Strooper B. Presenilin 1 controls &#x3b3;-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. J Cell Biol. 1999;147:277&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Armogida M, Petit A, Vincent B, Scarzello S, Alves da Costa C, Checler F. Endogenous &#x3b2;-amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nat Cell Biol. 2001;3:1030&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouillot C, Prochiantz A, Rougon G, Allinquant B. Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J Biol Chem. 1996;271:7640&#x2013;7644.</Citation><ArticleIdList><ArticleId IdType="pubmed">8631800</ArticleId></ArticleIdList></Reference><Reference><Citation>Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannou YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ. Niemann&#x2013;Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997;277:228&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">9211849</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Periak-Vance MA. Gene dose of apolipoprotein type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Sugii S, Yu C, Chang TY. Role of Niemann&#x2013;Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol. J Biol Chem. 2000;275:4013&#x2013;4021.</Citation><ArticleIdList><ArticleId IdType="pubmed">10660558</ArticleId></ArticleIdList></Reference><Reference><Citation>Culvenor JG, Maher F, Evin G, Malchiodi-Albedi F, Cappai R, Underwood JR, Davis JB, Karran EH, Roberts GW, Beyreuther K, Masters CL. Alzheimer's disease-associated presenilin 1 in neuronal cells: evidence for localization to the endoplasmic reticulum&#x2013;Golgi intermediate compartment. J Neurosci Res. 1997;49:719&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">9335259</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBose-Boyd RA, Brown MS, Li WP, Nohturfft A, Goldstein JL, Espenshade PJ. Transport-dependent proteolysis of SREBP: relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi. Cell. 1999;99:703&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">10619424</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113:1857&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806097</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Presenilins and the intramembrane proteolysis of proteins: facts and fiction. Nat Cell Biol. 2001;3:E221&#x2013;E225.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584280</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyrks T, Dyrks E, Monning U, Urmoneit B, Turner J, Beyreuther K. Generation of &#x3b2;A4 from the amyloid protein precursor and fragments thereof. FEBS Lett. 1993;335:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8243673</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk T, Garver WS, Erickson EP, Wilson JM, Yool AJ. Expression of Niemann&#x2013;Pick type C transcript in rodent cerebellum in vivo and in vitro. Brain Res. 1999;839:49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482798</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Simons M, Bergmann C, Stroick M, L&#xfc;tjohann D, Keller P, Runz H, K&#xfc;hl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease &#x3b2;-amyloid peptides A&#x3b2;42 and A&#x3b2;40 levels in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98:5856&#x2013;5861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33303</ArticleId><ArticleId IdType="pubmed">11296263</ArticleId></ArticleIdList></Reference><Reference><Citation>Frears ER, Stephens DJ, Walters CE, Davies H, Austin BM. The role of cholesterol in the biosynthesis of &#x3b2;-amyloid. NeuroReport. 1999;10:1699&#x2013;1705.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501560</ArticleId></ArticleIdList></Reference><Reference><Citation>Goslin K, Banker G. Rat hippocampal neurons in low-density culture. In: Banker G, Goslin K, editors. Cultivating nerve cells. MIT; Cambridge, MA: 1991. pp. 251&#x2013;281.</Citation></Reference><Reference><Citation>Herz J, Hamann U, Rogne S, Mykelbost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500 kD liver membrane protein related to the LDL receptor suggest a physiological role as lipoprotein receptor. EMBO J. 1988;7:4119&#x2013;4127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC455121</ArticleId><ArticleId IdType="pubmed">3266596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida N, Hartmann T, Pantel J, Schroeder J, Zerfass R, Foerstel H, Sandbrink R, Masters CL, Beyreuther K. Analysis of heterogeneous &#x3b2;A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908&#x2013;22914.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L. Quantification of Alzheimer amyloid &#x3b2;-peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med. 2000;6:291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949952</ArticleId><ArticleId IdType="pubmed">10949910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko DC, Gordon MD, Jin JY, Scott MP. Dynamic movements of organelles containing Niemann&#x2013;Pick C1 protein: NPC1 involvement in late endocytic events. Mol Biol Cell. 2001;12:601&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30967</ArticleId><ArticleId IdType="pubmed">11251074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Stang E, Fang KS, De Moerloose P, Parton RG, Gruenberg J. A lipid associated with the anti-phospholipid syndrome regulates endosome structure and function. Nature. 1998;392:193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">9515966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E, Gimpl G, Lammich S, M&#xe4;rz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the &#x3b1;-secretase ADAM10. Proc Natl Acad Sci USA. 2001;98:5815&#x2013;5820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33296</ArticleId><ArticleId IdType="pubmed">11309494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted &#x3b2;-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996;2:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">8574969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange Y, Ye J, Rigney M, Steck T. Cholesterol movement in Niemann&#x2013;Pick type C cells and in cells treated with amphiphiles. J Biol Chem. 2000;275:17468&#x2013;17475.</Citation><ArticleIdList><ArticleId IdType="pubmed">10751394</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscum L, Ruggiero RM, Faust JR. The intracellular transport of low-density lipoprotein-derived cholesterol is defective in Niemann&#x2013;Pick type C fibroblasts. J Cell Biol. 1989;108:1625&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115531</ArticleId><ArticleId IdType="pubmed">2715172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lusa S, Blom TS, Eskelinen EL, Kuismanen E, Mansson JE, Simons K, Ikonen E. Depletion of rafts in late endocytic membranes is controlled by NPC1-dependent recycling of cholesterol to the plasma membrane. J Cell Sci. 2001;114:1893&#x2013;1900.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329376</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;tjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, Bjorkhem I. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA. 1996;93:9799&#x2013;9804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38509</ArticleId><ArticleId IdType="pubmed">8790411</ArticleId></ArticleIdList></Reference><Reference><Citation>Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M, Lobel P. Identification of HE1 as the second gene of Niemann&#x2013;Pick C disease. Science. 2000;290:2298&#x2013;2301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125141</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeld EB, Wastney M, Patel S, Suresh S, Cooney AM, Dwyer NK, Roff CF, Ohno K, Morris JA, Carstea ED, Incardona JP, Strauss JF, III, Vanier MT, Patterson MC, Brady RO, Pentchev PG, Blanchette-Mackie EJ. The Niemann&#x2013;Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J Biol Chem. 1999;274:9627&#x2013;9635.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092649</ArticleId></ArticleIdList></Reference><Reference><Citation>Orci L, Brown MS, Goldstein JL, Garcia-Segura LM, Anderson G. Increase in membrane cholesterol: a possible trigger for degradation of HMG-CoA reductase and crystalloid endoplasmic reticulum in UT-1 cells. Cell. 1984;36:835&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">6705048</ArticleId></ArticleIdList></Reference><Reference><Citation>Papini E, Gottardi E, Satin B, de Bernard M, Massari P, Telford J, Rappuoli R, Sato SB, Montecucco C. The vacuolar ATPase proton pump is present on intracellular vacuoles induced by Helicobacter pylori. J Med Microbiol. 1996;45:84&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">8683556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pentchev PG, Comly ME, Kruth HS, Tokoro T, Butler J, Sokol J, Filling-Katz M, Quirk JM, Marshall DC, Patel S, Vanier MT, Brady RO. Group C Niemann&#x2013;Pick disease: faulty regulation of lipoprotein uptake and cholesterol storage in cultured fibroblasts. FASEB J. 1987;1:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">3609608</ArticleId></ArticleIdList></Reference><Reference><Citation>Pol A, Luetterforst R, Lindsay M, Heino S, Ikonen E, Parton R. A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol. 2001;152:1057&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198820</ArticleId><ArticleId IdType="pubmed">11238460</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Konopka G, Pack-Chung E, MacKenzie Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM. Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid &#x3b2;-peptide. Nat Cell Biol. 2001;3:905&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584272</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff KE, Pappolla MA. Hypercholesteremia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964604</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE. A cholesterol-lowering drug reduces &#x3b2;-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592856</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Christie G, Hussain I, Dingwall C. Compartmentalization of &#x3b2;-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol. 2001;11:1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakashita N, Miyazaki A, Takeya M, Horiuchi S, Chang CCY, Chang TY, Takahashi K. Localization of human acyl-CoA:cholesterol acyltransferase-1 in macrophages and in various tissues. Am J Pathol. 2000;156:227&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868616</ArticleId><ArticleId IdType="pubmed">10623671</ArticleId></ArticleIdList></Reference><Reference><Citation>Scales SJ, Pepperkok R, Kreis TE. Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPII and COPI. Cell. 1997;90:1137&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">9323141</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of &#x3b2;-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 1998;95:6460&#x2013;6464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Doms RW, Lee VM. Detection of a novel intraneuronal pool of insoluble amyloid &#x3b2;-protein that accumulates with time in culture. J Cell Biol. 1998;141:1031&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132781</ArticleId><ArticleId IdType="pubmed">9585420</ArticleId></ArticleIdList></Reference><Reference><Citation>Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE. Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA. 1999;96:6775&#x2013;6780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21991</ArticleId><ArticleId IdType="pubmed">10359788</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabas I, Rosoff WJ, Boykow GC. Acyl-coenzyme A:cholesterol acyltransferase in macrophages utilizes a cellular pool of cholesterol oxidase-accessible cholesterol as substrate. J Biol Chem. 1988;263:1266&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">3422077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tienari PJ, De Strooper B, Ikonen E, Simons M, Weidemann A, Czech C, Hartmann T, Ida N, Multhaup G, Masters CL, van Leuven F, Beyreuther K, Dotti CG. The &#x3b2;-amyloid domain is essential for axonal sorting of amyloid precursor protein. EMBO J. 1996;15:5218&#x2013;5229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452266</ArticleId><ArticleId IdType="pubmed">8895567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Ray WJ, Ostaszewski BL, Rahmati T, Kimberly WT, Wolfe MS, Zhang J, Goate AM, Selkoe DJ. Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid &#x3b2;-protein generation. Proc Natl Acad Sci USA. 2000;97:9299&#x2013;9304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16862</ArticleId><ArticleId IdType="pubmed">10922078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Chang TY, Haass C, Ihara Y. Accumulation and aggregation of amyloid &#x3b2;-protein in late endosomes of Niemann&#x2013;Pick type C cells. J Biol Chem. 2001;276:4454&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Dwyer NK, Neufeld EB, Love DC, Cooney A, Comly M, Patel S, Watari H, Strauss JF, III, Pentchev PG, Hanover JA, Blanchette-Mackie EJ. Sterol-modulated glycolipid sorting occurs in Niemann&#x2013;Pick C1 late endosomes. J Biol Chem. 2001;276:3417&#x2013;3425.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032830</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11880504</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1752</StartPage><EndPage>1762</EndPage><MedlinePgn>1752-62</MedlinePgn></Pagination><Abstract><AbstractText>Recent epidemiological and clinical data suggest that persons with low folic acid levels and elevated homocysteine levels are at increased risk of Alzheimer's disease (AD), but the underlying mechanism is unknown. We tested the hypothesis that impaired one-carbon metabolism resulting from folic acid deficiency and high homocysteine levels promotes accumulation of DNA damage and sensitizes neurons to amyloid beta-peptide (Abeta) toxicity. Incubation of hippocampal cultures in folic acid-deficient medium or in the presence of methotrexate (an inhibitor of folic acid metabolism) or homocysteine induced cell death and rendered neurons vulnerable to death induced by Abeta. Methyl donor deficiency caused uracil misincorporation and DNA damage and greatly potentiated Abeta toxicity as the result of reduced repair of Abeta-induced oxidative modification of DNA bases. When maintained on a folic acid-deficient diet, amyloid precursor protein (APP) mutant transgenic mice, but not wild-type mice, exhibited increased cellular DNA damage and hippocampal neurodegeneration. Levels of Abeta were unchanged in the brains of folate-deficient APP mutant mice. Our data suggest that folic acid deficiency and homocysteine impair DNA repair in neurons, which sensitizes them to oxidative damage induced by Abeta.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kruman</LastName><ForeName>Inna I</ForeName><Initials>II</Initials><AffiliationInfo><Affiliation>Laboratory of Neurosciences, National Institute on Aging Gerontology Research Center, Baltimore, Maryland 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumaravel</LastName><ForeName>T S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Lohani</LastName><ForeName>Althaf</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Ward A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Cutler</LastName><ForeName>Roy G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Kruman</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Haughey</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jaewon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical><Chemical><RegistryNumber>56HH86ZVCT</RegistryNumber><NameOfSubstance UI="D014498">Uracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="N">DNA Repair</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005494" MajorTopicYN="N">Folic Acid Deficiency</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020138" MajorTopicYN="N">Hyperhomocysteinemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014498" MajorTopicYN="N">Uracil</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11880504</ArticleId><ArticleId IdType="pmc">PMC6758871</ArticleId><ArticleId IdType="pii">22/5/1752</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-05-01752.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adamec E, Vonsattel JP, Nixon RA. DNA strand breaks in Alzheimer's disease. Brain Res. 1999;849:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10592288</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen DM, van Praag H, Ray J, Weaver Z, Winrow CJ, Carter TA, Braquet R, Harrington E, Ried T, Brown KD, Gage FH, Barlow C. Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev. 2001;15:554&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312645</ArticleId><ArticleId IdType="pubmed">11238376</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest. 1992;22:79&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">1572391</ArticleId></ArticleIdList></Reference><Reference><Citation>Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SN, Everson RB, Ames BN. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implication for cancer and neuronal damage. Proc Natl Acad Sci USA. 1997;94:3290&#x2013;3295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20362</ArticleId><ArticleId IdType="pubmed">9096386</ArticleId></ArticleIdList></Reference><Reference><Citation>Boerrigter ME, van Duijn CM, Mullaart E, Eikelenboom P, van der Togt CM, Knook DL, Hofman A, Vijg J. Decreased DNA repair capacity in familial, but not in sporadic, Alzheimer's disease. Neurobiol Aging. 1991;12:367&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961372</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate A&#x3b2;1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Branda RF, Blickensderfer DB. Folate deficiency increases genetic damage caused by alkylating agents and gamma-irradiation in Chinese hamster ovary cells. Cancer Res. 1993;53:5401&#x2013;5408.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221678</ArticleId></ArticleIdList></Reference><Reference><Citation>Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle aged and elderly subjects. J Intern Med. 1994;236:633&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">7989898</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Griffin WS, Mattson MP. Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. J Neurosci Res. 1999;57:315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412022</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr. 2000;130:129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">10720158</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pubmed">9823829</ArticleId></ArticleIdList></Reference><Reference><Citation>Copani A, Uberti D, Sortino AM, Bruno V, Nicoletti F, Memo M. Activation of cell cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends Neurosci. 2001;24:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163884</ArticleId></ArticleIdList></Reference><Reference><Citation>Culmsee C, Zhu Z, Yu QS, Chan SL, Camandola S, Guo Z, Greig N, Mattson MP. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid &#x3b2;-peptide. J Neurochem. 2001;77:220&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279278</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte SM, Sohn YK, Ganju N, Wands JR. p53- and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest. 1998;78:401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">9564885</ArticleId></ArticleIdList></Reference><Reference><Citation>Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746348</ArticleId></ArticleIdList></Reference><Reference><Citation>Duthie SJ, McMillan P. Uracil misincorporation in human DNA detected using single cell gel electrophoresis. Carcinogenesis. 1997;18:1709&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pubmed">9328165</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol. 1998;18:429&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairbairn DW, Olive PL, O'Neill KL. The comet assay: a comprehensive review. Mutat Res. 1995;339:37&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">7877644</ArticleId></ArticleIdList></Reference><Reference><Citation>Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, Selkoe DJ, Lansbury PT, Jr, Fink AL, Teplow DB. An improved method of preparing the amyloid &#x3b2;-protein for fibrillogenesis and neurotoxicity experiments. Amyloid. 2000;7:166&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11019857</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Lieberburg I, Schenk D. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobbel GT, Bellinzona M, Vogt AR, Gupta N, Fike JR, Chan PH. Response of postmitotic neurons to X-irradiation: implications for the role of DNA damage in neuronal apoptosis. J Neurosci. 1998;18:147&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793394</ArticleId><ArticleId IdType="pubmed">9412495</ArticleId></ArticleIdList></Reference><Reference><Citation>Golos B, Malec J. Enhancement of methotrexate-induced growth inhibition, cell killing, and DNA lesions in cultured L5178Y cells by the reduction of DNA repair efficiency. Biochem Pharmacol. 1989;38:1743&#x2013;1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">2735932</ArticleId></ArticleIdList></Reference><Reference><Citation>Green R, Miller JW. Folate deficiency beyond megaloblastic anemia: hyperhomocysteinemia and other manifestations of dysfunctional folate status. Semin Hematol. 1999;36:47&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930568</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieve A, Butcher SP, Griffiths R. Synaptosomal plasma membrane transport of excitatory sulphur amino acid transmitter candidates: kinetic characterization and analysis of carrier specificity. J Neurosci Res. 1992;32:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">1352830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueneau G, Drouet J, Privat A, Court L. Differential radiosensitivity of neurons and neuroglia of the hippocampus in the adult rabbit. Acta Neuropathol (Berl) 1979;48:199&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">525260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJ, Jensen EB. The efficacy of systematic sampling in stereology and its prediction. J Microsc. 1987;147:229&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">3430576</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, Bondada V, Rangnekar VM, Mattson MP. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med. 1998;4:957&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">9701251</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada J, Sugimoto M. Activation of caspase-3 in &#x3b2;-amyloid-induced apoptosis of cultured rat cortical neurons. Brain Res. 1999;842:311&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul. 1994;34:397&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">7942284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisby GE, Kabel H, Hugon J, Spencer P. Damage and repair of nerve cell DNA in toxic stress. Drug Metab Rev. 1999;31:589&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">10461542</ArticleId></ArticleIdList></Reference><Reference><Citation>Korr H, Schultze B. Unscheduled DNA synthesis in various types of cells of the mouse brain in vivo. Exp Brain Res. 1989;74:573&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">2707332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci. 1997;17:5089&#x2013;5100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573293</ArticleId><ArticleId IdType="pubmed">9185546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000;20:6920&#x2013;6926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772815</ArticleId><ArticleId IdType="pubmed">10995836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol. 1998;40:225&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9813406</ArticleId></ArticleIdList></Reference><Reference><Citation>Laval J, Jurado J, Saparbaev M, Sidorkina O. Anti-mutagenic role of base-excision repair enzymes upon free radical-induced DNA damage. Mutat Res. 1998;402:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">9675252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Duan W, Long JM, Ingram KD, Mattson MP. Dietary restriction increases survival of newly generated neural cells and induces BDNF expression in the dentate gyrus of rats. J Mol Neurosci. 2000;15:99&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220789</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JC, Kaminskas E. Deficient repair of DNA lesions in Alzheimer's disease fibroblasts. Biochem Biophys Res Commun. 1985;129:733&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">2409969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci USA. 1997;94:5923&#x2013;5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20882</ArticleId><ArticleId IdType="pubmed">9159176</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Mouton PR, Jucker M, Ingram DK. What counts in brain aging? Design-based stereological analysis of cell number. J Gerontol A Biol Sci Med Sci. 1999;54:B407&#x2013;B417.</Citation><ArticleIdList><ArticleId IdType="pubmed">10568523</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by &#x3b2;-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA. 1993;90:7951&#x2013;7955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47265</ArticleId><ArticleId IdType="pubmed">8367446</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain. 1999;122:247&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark RJ, Hensley K, Butterfield DA, Mattson MP. Amyloid &#x3b2;-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosci. 1995;15:6239&#x2013;6249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577674</ArticleId><ArticleId IdType="pubmed">7666206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid &#x3b2;-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci. 1997;17:1046&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573165</ArticleId><ArticleId IdType="pubmed">8994059</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA. Caspase-dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol. 1998;57:1041&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9825941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Cellular actions of &#x3b2;-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997;77:1081&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2000;1:120&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11253364</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. &#x3b2;-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992;12:376&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575616</ArticleId><ArticleId IdType="pubmed">1346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Tomaselli K, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated &#x3b2;-amyloid peptide are attenuated by basic FGF. Brain Res. 1993;621:35&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221072</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Keller JN, Begley JG. Evidence for synaptic apoptosis. Exp Neurol. 1998;153:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743565</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P, Lavin M, Kidson C. Control of DNA repair linked to neuroblastoma differentiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1976;29:523&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">1085761</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JW. Homocysteine and Alzheimer's disease. Nutr Rev. 1999;57:126&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">10228350</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol CD, Parikh SS, Putnam CD, Lo TP, Tainer JA. DNA repair mechanisms for the recognition and removal of damaged DNA bases. Annu Rev Biophys Biomol Struct. 1999;28:101&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">10410797</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol. 1996;134:757&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120941</ArticleId><ArticleId IdType="pubmed">8707853</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris EJ, Dreixler JC, Cheng KY, Wilson PM, Gin RM, Geller HM. Optimization of single-cell gel electrophoresis (SCGE) for quantitative analysis of neuronal DNA damage. Biotechniques. 1999;26:282&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">10023540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullaart E, Boerrigter ME, Ravid R, Swaab DF, Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging. 1990;11:169&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">2362649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler JV, Perry BW, Gentry C, Cotman CW. Degeneration of hippocampal CA3 pyramidal cells induced by intraventricular kainic acid. J Comp Neurol. 1980;192:333&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">7400401</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka F, Tarone RE, Seguin LR, Robbins JH. Hypersensitivity to ionizing radiation in cultured cells from Down syndrome patients. J Neurol Sci. 1985;69:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">3159854</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A. Amyloid &#x3b2;-peptide of Alzheimer's disease downregulates Bcl-2 and upregulates Bax expression in human neurons. J Neurosci. 1996;16:7533&#x2013;7539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579094</ArticleId><ArticleId IdType="pubmed">8922409</ArticleId></ArticleIdList></Reference><Reference><Citation>Park DS, Morris EJ, Stefanis L, Troy CM, Shelanski ML, Geller HM, Greene LA. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci. 1998;18:830&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792759</ArticleId><ArticleId IdType="pubmed">9437005</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogribny IP, Muskhelishvili L, Miller BJ, James SJ. Presence and consequence of uracil in preneoplastic DNA from folate/methyl-deficient rats. Carcinogenesis. 1997;18:2071&#x2013;2076.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395204</ArticleId></ArticleIdList></Reference><Reference><Citation>Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9509248</ArticleId></ArticleIdList></Reference><Reference><Citation>Robison SH, Munzer JS, Tandan R, Bradley WG. Alzheimer's disease cells exhibit defective repair of alkylating agent-induced DNA damage. Ann Neurol. 1987;21:250&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">3606032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler U, Calsou P, Boiteux S, Salles B. Detection of oxidative base DNA damage by a new biochemical assay. Arch Biochem Biophys. 2000;376:26&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">10729187</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JM, Weir DG. Folic acid, homocysteine, and one-carbon metabolism: a review of the essential biochemistry. J Cardiovasc Risk. 1998;5:223&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9919469</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidl R, Fang-Kircher S, Bidmon B, Cairns N, Lubec G. Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome. Neurosci Lett. 1999;260:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027687</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D, Leone G, DeGregori J, Ahmed MN, Qumsiyeh MB, Nevins JR. Induction of DNA replication in adult rat neurons by deregulation of the retinoblastoma/E2F G1 cell cycle pathway. Cell Growth Differ. 2000;11:625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">11149597</ArticleId></ArticleIdList></Reference><Reference><Citation>Smulson ME, Simbulan-Rosenthal CM, Boulares AH, Yakovlev A, Stoica B, Iyer S, Luo R, Haddad B, Wang ZQ, Pang T, Jung M, Dritschilo A, Rosenthal DS. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability, and functions of p53 and E2F-1. Adv Enzyme Regul. 2000;40:183&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">10828352</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr. 2000;71:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">10731508</ArticleId></ArticleIdList></Reference><Reference><Citation>Struthers L, Patel R, Clark J, Thomas S. Direct detection of 8-oxodeoxyguanosine and 8-oxoguanine by avidin and its analogs. Anal Biochem. 1998;255:20&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9448838</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol. 1997;56:86&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8990132</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain RA, St. Clair L. The role of folic acid in deficiency states and prevention of disease. J Fam Pract. 1997;44:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">9040515</ArticleId></ArticleIdList></Reference><Reference><Citation>Torp R, Su JH, Deng G, Cotman CW. GADD45 is induced in Alzheimer's disease and protects against apoptosis in vitro. Neurobiol Dis. 1998;5:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">9848094</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg M, van der Knaap MS, Boers GH, Stehouwer CD, Rauwerda JA, Valk J. Hyperhomocysteinaemia; with reference to its neuroradiological aspects. Neuroradiology. 1995;37:403&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477843</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins D, Rosenblatt DS. Functional methionine synthase deficiency (cblE and cblG): clinical and biochemical heterogeneity. Am J Med Genet. 1989;34:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">2688421</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">9535670</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 1999;22:51&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092043</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11880515</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1858</StartPage><EndPage>1867</EndPage><MedlinePgn>1858-67</MedlinePgn></Pagination><Abstract><AbstractText>Transgenic mice expressing mutant amyloid precursor proteins (APPs) have provided important new information about the pathogenesis of Alzheimer's disease (AD) histopathology. However, the molecular basis of memory loss in these mice is poorly understood. One of the major impediments has been the difficulty of distinguishing between age-dependent and age-independent behavioral changes. To address this issue we studied in parallel two lines of APP transgenic mice expressing comparable levels of mutant and wild-type human APP. This enabled us to identify age-independent behavioral deficits that were not specifically related to mutant APP expression. When mice with age-independent deficits were eliminated, we detected memory loss in transgenic mice expressing mutant APP (Tg2576 mice) starting at approximately 6 months, which coincided with the appearance of detergent-insoluble Abeta aggregates (Abeta(insol)). Genetically accelerating the formation of Abeta(insol) resulted in an earlier onset of memory decline. A facile interpretation of these results, namely that memory loss and Abeta(insol) were closely connected, was rejected when we extended our analysis to include older mice. No obvious correspondence between memory and Abeta(insol) was apparent in a combined group of old and young mice unless the mice were stratified by age, whereupon inverse correlations between memory and Abeta(insol) became evident. These results suggested that Abeta(insol) is a surrogate marker for small assemblies of Abeta that disrupt cognition and occur as intermediates during Abeta(insol) formation, and they are the first descriptive in vivo data supporting their role in impairing memory. These studies also provide a methodological framework within which to investigate these Abeta assemblies in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Westerman</LastName><ForeName>Marcus A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Clinical and Molecular Neurobiology, University of Minnesota, Minneapolis, Minnesota 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper-Blacketer</LastName><ForeName>Deirdre</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mariash</LastName><ForeName>Ami</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kotilinek</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kawarabayashi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Linda H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>George A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS033249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS33249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH11834</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 MH011834</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11880515</ArticleId><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pii">22/5/1858</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-05-01858.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada PV, Growdon JH, Hedley-White ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, Kandel ER. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci USA. 1999;96:5280&#x2013;5285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21855</ArticleId><ArticleId IdType="pubmed">10220457</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoo GT, Nochlin D, Chang D, Kim Y, Sumi SM. The mean A&#x3b2; load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:531&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellush LL, Wright AM, Walker JP, Kopchick J, Colvin RA. Caloric restriction and spatial learning in old mice. Physiol Behav. 1996;60:541&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">8840916</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol. 1993;50:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">8460956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993;259:514&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">8424174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000;408:975&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zucker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morrisette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of APP695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St. George Hyslop P, Selkoe DJ. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley JN. What's wrong with my mouse? Wiley; New York: 2000.</Citation></Reference><Reference><Citation>Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging. 1996;17:921&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363804</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaere P, Duyckaerts C, Masters C, Beyreuther K, Piette F, Hauw JJ. Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci Lett. 1990;116:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">2259457</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 1992;13:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Fordyce DE, Wehner JM. Effects of aging on spatial learning and hippocampal protein kinase C in mice. Neurobiol Aging. 1993;14:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">8367012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher M, Burwell R, Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci. 1993;107:618&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">8397866</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelotte P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagoplan S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburh I, Little S, Masliah E, McConlogue L. Alzheimer-type neuropathology in transgenic mice overexpressing V717F b-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta. 2000;1502:172&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging. 2001;22:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, Suzuki N, Younkin SG. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995;270:7013&#x2013;7016.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. Protofibrillar intermediates of amyloid &#x3b2;-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999;19:8876&#x2013;8884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet. 1999;29:177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing S, Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res. 1999;103:145&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">10513583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA. 1998;95:12683&#x2013;12688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22891</ArticleId><ArticleId IdType="pubmed">9770546</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompl PN, Mullan MJ, Bjugstad K, Arendash GW. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. J Neurosci Methods. 1999;87:87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">10065997</ArticleId></ArticleIdList></Reference><Reference><Citation>Quon D, Wang Y, Catalano R, Scardina JM, Murakami K, Cordell B. Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature. 1991;352:239&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">1906990</ArticleId></ArticleIdList></Reference><Reference><Citation>Roch JM, Masliah E, Roch-Levecq AC, Sundsmo MP, Otero DA, Veinbergs I, Saitoh T. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc Natl Acad Sci USA. 1994;91:7450&#x2013;7454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44418</ArticleId><ArticleId IdType="pubmed">8052602</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR. Morphology and toxicity of Abeta-(1&#x2013;42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem. 1996;271:20631&#x2013;20635.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702810</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott MR, Kohler R, Foster D, Prusiner SB. Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci. 1992;1:986&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142161</ArticleId><ArticleId IdType="pubmed">1338978</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett B, Babu-Khan S, Kahn S, Mendiaz E, Denis P, Teplow D, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski M, Biere AL, Curran E, Burgess T, Louis J-C. &#x3b2;-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999;158:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11880627</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation.</ArticleTitle><Pagination><StartPage>2754</StartPage><EndPage>2759</EndPage><MedlinePgn>2754-9</MedlinePgn></Pagination><Abstract><AbstractText>The fact that natural beta-sheet proteins are usually soluble but that fragments or designs of beta structure usually aggregate suggests that natural beta proteins must somehow be designed to avoid this problem. Regular beta-sheet edges are dangerous, because they are already in the right conformation to interact with any other beta strand they encounter. We surveyed edge strands in a large sample of all-beta proteins to tabulate features that could protect against further beta-sheet interactions. beta-barrels, of course, avoid edges altogether by continuous H-bonding around the barrel cylinder. Parallel beta-helix proteins protect their beta-sheet ends by covering them with loops of other structure. beta-propeller and single-sheet proteins use a combination of beta-bulges, prolines, strategically placed charges, very short edge strands, and loop coverage. beta-sandwich proteins favor placing an inward-pointing charged side chain on one of the edge strands where it would be buried by dimerization; they also use bulges, prolines, and other mechanisms. One recent beta-hairpin design has a constrained twist too great for accommodation into a larger beta-sheet, whereas some beta-sheet edges are protected by the bend and reverse twist produced by an Lbeta glycine. All free edge strands were seen to be protected, usually by several redundant mechanisms. In contrast, edge strands that natively form beta H-bonded dimers or rings have long, regular stretches without such protection. These results are relevant to understanding how proteins may assemble into beta-sheet amyloid fibers, and they are especially applicable to the de novo design of beta structure. Many edge-protection strategies used by natural proteins are beyond our current abilities to constrain by design, but one possibility stands out as especially useful: a single charged side chain near the middle of what would ordinarily be the hydrophobic side of the edge beta strand. This minimal negative-design strategy changes only one residue, requires no backbone distortion, and is easy to design. The accompanying paper [Wang, W. &amp; Hecht, M. H. (2002) Proc. Natl. Acad. Sci. USA 99, 2760-2765] makes use of the inward-pointing charge strategy with great success, turning highly aggregated beta-sandwich designs into soluble monomers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Jane S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Duke University, Durham, NC 27710-3711, USA. jsr@kinemage.biochem.duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>1A8D</AccessionNumber><AccessionNumber>1ALY</AccessionNumber><AccessionNumber>1AMM</AccessionNumber><AccessionNumber>1AMX</AccessionNumber><AccessionNumber>1AOL</AccessionNumber><AccessionNumber>1AOQ</AccessionNumber><AccessionNumber>1BKF</AccessionNumber><AccessionNumber>1CB8</AccessionNumber><AccessionNumber>1CQ3</AccessionNumber><AccessionNumber>1CRU</AccessionNumber><AccessionNumber>1CTF</AccessionNumber><AccessionNumber>1CZF</AccessionNumber><AccessionNumber>1CZS</AccessionNumber><AccessionNumber>1CZY</AccessionNumber><AccessionNumber>1D2S</AccessionNumber><AccessionNumber>1DAB</AccessionNumber><AccessionNumber>1DBG</AccessionNumber><AccessionNumber>1E7X</AccessionNumber><AccessionNumber>1ES6</AccessionNumber><AccessionNumber>1EWW</AccessionNumber><AccessionNumber>1EZG</AccessionNumber><AccessionNumber>1FUS</AccessionNumber><AccessionNumber>1FV1</AccessionNumber><AccessionNumber>1G61</AccessionNumber><AccessionNumber>1GBG</AccessionNumber><AccessionNumber>1GOTC</AccessionNumber><AccessionNumber>1HCB</AccessionNumber><AccessionNumber>1HOE</AccessionNumber><AccessionNumber>1HV9</AccessionNumber><AccessionNumber>1HXN</AccessionNumber><AccessionNumber>1IGD</AccessionNumber><AccessionNumber>1KAP</AccessionNumber><AccessionNumber>1KIT</AccessionNumber><AccessionNumber>1KNB</AccessionNumber><AccessionNumber>1LXA</AccessionNumber><AccessionNumber>1MOL</AccessionNumber><AccessionNumber>1NLS</AccessionNumber><AccessionNumber>1OSP</AccessionNumber><AccessionNumber>1PIN</AccessionNumber><AccessionNumber>1PLC</AccessionNumber><AccessionNumber>1PNE</AccessionNumber><AccessionNumber>1PSG</AccessionNumber><AccessionNumber>1QCX</AccessionNumber><AccessionNumber>1QJV</AccessionNumber><AccessionNumber>1QRE</AccessionNumber><AccessionNumber>1RIE</AccessionNumber><AccessionNumber>1RSY</AccessionNumber><AccessionNumber>1SAC</AccessionNumber><AccessionNumber>1SFP</AccessionNumber><AccessionNumber>1SLI</AccessionNumber><AccessionNumber>1SLT</AccessionNumber><AccessionNumber>1SLU</AccessionNumber><AccessionNumber>1SPH</AccessionNumber><AccessionNumber>1STM</AccessionNumber><AccessionNumber>1TEN</AccessionNumber><AccessionNumber>1THW</AccessionNumber><AccessionNumber>1TL2</AccessionNumber><AccessionNumber>1TTA</AccessionNumber><AccessionNumber>1TYU</AccessionNumber><AccessionNumber>1VJS</AccessionNumber><AccessionNumber>1WAP</AccessionNumber><AccessionNumber>1XNB</AccessionNumber><AccessionNumber>1XSO</AccessionNumber><AccessionNumber>1YGE</AccessionNumber><AccessionNumber>2ARC</AccessionNumber><AccessionNumber>2MCM</AccessionNumber><AccessionNumber>2PEC</AccessionNumber><AccessionNumber>2RHE</AccessionNumber><AccessionNumber>2XAT</AccessionNumber><AccessionNumber>3IL8,</AccessionNumber><AccessionNumber>3SSI</AccessionNumber><AccessionNumber>3TDT</AccessionNumber><AccessionNumber>4BCL</AccessionNumber><AccessionNumber>7RSA</AccessionNumber><AccessionNumber>8FAB</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>GM-15000</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="Y">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>27</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11880627</ArticleId><ArticleId IdType="pmc">PMC122420</ArticleId><ArticleId IdType="doi">10.1073/pnas.052706099</ArticleId><ArticleId IdType="pii">99/5/2754</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattice W L. Annu Rev Biophys Biophys Chem. 1989;18:93&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">2660835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, Blake C. Adv Prot Chem. 1997;50:123&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">9338080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutter M. Trends Biochem Sci. 1988;13:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">3076723</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson J S, Richardson D C, Tweedy N B, Gernext K M, Quinn T P, Hecht M H, Erickson B W, Yan Y, McClain R D, Donlan M E, Surles M C. Biophys J. 1992;63:1186&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1261423</ArticleId><ArticleId IdType="pubmed">1477272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pessi A, Bianchi E, Crameri A, Venturini S, Tramontano A, Sollazzo M. Nature (London) 1993;362:367&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">8455724</ArticleId></ArticleIdList></Reference><Reference><Citation>West M W, Wang W, Patterson J, Mancias J D, Beasley J R, Hecht M H. Proc Natl Acad Sci USA. 1999;96:11211&#x2013;11216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18013</ArticleId><ArticleId IdType="pubmed">10500156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecht M H, Richardson J S, Richardson D C, Ogden R C. Science. 1990;249:884&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">2392678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Hecht M H. Proc Natl Acad Sci USA. 2002;99:2760&#x2013;2765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122421</ArticleId><ArticleId IdType="pubmed">11880628</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman H M, Westbrook J, Feng Z, Gilliland G, Bhat T N, Weissig H, Shindyalov I N, Bourne P E. Nucleic Acids Res. 2000;28:235&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102472</ArticleId><ArticleId IdType="pubmed">10592235</ArticleId></ArticleIdList></Reference><Reference><Citation>Murzin A, Brenner S E, Hubband T, Chothia C. J Mol Biol. 1995;247:536&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">7723011</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson D C, Richardson J S. Protein Sci. 1992;1:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142077</ArticleId><ArticleId IdType="pubmed">1304880</ArticleId></ArticleIdList></Reference><Reference><Citation>Merritt E A, Bacon D J. Methods Enzymol. 1997;277:505&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">18488322</ArticleId></ArticleIdList></Reference><Reference><Citation>Word J M, Lovell S C, Richardson J S, Richardson D C. J Mol Biol. 1999;285:1735&#x2013;1747.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917408</ArticleId></ArticleIdList></Reference><Reference><Citation>Word J M, Lovell S C, LaBean T H, Taylor H C, Zalis M E, Presley B K, Richardson J S, Richardson D C. J Mol Biol. 1999;285:1711&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917407</ArticleId></ArticleIdList></Reference><Reference><Citation>Word J M, Bateman R C, Jr, Presley B K, Lovell S C, Richardson D C. Protein Sci. 2000;9:2251&#x2013;2259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2144501</ArticleId><ArticleId IdType="pubmed">11152136</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson J S, Getzoff E D, Richardson D C. Proc Natl Acad Sci USA. 1978;75:2574&#x2013;2578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC392604</ArticleId><ArticleId IdType="pubmed">275827</ArticleId></ArticleIdList></Reference><Reference><Citation>Salemme F R. Prog Biophys Mol Biol. 1983;42:95&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">6359272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberg M J E, Thornton J M. J Mol Biol. 1977;115:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">926175</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggeli A, Bell M, Boden N, Keen J N, Knowles P F, McLeish T C B, Pitkeathly M, Radford S E. Nature (London) 1997;386:259&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">9069283</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran A G, Skelton N J, Starovasnik M A. Proc Natl Acad Sci USA. 2001;98:5578&#x2013;5583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33255</ArticleId><ArticleId IdType="pubmed">11331745</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell S J, Cochran A G. J Am Chem Soc. 2000;122:12600&#x2013;12601.</Citation></Reference><Reference><Citation>Lovell S C, Word J M, Richardson J S, Richardson D C. Proteins Struct Funct Genet. 2000;40:389&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861930</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson J S. Adv Prot Chem. 1981;34:167&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">7020376</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson D C, Richardson J S. In: Prediction of Protein Structure and the Principles of Protein Conformation. Fasman G D, editor. New York: Plenum; 1989. pp. 1&#x2013;98.</Citation></Reference><Reference><Citation>Nesloney C L, Kelly J W. J Am Chem Soc. 1996;118:5836&#x2013;5845.</Citation></Reference><Reference><Citation>Doig A J. Chem. Commun. 1997. 2153&#x2013;2154.</Citation></Reference><Reference><Citation>Iverson T M, Alber B E, Kisker C, Ferry J G, Rees D C. Biochemistry. 2000;39:9222&#x2013;9231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924115</ArticleId></ArticleIdList></Reference><Reference><Citation>Beisel H G, Kawabata S, Iwanaga S, Huber R, Bode W. EMBO J. 1999;18:2313&#x2013;2322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171314</ArticleId><ArticleId IdType="pubmed">10228146</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon A, Gleichmann T, Kalb A J, Price H, Raftery J, Bradbrook G, Yariv J, Helliwell J R. J Chem Soc Faraday Trans. 1997;93:4305&#x2013;4312.</Citation></Reference><Reference><Citation>Liao D I, Kapadia G, Ahmed H, Vasta G R, Herzberg O. Proc Natl Acad Sci USA. 1994;91:1428&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43172</ArticleId><ArticleId IdType="pubmed">8108426</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley J, White H E, O'Hara B P, Oliva G, Srinivasan N, Tickle I J, Blundell T L, Pepys M B, Wood S P. Nature (London) 1994;367:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">8114934</ArticleId></ArticleIdList></Reference><Reference><Citation>Crennell S, Garman E, Laver G, Vimr E, Taylor G. Structure (London) 1994;2:535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">7922030</ArticleId></ArticleIdList></Reference><Reference><Citation>Derrick J P, Wigley D B. J Mol Biol. 1994;243:906&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">7966308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton J A, Steinrauf L K, Braden B C, Liepnieks J, Benson M D, Holmgren G, Sandgren O, Steen L. J Biol Chem. 1993;268:2416&#x2013;2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428915</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11881998</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-2623</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1292</StartPage><EndPage>1299</EndPage><MedlinePgn>1292-9</MedlinePgn></Pagination><Abstract><AbstractText>Glycogen synthase kinase 3 beta (GSK-3beta) has a central role in Alzheimer's disease (AD). Selective inhibitors which avoid tau hyperphosphorylation may represent an effective therapeutical approach to the AD pharmacotherapy and other neurodegenerative disorders. Here, we describe the synthesis, biological evaluation, and SAR of the small heterocyclic thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3beta. Their synthesis is based on the reactivity of sulfenyl chlorides. In GSK-3beta assays, TDZD derivatives showed IC(50) values in the micromolar range, whereas in other protein kinases assays they were devoid of any inhibitory activity. SAR studies allowed the identification of the key structural features. Finally, a possible enzymatic binding mode is proposed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Qu&#xed;mica M&#xe9;dica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain. iqmam06@pinar2.csic.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>Concepci&#xf3;n</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013830">Thiadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.-</RegistryNumber><NameOfSubstance UI="D038341">Glycogen Synthase Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D017871">Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017871" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038341" MajorTopicYN="N">Glycogen Synthase Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013830" MajorTopicYN="N">Thiadiazoles</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>27</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11881998</ArticleId><ArticleId IdType="doi">10.1021/jm011020u</ArticleId><ArticleId IdType="pii">jm011020u</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11889469</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>307</EndPage><MedlinePgn>301-7</MedlinePgn></Pagination><Abstract><AbstractText>Copper-mediated oxidative damage is proposed to play a critical role in the pathogenesis of Cu/Zn superoxide dismutase (SOD1)-linked familial amyotrophic lateral sclerosis (FALS). We tested this hypothesis by ablating the gene encoding the copper chaperone for SOD1 (CCS) in a series of FALS-linked SOD1 mutant mice. Metabolic 64Cu labeling in SOD1-mutant mice lacking the CCS showed that the incorporation of copper into mutant SOD1 was significantly diminished in the absence of CCS. Motor neurons in CCS-/- mice showed increased rate of death after facial nerve axotomy, a response documented for SOD1-/- mice. Thus, CCS is necessary for the efficient incorporation of copper into SOD1 in motor neurons. Although the absence of CCS led to a significant reduction in the amount of copper-loaded mutant SOD1, however, it did not modify the onset and progression of motor neuron disease in SOD1-mutant mice. Hence, CCS-dependent copper loading of mutant SOD1 plays no role in the pathogenesis of motor neuron disease in these mouse models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Jamuna R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Avenue, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>W Ernest</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bartnikas</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Gitlin</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114678">CCS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491962">Ccs protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014020">Tissue Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2002 Apr;5(4):287-8. doi: 10.1038/nn0402-287.</RefSource><PMID Version="1">11914714</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2002 Oct;5(10):919; author reply 919-20. doi: 10.1038/nn1002-919a.</RefSource><PMID Version="1">12352974</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019771" MajorTopicYN="N">Axotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008017" MajorTopicYN="N">Life Expectancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014020" MajorTopicYN="N">Tissue Extracts</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11889469</ArticleId><ArticleId IdType="doi">10.1038/nn823</ArticleId><ArticleId IdType="pii">nn823</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11890840</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum lipoprotein levels, statin use, and cognitive function in older women.</ArticleTitle><Pagination><StartPage>378</StartPage><EndPage>384</EndPage><MedlinePgn>378-84</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few strategies are available for the prevention of cognitive impairment in elderly persons. Serum lipoprotein levels may be important predictors of cognitive function, and drugs that lower cholesterol may be effective for the prevention of cognitive impairment.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether serum lipoprotein levels, the 4-year change in serum lipoprotein levels, and the use of statin drugs are associated with cognition in older women without dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">An observational study of 1037 postmenopausal women with coronary heart disease enrolled in the Heart and Estrogen/progestin Replacement Study (participants at 10 of 20 centers).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">The Modified Mini-Mental State Examination was administered at the end of the study after 4 years of follow-up. Women whose score was less than 84 points (&gt;1.5 SDs below the mean) were classified as having cognitive impairment. Lipoprotein levels (total, high-density lipoprotein, and low-density lipoprotein [LDL] cholesterol and triglycerides) were measured at baseline and at the end of the study; statin use was documented at each visit.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with women in the lower quartiles, women in the highest LDL cholesterol quartile at cognitive testing had worse mean plus minus SD Modified Mini-Mental State Examination scores (93.7 plus minus 6.0 vs 91.9 plus minus 7.6; P =.002) and an increased likelihood of cognitive impairment (adjusted odds ratio, 1.76; 95% confidence interval, 1.04-2.97). A reduction in the LDL cholesterol level during the 4 years tended to be associated with a lower odds of impairment (adjusted odds ratio, 0.61; 95% confidence interval, 0.36-1.03) compared with women whose levels increased. Higher total and LDL cholesterol levels, corrected for lipoprotein(a) levels, were also associated with a worse Modified Mini-Mental State Examination score and a higher likelihood of impairment, whereas high-density lipoprotein cholesterol and triglyceride levels were not associated with cognition. Compared with nonusers, statin users had higher mean plus minus SD Modified Mini-Mental State Examination scores (92.7 plus minus 7.1 vs 93.7 plus minus 6.1; P =.02) and a trend for a lower likelihood of cognitive impairment (odds ratio, 0.67; 95% confidence interval, 0.42-1.05), findings that seemed to be independent of lipid levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High LDL and total cholesterol levels are associated with cognitive impairment, and lowering these lipoprotein levels may be a strategy for preventing impairment. The association between statin use and better cognitive function in women without dementia requires further study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, University of California, San Francisco, 4150 Clement St, Campus Box 111G, San Francisco, CA 94121, USA. kyaffe@itsa.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett-Connor</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Grady</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG 00888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000960" MajorTopicYN="N">Hypolipidemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11890840</ArticleId><ArticleId IdType="doi">10.1001/archneur.59.3.378</ArticleId><ArticleId IdType="pii">noc10119</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11896164</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.</ArticleTitle><Pagination><StartPage>2246</StartPage><EndPage>2254</EndPage><MedlinePgn>2246-54</MedlinePgn></Pagination><Abstract><AbstractText>3-4-(2-Fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester (NCX-2216), a nitric oxide (NO)-releasing derivative of the cyclooxygenase-1-preferring nonsteroidal anti-inflammatory drug (NSAID) flurbiprofen, dramatically reduced both beta-amyloid (Abeta) loads and Congo red staining in doubly transgenic (Tg) amyloid precursor protein plus presenilin-1 mice when administered at 375 ppm in diet between 7 and 12 months of age. This reduction was associated with a dramatic increase in the number of microglia expressing major histocompatibility complex-II antigen, a marker for microglial activation. In contrast, ibuprofen at 375 ppm in diet caused modest reductions in Abeta load but not Congo red staining, suggesting that the effects of this nonselective NSAID were restricted primarily to nonfibrillar deposits. We detected no effects of the cyclooxygenase-2-selective NSAID celecoxib at 175 ppm on amyloid deposition. In short-term studies of 12-month-old Tg mice, we found that the microglia-activating properties of NCX-2216 (7.5 mg small middle dot kg(-1) small middle dot d(-1), s.c.) were present after 2 weeks of treatment. Microglia were not activated by NCX-2216 in non-Tg mice lacking Abeta deposits, nor were microglia activated in Tg animals by flurbiprofen (5 mg small middle dot kg(-1) small middle dot d(-1)) alone. These data are consistent with the argument that activated microglia can clear Abeta deposits. We conclude that the NO-generating component of NCX-2216 confers biological actions that go beyond those of typical NSAIDs. In conclusion, NCX-2216 is more efficacious than ibuprofen or celecoxib in clearing Abeta deposits from the brains of Tg mice, implying potential benefit in the treatment of Alzheimer's dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jantzen</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Alzheimer's Research Laboratory, University of South Florida, Tampa, Florida 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>DiCarlo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wenk</LastName><ForeName>Gary L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>John L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Rojiani</LastName><ForeName>Amyn M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Domenico</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Dave</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Marcia N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG015490</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 15490</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C450321">(3-4-(2-fluoromethyl-(1,1'-biphenyl)-4-acetyloxy)-3-methoxyphenyl)-2-propenoic acid 4-nitrooxy butyl ester</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>5GRO578KLP</RegistryNumber><NameOfSubstance UI="D005480">Flurbiprofen</NameOfSubstance></Chemical><Chemical><RegistryNumber>JCX84Q7J1L</RegistryNumber><NameOfSubstance UI="D000068579">Celecoxib</NameOfSubstance></Chemical><Chemical><RegistryNumber>WK2XYI10QM</RegistryNumber><NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000943" MajorTopicYN="N">Antigens, Differentiation</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068579" MajorTopicYN="N">Celecoxib</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005480" MajorTopicYN="N">Flurbiprofen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007052" MajorTopicYN="N">Ibuprofen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11896164</ArticleId><ArticleId IdType="pmc">PMC6758281</ArticleId><ArticleId IdType="pii">22/6/2246</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-06-02246.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>al Swayeh OA, Futter LE, Clifford RH, Moore PK. Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity. Br J Pharmacol. 2000;130:1453&#x2013;1456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572245</ArticleId><ArticleId IdType="pubmed">10928944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD. Scavenging of Alzheimer's amyloid &#x3b2;-protein by microglia in culture. J Neurosci Res. 1996;43:190&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">8820967</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman B. Anti-amyloid-&#x3b2; antibodies promote clearance of amyloid-&#x3b2; deposits imaged in vivo in PDAPP mice. Soc Neurosci Abstr. 2000;26:1059.</Citation></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B. Peripherally administered antibodies against amyloid &#x3b2;-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzing WC, Wujek JR, Ward EK, Schaffer D, Ashe KH, Younkin SG, Brunden KR. Evidence for glial-mediated inflammation in APPsw transgenic mice. Neurobiol Aging. 1999;20:581&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">10674423</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazil MI, Chung H, Maxfield FR. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J Biol Chem. 2000;275:16941&#x2013;16947.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747968</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med. 1996;47:401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">8712791</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC. Epidemiologic clues to the causes and routes to prevention of Alzheimer disease. J Neural Transm Suppl. 2000;59:251&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">10961436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhary S, Townend JN. Nitric oxide and hypertension: not just an endothelium-derived relaxing factor! J Hum Hypertens. 2001;15:219&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11319669</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid &#x3b2;-peptide by microglial cells. J Biol Chem. 1999;274:32301&#x2013;32308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542270</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L. Clinico-pathological studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology. 1988;38:1682&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58:376&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Soldato P, Sorrentino R, Pinto A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci. 1999;20:319&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431210</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A&#x3b2; antibody alters CNS and plasma A&#x3b2; clearance and decreases brain A&#x3b2; burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce A&#x3b2; load in APP+PS1 transgenic mice. Neurobiol Aging. 2001;22:1007&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755009</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-&#x3b2;42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorucci S, Santucci L, Cirino G, Mencarelli A, Familiari L, Soldato PD, Morelli A. IL-1&#x3b2;-converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J Immunol. 2000;165:5245&#x2013;5254.</Citation><ArticleIdList><ArticleId IdType="pubmed">11046058</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce &#x3b2;-amyloid fibrils. Acta Neuropathol (Berl) 1992;84:225&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">1414275</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Cole GM, Baird A. Phagocytosis and deposition of vascular &#x3b2;-amyloid in rat brains injected with Alzheimer &#x3b2;-amyloid. Am J Pathol. 1992;140:1389&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886549</ArticleId><ArticleId IdType="pubmed">1376558</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Futter LE, al Swayeh OA, Moore PK. A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br J Pharmacol. 2001;132:10&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572565</ArticleId><ArticleId IdType="pubmed">11156555</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Schreier WA, Ou X, Holcomb LA, Morgan DG. Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. J Comp Neurol. 1997;388:106&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">9364241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Connor K, Melachrino JO, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic mPS1+mAPP mouse. Exp Neurol. 2002;173:183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11822882</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf E. Antioxidant potential of ferulic acid. Free Radic Biol Med. 1992;13:435&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">1398220</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi S, Pettorossi VE. Synaptic plasticity in the medial vestibular nuclei: role of glutamate receptors and retrograde messengers in rat brainstem slices. Prog Neurobiol. 2001;64:527&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311461</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM, Shepherd CE, McCann H, Reid WG, Grayson DA, Broe GA, Kril JJ. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol. 2000;57:831&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauss-Wegrzyniak B, Vraniak P, Wenk GL. The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol Aging. 1999a;20:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauss-Wegrzyniak B, Willard LB, Del Soldato P, Pepeu G, Wenk GL. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res. 1999b;815:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9974120</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Benkovic SA, Morgan DG. A&#x3b2; and perlecan in rat brain. Glial activation, gradual clearance and limited neurotoxicity. Mech Ageing Dev. 1999a;112:135&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">10690926</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Gen. 1999b;29:177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>James DS. The multisystem adverse effects of NSAID therapy. J Am Osteopath Assoc. 1999;99:S1&#x2013;S7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26981697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">8843599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A&#x3b2; peptides of Alzheimer's disease. Biochim Biophys Acta. 1998;1406:291&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE. Comparative analysis of amyloid-&#x3b2; chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem. 2001;276:12991&#x2013;12998.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue L, Brachova L, Civin H, Rogers J. Inflammation, A&#x3b2; deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996;55:1083&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR. Antiinflammatory drugs in the treatment of Alzheimer's disease. J Rheumatol. 1996;23:806&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">8724288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50:986&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566383</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein and Alzheimer's disease. J Neurosci. 1996;16:5795&#x2013;5811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 2001;158:1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol. 1998;33:371&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762518</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P, McGeer EG. Inflammation, autotoxicity, and Alzheimer's disease. Neurobiol Aging. 2001;22:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">11754986</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, Yu X, Uljon S, Wang R, Mann D, Dickson D, Duff K. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis. 1999;6:231&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448051</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L, Polazzi E, Nicolini A, Greco A, Levi G. Possible role of microglial prostanoids and free radicals in neuroprotection and neurodegeneration. Adv Exp Med Biol. 1999;468:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">10635023</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S, Thanos S. The concept of microglia in relation to central nervous system disease and regeneration. Prog Neurobiol. 1996;48:441&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">8804116</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A&#x3b2; peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">11292358</ArticleId></ArticleIdList></Reference><Reference><Citation>Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V, Condorelli M, Pinto A, Ignarro LJ. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc Natl Acad Sci USA. 2001;98:2860&#x2013;2864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30230</ArticleId><ArticleId IdType="pubmed">11226331</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra P, Dello RC, Mancuso C, Preziosi P, Grossman A. Gaseous neuromodulators in the control of neuroendocrine stress axis. Ann NY Acad Sci. 2000;917:638&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268392</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid &#x3b2;-protein via a scavenger receptor. Neuron. 1996;17:553&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>Prechel MM, Ding C, Washington RL, Kolodziej MS, Young MR. In vivo indomethacin treatment causes microglial activation in adult mice. Neurochem Res. 2000;25:357&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">10761979</ArticleId></ArticleIdList></Reference><Reference><Citation>Raine CS. Inflammation in Alzheimer's disease: a view from the periphery. Neurobiol Aging. 2000;21:437&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858590</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofiled C, Mansukhani L, Wilson P, Kogan F. Clinical trail of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging. 1996;17:681&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892340</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ. Structural alterations in the peptide backbone of &#x3b2;-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem. 1993a;268:3072&#x2013;3083.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428986</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem. 1993b;61:1916&#x2013;1926.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y. Microglial activation in early stages of amyloid &#x3b2; protein deposition. Acta Neuropathol (Berl) 1997;94:316&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341931</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C. Immunization with amyloid-&#x3b2; attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RC, Younkin SG, Brunden KR. Amyloid &#x3b2; protein (A&#x3b2;) removal by neuroglial cells in culture. Neurobiol Aging. 1995;16:737&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532106</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA. Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist. 1997;37:150&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9127971</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 1994;107:173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">8020659</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Complement component C1q modulates the phagocytosis of A&#x3b2; by microglia. Exp Neurol. 2000;161:127&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683279</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Antibody-mediated phagocytosis of the amyloid &#x3b2;-peptide in microglia is differentially modulated by C1q. J Immunol. 2001;166:7496&#x2013;7503.</Citation><ArticleIdList><ArticleId IdType="pubmed">11390503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Chauhan A, Wisniewski HM, Nowakowski J, Wang KC, Le Vine H. Promotion of synthetic amyloid &#x3b2;-peptide fibrillization by cell culture media and cessation of fibrillization by serum. Neurosci Lett. 1996;211:151&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">8817563</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW. Fibrillar &#x3b2;-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci. 1998;18:2161&#x2013;2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792921</ArticleId><ArticleId IdType="pubmed">9482801</ArticleId></ArticleIdList></Reference><Reference><Citation>West M, Slomianka L, Gunderson H. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231:482&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">1793176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D. Number of A&#x3b2; inoculations in APP + PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 2001;20:731&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. TGF-&#x3b2;1 promotes microglial amyloid-&#x3b2; clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH, Song DK. Protection against &#x3b2;-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol. 2001;133:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572763</ArticleId><ArticleId IdType="pubmed">11325798</ArticleId></ArticleIdList></Reference><Reference><Citation>Young MR. Eicosanoids and the immunology of cancer. Cancer Metastasis Rev. 1994;13:337&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">7712595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zicari A, Lipari M, Di Renzo L, Salerno A, Losardo A, Pontieri GM. Stimulation of macrophages with IFN &#x3b3; or TNF &#x3b1; shuts off the suppressive effect played by PGE2. Int J Immunopharmacol. 1995;17:779&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">8582790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11901170</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9525</ISSN><JournalIssue CitedMedium="Print"><Volume>156</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of cell biology</Title><ISOAbbreviation>J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress.</ArticleTitle><Pagination><StartPage>1051</StartPage><EndPage>1063</EndPage><MedlinePgn>1051-63</MedlinePgn></Pagination><Abstract><AbstractText>We studied the effect of microtubule-associated tau protein on trafficking of vesicles and organelles in primary cortical neurons, retinal ganglion cells, and neuroblastoma cells. Tau inhibits kinesin-dependent transport of peroxisomes, neurofilaments, and Golgi-derived vesicles into neurites. Loss of peroxisomes makes cells vulnerable to oxidative stress and leads to degeneration. In particular, tau inhibits transport of amyloid precursor protein (APP) into axons and dendrites, causing its accumulation in the cell body. APP tagged with yellow fluorescent protein and transfected by adenovirus associates with vesicles moving rapidly forward in the axon (approximately 80%) and slowly back (approximately 20%). Both movements are strongly inhibited by cotransfection with fluorescently tagged tau (cyan fluorescent protein-tau) as seen by two-color confocal microscopy. The data suggests a linkage between tau and APP trafficking, which may be significant in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stamer</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Thies</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E-M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biol</MedlineTA><NlmUniqueID>0375356</NlmUniqueID><ISSNLinking>0021-9525</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002642" MajorTopicYN="N">Chick Embryo</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015388" MajorTopicYN="N">Organelles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020675" MajorTopicYN="N">Peroxisomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022161" MajorTopicYN="N">Transport Vesicles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>27</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11901170</ArticleId><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="doi">10.1083/jcb.200108057</ArticleId><ArticleId IdType="pii">jcb.200108057</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amaratunga, A., and R.E. Fine. 1995. Generation of amyloidogenic C-terminal fragments during rapid axonal transport in vivo of beta-amyloid precursor protein in the optic nerve. J. Biol. Chem. 270:17268&#x2013;17272.</Citation><ArticleIdList><ArticleId IdType="pubmed">7542234</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaratunga, A., S.E. Leeman, K.S. Kosik, and R.E. Fine. 1995. Inhibition of kinesin synthesis in vivo inhibits the rapid transport of representative proteins for three transport vesicle classes into the axon. J. Neurochem. 64:2374&#x2013;2376.</Citation><ArticleIdList><ArticleId IdType="pubmed">7536813</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada, P.V., J.H. Growdon, E.T. Hedley-Whyte, and B.T. Hyman. 1992. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas, P.W. 1999. Microtubules and neuronal polarity: lessons from mitosis. Neuron. 22:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027286</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker, G.A., and K. Goslin. 1998. Culturing Nerve Cells. MIT Press, Cambridge, Massachusetts. 666 pp.</Citation></Reference><Reference><Citation>Binder, L.I., A. Frankfurter, and L.I. Rebhun. 1985. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 101:1371&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H., and E. Braak. 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradke, F., and C.G. Dotti. 1998. Membrane traffic in polarized neurons. Biochim. Biophys. Acta. 1404:245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">9714822</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt, R., J. Leger, and G. Lee. 1995. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J. Cell Biol. 131:1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120645</ArticleId><ArticleId IdType="pubmed">8522593</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee, L., T. Bussiere, V. Buee-Scherrer, A. Delacourte, and P.R. Hof. 2000. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulinski, J.C., T.E. McGraw, D. Gruber, H.L. Nguyen, and M.P. Sheetz. 1997. Overexpression of MAP4 inhibits organelle motility and trafficking in vivo. J. Cell Sci. 110:3055&#x2013;3064.</Citation><ArticleIdList><ArticleId IdType="pubmed">9365275</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres, A., and K.S. Kosik. 1990. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature. 343:461&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">2105469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, X., and T.C. Sudhof. 2001. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou, Y.H., B.T. Helfand, and R.D. Goldman. 2001. New horizons in cytoskeletal dynamics: transport of intermediate filaments along microtubule tracks. Curr. Opin. Cell Biol. 13:106&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163141</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland, D.W., S.Y. Hwo, and M.W. Kirschner. 1977. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J. Mol. Biol. 116:227&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">146092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringen, R., L. Kussmaul, J.M. Gutterer, J. Hirrlinger, and B. Hamprecht. 1999. The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. J. Neurochem. 72:2523&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">10349863</ArticleId></ArticleIdList></Reference><Reference><Citation>Drubin, D.G., and M.W. Kirschner. 1986. Tau protein function in living cells. J. Cell Biol. 103:2739&#x2013;2746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114585</ArticleId><ArticleId IdType="pubmed">3098742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebneth, A., R. Godemann, K. Stamer, S. Illenberger, B. Trinczek, and E. Mandelkow. 1998. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 143:777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148132</ArticleId><ArticleId IdType="pubmed">9813097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellenberg, J., J. Lippincott-Schwartz, and J.F. Presley. 1999. Dual-colour imaging with GFP variants. Trends Cell Biol. 9:52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10087618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira, A., A. Caceres, and K.S. Kosik. 1993. Intraneuronal compartments of the amyloid precursor protein. J. Neurosci. 13:3112&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576677</ArticleId><ArticleId IdType="pubmed">8331388</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia, M.L., and D.W. Cleveland. 2001. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. 13:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein, L.S. 2001. Kinesin molecular motors: transport pathways, receptors, and human disease. Proc. Natl. Acad. Sci. USA. 98:6999&#x2013;7003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34613</ArticleId><ArticleId IdType="pubmed">11416178</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonatas, N.K., and S. Avrameas. 1977. Detection of carbohydrates with lectin-peroxidase conjugates. Methods Cell Biol. 15:387&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">327205</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz, J., F. Chen, J. van Dorpe, and R.M. Nitsch. 2001. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by AB42 fibrils. Science. 293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield, J.P., J. Tsai, G.K. Gouras, B. Hai, G. Thinakaran, F. Checler, S.S. Sisodia, P. Greengard, and H. Xu. 1999. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc. Natl. Acad. Sci. USA. 96:742&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15207</ArticleId><ArticleId IdType="pubmed">9892704</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen, G.G., and T.A. Cook. 1999. Microtubules and signal transduction. Curr. Opin. Cell Biol. 11:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10047525</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada, A., K. Oguchi, S. Okabe, J. Kuno, S. Terada, T. Ohshima, R. Sato-Yoshitake, Y. Takei, T. Noda, and N. Hirokawa. 1994. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 369:488&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">8202139</ArticleId></ArticleIdList></Reference><Reference><Citation>He, T.C., S. Zhou, L.T. da Costa, J. Yu, K.W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA. 95:2509&#x2013;2514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19394</ArticleId><ArticleId IdType="pubmed">9482916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa, N., Y. Noda, and Y. Okada. 1998. Kinesin and dynein superfamily proteins in organelle transport and cell division. Curr. Opin. Cell Biol. 10:60&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484596</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton, M. 2001. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology. 56:S21&#x2013;S25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara, T., M. Hong, B. Zhang, Y. Nakagawa, M.K. Lee, J.Q. Trojanowski, and V.M. Lee. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 24:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara, T., M. Higuchi, B. Zhang, Y. Yoshiyama, M. Hong, J.Q. Trojanowski, and V.M. Lee. 2001. Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. J. Neurosci. 21:6026&#x2013;6035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763173</ArticleId><ArticleId IdType="pubmed">11487626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether, C., P. Skehel, and C.G. Dotti. 2000. Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol. Biol. Cell. 11:1213&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14842</ArticleId><ArticleId IdType="pubmed">10749925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal, A., G.B. Stokin, Z. Yang, C.H. Xia, and L.S. Goldstein. 2000. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron. 28:449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144355</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatoon, S., I. Grundke-Iqbal, and K. Iqbal. 1992. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 59:750&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">1629745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopito, R.R. 2000. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10:524&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121744</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, G., S.T. Newman, D.L. Gard, H. Band, and G. Panchamoorthy. 1998. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 111:3167&#x2013;3177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9763511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, J., D.W. Dickson, W.L. Lin, L. Chisholm, A. Corral, G. Jones, S.H. Yen, N. Sahara, L. Skipper, D. Yager, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, G., and G.G. Gundersen. 1998. Kinesin is a candidate for cross-bridging microtubules and intermediate filaments. Selective binding of kinesin to detyrosinated tubulin and vimentin. J. Biol. Chem. 273:9797&#x2013;9803.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545318</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, H., Y. Li, D.L. Brautigan, and G.G. Gundersen. 1998. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau. J. Biol. Chem. 273:21901&#x2013;21908.</Citation><ArticleIdList><ArticleId IdType="pubmed">9705329</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, M., and K.S. Kosik. 2001. Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol. Biol. Cell. 12:171&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30576</ArticleId><ArticleId IdType="pubmed">11160831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell, J.W., and G.A. Banker. 1996. A spatial gradient of tau protein phosphorylation in nascent axons. J. Neurosci. 16:5727&#x2013;5740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578967</ArticleId><ArticleId IdType="pubmed">8795628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson, M.P., S.W. Barger, J.G. Begley, and R.J. Mark. 1995. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol. 46:187&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">7541884</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin, P.J., C.R. Abraham, A. Amaratunga, R.J. Johnson, G. Huber, J.H. Sandell, and R.E. Fine. 1993. Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J. Neurochem. 61:464&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">7687653</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris, R.L., and P.J. Hollenbeck. 1995. Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons. J. Cell Biol. 131:1315&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120647</ArticleId><ArticleId IdType="pubmed">8522592</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchowski, P.J., G. Schaffar, A. Sittler, E.E. Wanker, M.K. Hayer-Hartl, and F.U. Hartl. 2000. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA. 97:7841&#x2013;7846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16632</ArticleId><ArticleId IdType="pubmed">10859365</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss, U., J. Biernat, E.M. Mandelkow, and E. Mandelkow. 1997. The &#x2018;jaws&#x2019; model of tau-microtubule interaction examined in CHO cells. J. Cell Sci. 110:789&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9099953</ArticleId></ArticleIdList></Reference><Reference><Citation>Price, D.L., S.S. Sisodia, and D.R. Borchelt. 1998. Genetic neurodegenerative diseases: the human illness and transgenic models. Science. 282:1079&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804539</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner, N., G.S. Bloom, and S.T. Brady. 1998. A role for cyclin-dependent kinase(s) in the modulation of fast anterograde axonal transport: effects defined by olomoucine and the APC tumor suppressor protein. J. Neurosci. 18:7717&#x2013;7726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793030</ArticleId><ArticleId IdType="pubmed">9742142</ArticleId></ArticleIdList></Reference><Reference><Citation>Riederer, B.M., and L.I. Binder. 1994. Differential distribution of tau proteins in developing cat cerebellum. Brain Res. Bull. 33:155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">8275333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers, S.L., and V.I. Gelfand. 2000. Membrane trafficking, organelle transport, and the cytoskeleton. Curr. Opin. Cell Biol. 12:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679352</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy, S., P. Coffee, G. Smith, R.K. Liem, S.T. Brady, and M.M. Black. 2000. Neurofilaments are transported rapidly but intermittently in axons: implications for slow axonal transport. J. Neurosci. 20:6849&#x2013;6861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772820</ArticleId><ArticleId IdType="pubmed">10995829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato-Harada, R., S. Okabe, T. Umeyama, Y. Kanai, and N. Hirokawa. 1996. Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct. Funct. 21:283&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118234</ArticleId></ArticleIdList></Reference><Reference><Citation>Savaskan, N.E., and R. Nitsch. 2001. Molecules involved in reactive sprouting in the hippocampus. Rev. Neurosci. 12:195&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11560368</ArticleId></ArticleIdList></Reference><Reference><Citation>Setou, M., T. Nakagawa, D.H. Seog, and N. Hirokawa. 2000. Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. Science. 288:1796&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846156</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea, T.B., and L.A. Flanagan. 2001. Kinesin, dynein and neurofilament transport. Trends Neurosci. 24:644&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11672808</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheetz, M.P., K.K. Pfister, J.C. Bulinski, and C.W. Cotman. 1998. Mechanisms of trafficking in axons and dendrites: implications for development and neurodegeneration. Prog. Neurobiol. 55:577&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">9670219</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons, M., E. Ikonen, P.J. Tienari, A. Cid-Arregui, U. Monning, K. Beyreuther, and C.G. Dotti. 1995. Intracellular routing of human amyloid protein precursor: axonal delivery followed by transport to the dendrites. J. Neurosci. Res. 41:121&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">7674373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag, E., V. Nunbhakdi-Craig, G. Lee, R. Brandt, C. Kamibayashi, J. Kuret, C.L. White III, M.C. Mumby, and G.S. Bloom. 1999. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J. Biol. Chem. 274:25490&#x2013;25498.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464280</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei, Y., J. Teng, A. Harada, and N. Hirokawa. 2000. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J. Cell Biol. 150:989&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175245</ArticleId><ArticleId IdType="pubmed">10973990</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry, R.D. 1998. The cytoskeleton in Alzheimer disease. J. Neural Transm. Suppl. 53:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700652</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran, G., D.B. Teplow, R. Siman, B. Greenberg, and S.S. Sisodia. 1996. Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;beta-secretase&#x201d; site occurs in the golgi apparatus. J. Biol. Chem. 271:9390&#x2013;9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek, B., A. Ebneth, E.M. Mandelkow, and E. Mandelkow. 1999. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J. Cell Sci. 112:2355&#x2013;2367.</Citation><ArticleIdList><ArticleId IdType="pubmed">10381391</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhey, K.J., D. Meyer, R. Deehan, J. Blenis, B.J. Schnapp, T.A. Rapoport, and B. Margolis. 2001. Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J. Cell Biol. 152:959&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198804</ArticleId><ArticleId IdType="pubmed">11238452</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter, J., B. Kern-Veits, J. Huf, B. Stolze, and F. Bonhoeffer. 1987. Recognition of position-specific properties of tectal cell membranes by retinal axons in vitro. Development. 101:685&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">3503693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L., C.L. Ho, D. Sun, R.K. Liem, and A. Brown. 2000. Rapid movement of axonal neurofilaments interrupted by prolonged pauses. Nat. Cell Biol. 2:137&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann, C.W., M.F. Wszolek, J.M. Shulman, P.M. Salvaterra, J. Lewis, M. Hutton, and M.B. Feany. 2001. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, H., D. Sweeney, R. Wang, G. Thinakaran, A.C. Lo, S.S. Sisodia, P. Greengard, and S. Gandy. 1997. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc. Natl. Acad. Sci. USA. 94:3748&#x2013;3752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabe, J.T., A. Pimenta, and T.B. Shea. 1999. Kinesin-mediated transport of neurofilament protein oligomers in growing axons. J. Cell Sci. 112:3799&#x2013;3814.</Citation><ArticleIdList><ArticleId IdType="pubmed">10523515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, H.M., I. Brust-Mascher, and J.M. Scholey. 2001. Direct visualization of the movement of the monomeric axonal transport motor UNC-104 along neuronal processes in living Caenorhabditis elegans. J. Neurosci. 21:3749&#x2013;3755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762686</ArticleId><ArticleId IdType="pubmed">11356862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11910111</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>295</Volume><Issue>5563</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2264</StartPage><EndPage>2267</EndPage><MedlinePgn>2264-7</MedlinePgn></Pagination><Abstract><AbstractText>The deposition of amyloid-beta (Abeta) peptides into amyloid plaques precedes the cognitive dysfunction of Alzheimer's disease (AD) by years. Biomarkers indicative of brain amyloid burden could be useful for identifying individuals at high risk for developing AD. As in AD in humans, baseline plasma Abeta levels in a transgenic mouse model of AD did not correlate with brain amyloid burden. However, after peripheral administration of a monoclonal antibody to Abeta (m266), we observed a rapid increase in plasma Abeta and the magnitude of this increase was highly correlated with amyloid burden in the hippocampus and cortex. This method may be useful for quantifying brain amyloid burden in patients at risk for or those who have been diagnosed with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeMattos</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Center for the Study of Nervous System Injury, Alzheimer's Disease Research Center, Department of Neurology, Molecular Biology and Pharmacology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Cummins</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG20222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11910111</ArticleId><ArticleId IdType="doi">10.1126/science.1067568</ArticleId><ArticleId IdType="pii">295/5563/2264</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11916484</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1043-0342</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Human gene therapy</Title><ISOAbbreviation>Hum Gene Ther</ISOAbbreviation></Journal><ArticleTitle>Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.</ArticleTitle><Pagination><StartPage>605</StartPage><EndPage>612</EndPage><MedlinePgn>605-12</MedlinePgn></Pagination><Abstract><AbstractText>Somatic cell gene transfer was used to express a mutant form of alpha-synuclein (alpha-syn) that is associated with Parkinson's disease (PD) in the rat substantia nigra (SN), a brain region that, in humans, degenerates during PD. DNA encoding the A30P mutant of human alpha-syn linked to familial PD was incorporated into an adeno-associated virus vector, which was injected into the adult rat midbrain. The cytomegalovirus/chicken beta-actin promoter was used to drive transgene expression. Over a 1-year time course, this treatment produced three significant features relevant to PD: (1) accumulation of alpha-syn in SN neuron perikarya, (2) Lewy-like dystrophic neurites in the SN and the striatum, and (3) a 53% loss of SN dopamine neurons. However, motor dysfunction was not found in either rotational or rotating rod testing. The lack of behavioral deficits, despite the significant cell loss, may reflect pathogenesis similar to that of PD, where greater than 50% losses occur before motor behavior is affected.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, FL 32610-0267, USA. ronklein@ufl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Hamby</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Edwin M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG10485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Gene Ther</MedlineTA><NlmUniqueID>9008950</NlmUniqueID><ISSNLinking>1043-0342</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497606">Snca protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11916484</ArticleId><ArticleId IdType="doi">10.1089/10430340252837206</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11917105</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.</ArticleTitle><Pagination><StartPage>4708</StartPage><EndPage>4713</EndPage><MedlinePgn>4708-13</MedlinePgn></Pagination><Abstract><AbstractText>Intrastriatal delivery of the tyrosine hydroxylase gene by viral vectors is being explored as a tool for local delivery of L-dopa in animals with lesions of the nigrostriatal pathway. The functional effects reported using this approach have been disappointing, probably because the striatal L-dopa levels attained have been too low. In the present study, we have defined a critical threshold level of L-dopa, 1.5 pmol/mg of tissue, that has to be reached to induce any significant functional effects. Using new generation high-titer recombinant adeno-associated virus vectors, we show that levels of striatal L-dopa production exceeding this threshold can be obtained provided that tyrosine hydroxylase is coexpressed with the cofactor synthetic enzyme, GTP-cyclohydrolase-1. After striatal transduction with this combination of vectors, substantial functional improvement in both drug-induced and spontaneous behavior was observed in rats with either complete or partial 6-hydroxydopamine lesions of the nigrostriatal pathway. However, complete reversal of motor deficits occurred only in animals in which part of the striatal dopamine innervation was left intact. Spared nigrostriatal fibers thus may convert L-dopa to dopamine and store and release dopamine in a more physiologically relevant manner in the denervated striatum to mediate better striatal output-dependent motor function. We conclude that intrastriatal L-dopa delivery may be a viable strategy for treatment and control of adverse side effects associated with oral L-dopa therapy such as on-off fluctuations and drug-induced dyskinesias in patients with Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirik</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Wallenberg Neuroscience Center, Department of Physiological Sciences, Division of Neurobiology, Lund University, BMC A11, S-221 84, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Georgievska</LastName><ForeName>Biljana</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Burger</LastName><ForeName>Corinna</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Muzyczka</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mandel</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Bjorklund</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS036302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS36302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.16</RegistryNumber><NameOfSubstance UI="D006136">GTP Cyclohydrolase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006136" MajorTopicYN="N">GTP Cyclohydrolase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022761" MajorTopicYN="N">Gene Transfer, Horizontal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11917105</ArticleId><ArticleId IdType="pmc">PMC123712</ArticleId><ArticleId IdType="doi">10.1073/pnas.062047599</ArticleId><ArticleId IdType="pii">062047599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mouradian M M, Chase T N. Exp Neurol. 1997;144:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt J G, Obeso J A, Stocchi F. Trends Neurosci. 2000;23:S109&#x2013;S115.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052228</ArticleId></ArticleIdList></Reference><Reference><Citation>Horellou P, Brundin P, Kalen P, Mallet J, Bj&#xf6;rklund A. Neuron. 1990;5:393&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">2119630</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher L J, Jinnah H A, Kale L C, Higgins G A, Gage F H. Neuron. 1991;6:371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">1672072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachtel S R, Bencsics C, Kang U J. J Neurochem. 1997;69:2055&#x2013;2063.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349551</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida K, Tsuzaki N, Nagatsu T, Kohsaka S. Dev Neurosci (Basel) 1992;14:173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">1356749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg C, Horellou P, Mallet J, Bj&#xf6;rklund A. Exp Neurol. 1996;139:39&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8635567</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton R, Kordower J H, Maidment N T, Manaster J S, Kane D J, Rabizadeh S, Schueller S B, Yang J, Edwards R H, Markham C H, et al. Exp Neurol. 1994;127:207&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7518394</ArticleId></ArticleIdList></Reference><Reference><Citation>Bencsics C, Wachtel S R, Milstien S, Hatakeyama K, Becker J B, Kang U J. J Neurosci. 1996;16:4449&#x2013;4456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578851</ArticleId><ArticleId IdType="pubmed">8699255</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Muramatsu S I, Ikeguchi K, Fujimoto K I, Fan D S, Ogawa M, Mizukami H, Urabe M, Kume A, Nagatsu I, et al. Hum Gene Ther. 2000;11:1509&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">10945765</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel R J, Rendahl K G, Spratt S K, Snyder R O, Cohen L K, Leff S E. J Neurosci. 1998;18:4271&#x2013;4284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792786</ArticleId><ArticleId IdType="pubmed">9592104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplitt M G, Leone P, Samulski R J, Xiao X, Pfaff D W, O'Malley K L, During M J. Nat Genet. 1994;8:148&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">7842013</ArticleId></ArticleIdList></Reference><Reference><Citation>Horellou P, Vigne E, Castel M N, Barneoud P, Colin P, Perricaudet M, Delaere P, Mallet J. NeuroReport. 1994;6:49&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">7703427</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan D S, Ogawa M, Fujimoto K I, Ikeguchi K, Ogasawara Y, Urabe M, Nishizawa M, Nakano I, Yoshida M, Nagatsu I, et al. Hum Gene Ther. 1998;9:2527&#x2013;2535.</Citation><ArticleIdList><ArticleId IdType="pubmed">9853519</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti O, Sanchez-Capelo A, Colin P, Hanoun N, Hamon M, Mallet J. Proc Natl Acad Sci USA. 1999;96:12120&#x2013;12125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18422</ArticleId><ArticleId IdType="pubmed">10518586</ArticleId></ArticleIdList></Reference><Reference><Citation>Isacson O. Science. 1995;269:856&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel R J, Rendahl K G, Snyder R O, Leff S E. Exp Neurol. 1999;159:47&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">10486174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D, Rosenblad C, Bj&#xf6;rklund A. Exp Neurol. 1998;152:259&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauswirth W W, Lewin A S, Zolotukhin S, Muzyczka N. Methods Enzymol. 2000;316:743&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">10800712</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm D, Kern A, Rittner K, Kleinschmidt J A. Hum Gene Ther. 1998;9:2745&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S, Byrne B J, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski R J, Muzyczka N. Gene Ther. 1999;6:973&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">10455399</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin S K, Collis P, Hermonat P L, Muzyczka N. J Virol. 1988;62:1963&#x2013;1973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253280</ArticleId><ArticleId IdType="pubmed">2835501</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Daly T, Gao C, Flotte T R, Song S, Byrne B J, Sands M S, Parker Ponder K. Hum Gene Ther. 2001;12:563&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungerstedt U, Arbuthnott G. Brain Res. 1970;24:485&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">5494536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schallert T, Tillerson J L. Innovative Models of CNS Disease: From Molecule to Therapy. Clifton, NJ: Humana; 1999.</Citation></Reference><Reference><Citation>Kirik D, Rosenblad C, Bj&#xf6;rklund A, Mandel R J. J Neurosci. 2000;20:4686&#x2013;4700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772474</ArticleId><ArticleId IdType="pubmed">10844038</ArticleId></ArticleIdList></Reference><Reference><Citation>West M J. Trends Neurosci. 1999;22:51&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen H J G, Jensen E B. J Microsc (Oxford) 1987;147:229&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">3430576</ArticleId></ArticleIdList></Reference><Reference><Citation>Demarest K T, Moore K E. J Neural Transm. 1979;46:263&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">528998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R H, Ingvar M, Lindvall O, Stenevi U, Bj&#xf6;rklund A. J Neurochem. 1982;38:737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">6120214</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J W, Wachtel S R, Young D, Kang U J. Neuroscience. 1999;88:617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel R J. Exp Neurol. 2000;161:212&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683287</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson A, Davis J N, Kehr W, Lindqvist M, Atack C V. Naunyn Schmiedebergs Arch Pharmacol. 1972;275:153&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">4404948</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R H, Bj&#xf6;rklund A, Stenevi U, Dunnett S B, Gage F H. Acta Physiol Scand Suppl. 1983;522:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">6326471</ArticleId></ArticleIdList></Reference><Reference><Citation>Agid Y, Javoy F, Glowinski J. Nat New Biol. 1973;245:150&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">4517903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff J A, Fisher L J, Xu L, Jinnah H A, Langlais P J, Iuvone P M, O'Malley K L, Rosenberg M B, Shimohama S, Friedmann T, et al. Proc Natl Acad Sci USA. 1989;86:9011&#x2013;9014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298422</ArticleId><ArticleId IdType="pubmed">2573072</ArticleId></ArticleIdList></Reference><Reference><Citation>Leff S E, Rendahl K G, Spratt S K, Kang U J, Mandel R J. Exp Neurol. 1998;151:249&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9628761</ArticleId></ArticleIdList></Reference><Reference><Citation>During M J, Naegele J R, O'Malley K L, Geller A I. Science. 1994;266:1399&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638002</ArticleId><ArticleId IdType="pubmed">7669103</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczypka M S, Mandel R J, Donahue B A, Snyder R O, Leff S E, Palmiter R D. Neuron. 1999;22:167&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel R J. Brain Res. 2000;886:82&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11119690</ArticleId></ArticleIdList></Reference><Reference><Citation>Oorschot D E. Prog Neurobiol. 1994;44:233&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">7886226</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11917117</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP.</ArticleTitle><Pagination><StartPage>4697</StartPage><EndPage>4702</EndPage><MedlinePgn>4697-702</MedlinePgn></Pagination><Abstract><AbstractText>Presenilins mediate an unusual intramembranous proteolytic activity known as gamma-secretase, two substrates of which are the Notch receptor (Notch) and the beta-amyloid precursor protein (APP). Gamma-secretase-mediated cleavage of APP, like that of Notch, yields an intracellular fragment [APP intracellular domain (AICD)] that forms a transcriptively active complex. We now demonstrate a functional role for AICD in regulating phosphoinositide-mediated calcium signaling. Genetic ablation of the presenilins or pharmacological inhibition of gamma-secretase activity (and thereby AICD production) attenuated calcium signaling in a dose-dependent and reversible manner through a mechanism involving the modulation of endoplasmic reticulum calcium stores. Cells lacking APP (and hence AICD) exhibited similar calcium signaling deficits, and-notably-these disturbances could be reversed by transfection with APP constructs containing an intact AICD, but not by constructs lacking this domain. Our findings indicate that the AICD regulates phosphoinositide-mediated calcium signaling through a gamma-secretase-dependent signaling pathway, suggesting that the intramembranous proteolysis of APP may play a signaling role analogous to that of Notch.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leissring</LastName><ForeName>Malcolm A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neuropathogenesis, Department of Neurobiology and Behavior, University of California, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>M Paul</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Tonya R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Yama</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sugarman</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Jannatipour</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Anliker</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Saftig</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039072</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39072</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11917117</ArticleId><ArticleId IdType="pmc">PMC123710</ArticleId><ArticleId IdType="doi">10.1073/pnas.072033799</ArticleId><ArticleId IdType="pii">072033799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolfe M S, Haass C. J Biol Chem. 2001;276:5413&#x2013;5416.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134059</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm J S, Schroeter E H, Schrijvers V, Wolfe M S, Ray W J, et al. Nature (London) 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Artavanis-Tsakonas S, Rand M D, Lake R J. Science. 1999;284:770&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221902</ArticleId></ArticleIdList></Reference><Reference><Citation>Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens J R, Cumano A, Roux P, Black R A, Isra&#xeb;l A. Mol Cell. 2000;5:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882063</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwald I. Genes Dev. 1998;12:1751&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">9637676</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B. J Neurochem. 2001;78:1168&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly W T, Zheng J B, Guenette S Y, Selkoe D J. J Biol Chem. 2001;276:40288&#x2013;40292.</Citation><ArticleIdList><ArticleId IdType="pubmed">11544248</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof T C. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore F, Zambrano N, Minopoli G, Donini V, Duilio A, Russo T. J Biol Chem. 1995;270:30853&#x2013;30866.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537337</ArticleId></ArticleIdList></Reference><Reference><Citation>Minopoli G, de Candia P, Bonetti A, Faraonio R, Zambrano N, Russo T. J Biol Chem. 2001;276:6545&#x2013;6550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085987</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Furukawa K, Sopher B L, Pham D G, Xie J, Robinson N, Martin G M, Mattson M P. NeuroReport. 1996;8:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051814</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M A, Paul B A, Parker I, Cotman C W, LaFerla F M. J Neurochem. 1999;72:1061&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037477</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M A, Parker I, LaFerla F M. J Biol Chem. 1999;274:32535&#x2013;32538.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551803</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M A, Akbari Y, Fanger C M, Cahalan M D, Mattson M P, LaFerla F M. J Cell Biol. 2000;149:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo A S, Cheng I, Chung S, Grenfell T Z, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, et al. Neuron. 2000;27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung T T, Cai X D, Odaka A, Otvos L, Jr, Eckman C, Golde T E, Younkin S G. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>McLendon C, Xin T, Ziani-Cherif C, Murphy M P, Findlay K A, Lewis P A, Pinnix I, Sambamurti K, Wang R, Fauq A, Golde T E. FASEB J. 2000;14:2383&#x2013;2386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11024004</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Nature (London) 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, et al. Proc Natl Acad Sci USA. 1999;96:11872&#x2013;11877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin L, Saido T, Shoji M, Ashe K, Younkin S. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Harris C L, Ratovitski T, Davenport F, Slunt H H, Price D L, Borchelt D R, Sisodia S S. J Biol Chem. 1997;272:28415&#x2013;28422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353300</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y M, Xu M, Lai M T, Huang Q, Castro J L, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil J G, et al. Nature (London) 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, von Kretzschmar H, von Koch C, Sisodia S, Tremml P, et al. J Neurosci. 2000;20:7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo E H, Squazzo S L. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D C, Rabizadeh S, Chandra S, Shayya R F, Ellerby L M, Ye X, Salvesen G S, Koo E H, Bredesen D E. Nat Med. 2000;6:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10742146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, Buxbaum J D, Minopoli G, Fiore F, De Candia P, De Renzis S, Faraonio R, Sabo S, Cheetham J, Sudol M, Russo T. J Biol Chem. 1997;272:6399&#x2013;6405.</Citation><ArticleIdList><ArticleId IdType="pubmed">9045663</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter E H, Kisslinger J A, Kopan R. Nature (London) 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M A, LaFerla F M, Callamaras N, Parker I. Neurobiol Dis. 2001;8:469&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H, Kretzschmar H, Godaux E, et al. J Biol Chem. 2001;276:11539&#x2013;11544.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278803</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron M M, Teplow D B, Haass C. EMBO Rep. 2001;2:835&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084035</ArticleId><ArticleId IdType="pubmed">11520861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11923434</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy.</ArticleTitle><Pagination><StartPage>2690</StartPage><EndPage>2700</EndPage><MedlinePgn>2690-700</MedlinePgn></Pagination><Abstract><AbstractText>Lymphocytes respond to myelin proteins after spinal cord injury (SCI) and may contribute to post-traumatic secondary degeneration. However, there is increasing evidence that autoreactive T-lymphocytes may also convey neuroprotection and promote functional recovery after CNS injury. To clarify the role of myelin autoreactive lymphocytes after SCI, we performed contusion injuries in the thoracic spinal cord of transgenic (Tg) mice in which &gt;95% of all CD4+ T-lymphocytes are reactive with myelin basic protein (MBP). We observed significantly impaired recovery of locomotor and reflex function in Tg mice compared with non-Tg (nTg) littermates. Measures of functional impairment in Tg mice correlated with significantly less white matter at the injury site, and morphometric comparisons of injured Tg and nTg spinal cords revealed increased rostrocaudal lesion expansion (i.e., secondary degeneration) in Tg mice. Rostrocaudal to the impact site in SCI-nTg mice, demyelination was restricted to the dorsal funiculus, i.e., axons undergoing Wallerian degeneration. The remaining white matter appeared normal. In contrast, lymphocytes were colocalized with regions of demyelination and axon loss throughout the white matter of SCI-Tg mice. Impaired neurological function and exacerbated neuropathology in SCI-Tg mice were associated with increased intraspinal production of proinflammatory cytokine mRNA; neurotrophin mRNA was not elevated. These data suggest that endogenous MBP-reactive lymphocytes, activated by traumatic SCI, can contribute to tissue injury and impair functional recovery. Any neuroprotection afforded by myelin-reactive T-cells is likely to be an indirect effect mediated by other non-CNS-reactive lymphocytes. Similar to the Tg mice in this study, a subset of humans that are genetically predisposed to autoimmune diseases of the CNS may be adversely affected by vaccine therapies designed to boost autoreactive lymphocyte responses after CNS trauma. Consequently, the safe implementation of such therapies requires that future studies define the mechanisms that control T-cell function within the injured CNS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>T Bucky</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>The Neuroscience Graduate Studies Program, School of Allied Medical Professions, The Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>D Michele</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Sodhi</LastName><ForeName>Ajeet</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jonathan Z</ForeName><Initials>JZ</Initials></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Ronald P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>MacCallum</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sunhee</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Whitacre</LastName><ForeName>Caroline C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Popovich</LastName><ForeName>Phillip G</ForeName><Initials>PG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004676">Myelin Basic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020278" MajorTopicYN="N">Demyelinating Autoimmune Diseases, CNS</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006614" MajorTopicYN="N">Hindlimb</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016233" MajorTopicYN="N">Immunotherapy, Active</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008221" MajorTopicYN="N">Lymphoid Tissue</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004676" MajorTopicYN="N">Myelin Basic Protein</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012018" MajorTopicYN="N">Reflex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>12</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11923434</ArticleId><ArticleId IdType="pmc">PMC6758306</ArticleId><ArticleId IdType="pii">22/7/2690</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-07-02690.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML. Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol. 2001;158:2127&#x2013;2138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891982</ArticleId><ArticleId IdType="pubmed">11395390</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan SM, Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2001;2:734&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584311</ArticleId></ArticleIdList></Reference><Reference><Citation>Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA. 1997;94:599&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19559</ArticleId><ArticleId IdType="pubmed">9012830</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783230</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso DM, Beattie MS, Bresnahan JC, Anderson DK, Faden AI, Gruner JA, Holford TR, Hsu CY, Noble LJ, Nockels R, Perot PL, Salzman SK, Young W. MASCIS evaluation of open field locomotor scores: Effects of experience and teamwork on reliability. J Neurotrauma. 1996;13:343&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell MD, Taub DD, Perry VH. Overriding the brain's intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience. 1996;74:283&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">8843093</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson JM, Stuckman SS, Cox KL, Wardrop RM, Gienapp IE, Cross AH, Trotter JL, Whitacre CC. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis. J Immunol. 1999;162:6247&#x2013;6254.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethea JR, Nagashima H, Acosta MC, Briceno C, Gomez F, Marcillo AE, Loor K, Green J, Dietrich WD. Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma. 1999;16:851&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen IR, Schwartz M. Autoimmune maintenance and neuroprotection of the central nervous system. J Neuroimmunol. 1999;100:111&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">10695721</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross AH, Cannella B, Brosnan CF, Raine CS. Homing to central nervous system vasculature by antigen specific lymphocytes. I. Localization of C14-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. Lab Invest. 1990;63:162&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">1696331</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowder MJ, Hand DJ. Analysis of repeated measures. Chapman &amp; Hall; London: 1990.</Citation></Reference><Reference><Citation>Dusart I, Schwab ME. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci. 1994;6:712&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">8075816</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Bloom BR. A T-helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T-cells and protects against experimental allergic encephalomyelitis. J Exp Med. 1997;185:901&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196156</ArticleId><ArticleId IdType="pubmed">9120396</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher J, Levkovitch-Verbin H, Schori H, Yoles E, Butovsky O, Kaye JF, Ben Nun A, Schwartz M. Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J Neurosci. 2001;21:136&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762428</ArticleId><ArticleId IdType="pubmed">11150329</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberger ME, Bregman BS, Vierck CJ, Jr, Brown M. Criteria for assessing recovery of function after spinal cord injury: behavioral methods. Exp Neurol. 1990;107:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">2406161</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein H. Multilevel statistical models. Halsted; New York: 1995.</Citation></Reference><Reference><Citation>Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, Svenningsson A, Linda H, Der Meide PH, Cullheim S, Olsson T, Piehl F. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci. 2000;20:5283&#x2013;5291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772346</ArticleId><ArticleId IdType="pubmed">10884312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, Mor F, Leibowitz-Amit R, Pevsner E, Akselrod S, Neeman M, Cohen IR, Schwartz M. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci. 2000a;20:6421&#x2013;6430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772980</ArticleId><ArticleId IdType="pubmed">10964948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben E, Nevo U, Yoles E, Moalem G, Agranov E, Mor F, Akselrod S, Neeman M, Cohen IR, Schwartz M. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet. 2000b;355:286&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">10675079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, Smirnov I, Steinman L, Schwartz M. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest. 2001;108:591&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC209402</ArticleId><ArticleId IdType="pubmed">11518733</ArticleId></ArticleIdList></Reference><Reference><Citation>Heese K, Hock C, Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem. 1998;70:699&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">9453564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschberg DL, Moalem G, He J, Mor F, Cohen IR, Schwartz M. Accumulation of passively transferred primed T cells independently of their antigen specificity following central nervous system trauma. J Neuroimmunol. 1998;89:88&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726830</ArticleId></ArticleIdList></Reference><Reference><Citation>Irani DN, Lin KI, Griffin DE. Regulation of brain-derived T cells during acute central nervous system inflammation. J Immunol. 1997;158:2318&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">9036980</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakeman LB, Guan Z, Wei P, Ponnappan R, Dzwonczyk R, Popovich PG, Stokes BT. Traumatic spinal cord injury produced by controlled contusion in mouse. J Neurotrauma. 2000;17:299&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">10776914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WEF, Kolbeck R, Hoppe E, Oropeza-Wekerle R-L, Bartke I, Stadelmann C, Lassman H, Wekerle H, Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999;189:865&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192942</ArticleId><ArticleId IdType="pubmed">10049950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kil K, Zang YCQ, Yang D, Markowski J, Fuoco GS, Vendetti GC, Rivera VM, Zhang JZ. T-cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999;98:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J, Yoles E, Schori H, Hauben E, Shaked I, Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci. 2001;21:4564&#x2013;4571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762348</ArticleId><ArticleId IdType="pubmed">11425884</ArticleId></ArticleIdList></Reference><Reference><Citation>Krakowski ML, Owens T. The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis. Eur J Immunol. 1997;27:2840&#x2013;2847.</Citation><ArticleIdList><ArticleId IdType="pubmed">9394808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PL, Wrathall JR. A mouse model of graded contusive spinal cord injury. J Neurotrauma. 1998;15:125&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephaloymyelitis in immunodeficient anti-myelin basic protein T-cell receptor transgenic mice. Cell. 1994;78:399&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">7520367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann S, Kincaid C, Asensio VC, Campbell IL. Induction of type 1 immune pathology in the brain following immunization without central nervous system autoantigen in transgenic mice with astrocyte-targeted expression of il-12. J Immunol. 2001;167:5485&#x2013;5493.</Citation><ArticleIdList><ArticleId IdType="pubmed">11673569</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebl DJ, Huang W, Young W, Parada LF. Regulation of Trk receptors following contusion of the rat spinal cord. Exp Neurol. 2001;167:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11161589</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus R. On the cooperation and interference of reflexes from other sense organs with those of the labyrinths. Laryngoscope. 1926;36:701&#x2013;712.</Citation></Reference><Reference><Citation>Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">1375472</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason JL, Suzuki K, Chaplin DD, Matsushima GK. Interleukin-1beta promotes repair of the CNS. J Neurosci. 2001;21:7046&#x2013;7052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762979</ArticleId><ArticleId IdType="pubmed">11549714</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 1996;19:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">8843602</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T-cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999a;5:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883839</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J. 1999b;13:1207&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">10385611</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalem G, Gdalyahu A, Leibowitz-Amit R, Yoles E, Muller-Gilor S, Shani Y, Mor F, Tooen U, Cohen IR, Schwartz M. Production of neurotrophins by activated T-cells: implications for neuroprotective autoimmunity. J Autoimmun. 2000a;15:331&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">11040074</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalem G, Yoles E, Leibowitz-Amit R, Muller-Gilor S, Mor F, Cohen IR, Schwartz M. Autoimmune T cells retard the loss of function in injured rat optic nerves. J Neuroimmunol. 2000b;106:189&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814797</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol. 2000;10:542&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121747</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivares-Villagomez D, Wang Y, Lafaille JJ. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med. 1998;188:1883&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212402</ArticleId><ArticleId IdType="pubmed">9815266</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson T, Diener P, Ljungdahl A, Hojeberg B, van der Meide PH, Kristensson K. Facial nerve transection causes expansion of myelin autoreactive T cells in regional lymph nodes and T cell homing to the facial nucleus. J Autoimmun. 1992;13:117&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">1281678</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson T, Sun JB, Solders G, Xiao BG, Hojeberg B, Ekre HP, Link H. Autoreactive T and B cell responses to myelin antigens after diagnostic sural nerve biopsy. J Neurol Sci. 1993;117:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">7691993</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellis SM, Pellis VC, Teitelbaum P. Air righting without the cervical righting reflex in adult rats. Behav Brain Res. 1991;45:185&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789926</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovich PG, Stokes BT, Whitacre CC. Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. J Neurosci Res. 1996;45:349&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">8872895</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovich PG, Wei P, Stokes BT. The cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol. 1997;377:443&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">8989657</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovich PG, Stuckman S, Gienapp IE, Whitacre CC. Alterations in immune cell phenotype and function after experimental spinal cord injury. J Neurotrauma. 2001;18:957&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">11565606</ArticleId></ArticleIdList></Reference><Reference><Citation>Poser CM. The role of trauma in the pathogenesis of multiple sclerosis: a review. Clin Neurol Neurosurg. 1994;96:103&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">7924071</ArticleId></ArticleIdList></Reference><Reference><Citation>Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today. 2000;21:479&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071525</ArticleId></ArticleIdList></Reference><Reference><Citation>Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem. 1997;245:154&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">9056205</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell L, Fearn S, Klassen H, Schwab ME, Perry VH. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur J Neurosci. 1999a;11:3648&#x2013;3658.</Citation><ArticleIdList><ArticleId IdType="pubmed">10564372</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell L, Fearn S, Schwab M, Perry VH, Anthony DC. Cytokine-induced acute inflammation in the brain and spinal cord. J Neuropathol Exp Neurol. 1999b;58:245&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197816</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Solomon A, Lavie V, Ben-Bassat S, Belkin M, Cohen A. Tumor necrosis factor facilitates regeneration of injured central nervous system axons. Brain Res. 1991;545:334&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">1860055</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Cohen I, Lazarov-Spiegler O, Moalem G, Yoles E. The remedy may lie in ourselves: prospects for immune cell therapy in central nervous system protection and repair. J Mol Med. 1999a;77:713&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">10606206</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 1999b;22:295&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">10370250</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith T, Schmied M, Hewson AK, Lassmann H, Cuzner ML. Apoptosis of T cells and macrophages in the central nervous system of intact and adrenalectomized Lewis rats during experimental allergic encephalomyelitis. J Autoimmun. 1996;9:167&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738960</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci USA. 1996;93:2253&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39781</ArticleId><ArticleId IdType="pubmed">8637858</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol. 1998;152:74&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682014</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Keere F, Tonegawa S. CD4(+) T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J Exp Med. 1998;188:1875&#x2013;1882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212404</ArticleId><ArticleId IdType="pubmed">9815265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, Kuchroo V, Cohen IR, Weiner H, Schwartz M. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci. 2001;21:3740&#x2013;3748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762728</ArticleId><ArticleId IdType="pubmed">11356861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11923443</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.</ArticleTitle><Pagination><StartPage>2780</StartPage><EndPage>2791</EndPage><MedlinePgn>2780-91</MedlinePgn></Pagination><Abstract><AbstractText>Recombinant adeno-associated viral vectors display efficient tropism for transduction of the dopamine neurons of the substantia nigra. Taking advantage of this unique property of recombinant adeno-associated viral vectors, we expressed wild-type and A53T mutated human alpha-synuclein in the nigrostriatal dopamine neurons of adult rats for up to 6 months. Cellular and axonal pathology, including alpha-synuclein-positive cytoplasmic inclusions and swollen, dystrophic neurites similar to those seen in brains from patients with Parkinson's disease, developed progressively over time. These pathological alterations occurred preferentially in the nigral dopamine neurons and were not observed in other nondopaminergic neurons transduced by the same vectors. The degenerative changes were accompanied by a loss of 30-80% of the nigral dopamine neurons, a 40-50% reduction of striatal dopamine, and tyrosine hydroxylase levels that was fully developed by 8 weeks. Significant motor impairment developed in those animals in which dopamine neuron cell loss exceeded a critical threshold of 50-60%. At 6 months, signs of cell body and axonal pathology had subsided, suggesting that the surviving neurons had recovered from the initial insult, despite the fact that alpha-synuclein expression was maintained at a high level. These results show that nigral dopamine neurons are selectively vulnerable to high levels of either wild-type or mutant alpha-synuclein, pointing to a key role for alpha-synuclein in the pathogenesis of Parkinson's disease. Targeted overexpression of alpha-synuclein in the nigrostriatal system may provide a new animal model of Parkinson's disease that reproduces some of the cardinal pathological, neurochemical, and behavioral features of the human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirik</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Wallenberg Neuroscience Center, Department of Physiological Sciences, Division of Neurobiology, Lund University, 221 84, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenblad</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Burger</LastName><ForeName>Corinna</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lundberg</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Johansen</LastName><ForeName>Teit E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Muzyczka</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mandel</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Bj&#xf6;rklund</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS036302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS36302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497606">Snca protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>102-32-9</RegistryNumber><NameOfSubstance UI="D015102">3,4-Dihydroxyphenylacetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015102" MajorTopicYN="N">3,4-Dihydroxyphenylacetic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018390" MajorTopicYN="N">Gene Targeting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>12</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11923443</ArticleId><ArticleId IdType="pmc">PMC6758323</ArticleId><ArticleId IdType="pii">22/7/2780</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-07-02780.2002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arima K, Ueda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein- epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 1998;808:93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9795161</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 2000;886:82&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11119690</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol [Suppl 2] 2000;247:3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">10991663</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol. 1997;71:8780&#x2013;8789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192344</ArticleId><ArticleId IdType="pubmed">9343238</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Lee VM, Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res. 2000;61:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878583</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746727</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996;70:3227&#x2013;3234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190186</ArticleId><ArticleId IdType="pubmed">8627803</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, Lee VM. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res. 2000a;59:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679792</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000b;290:985&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashida K, Oyanagi S, Mizutani Y, Yokochi M. An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism. Acta Neuropathol. 1993;85:445&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">8480516</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffner TG, Zigmond MJ, Stricker EM. Effects of dopaminergic agonists and antagonists of feeding in intact and 6-hydroxydopamine-treated rats. J Pharmacol Exp Ther. 1977;201:386&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">859104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E. alpha-synuclein promotes mitochondrial deficit, oxidative stress. Am J Pathol. 2000;157:401&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850140</ArticleId><ArticleId IdType="pubmed">10934145</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, Hyman BT. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998;57:334&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">9600226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365&#x2013;6373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772969</ArticleId><ArticleId IdType="pubmed">10964942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience. 2000;97:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D, Rosenblad C, Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol. 1998;152:259&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710526</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci. 2000;20:4686&#x2013;4700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772474</ArticleId><ArticleId IdType="pubmed">10844038</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RL, Meyer EM, Peel AL, Zolotukhin S, Meyers C, Muzyczka N, King MA. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol. 1998;150:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9527887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CS, Sauer H, Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience. 1996;72:641&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">9157311</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774100</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP- cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci. 1998;18:4271&#x2013;4284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792786</ArticleId><ArticleId IdType="pubmed">9592104</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JF. Somatosensory inattention after dopamine-depleting intracerebral 6-OHDA injections: spontaneous recovery and pharmacological control. Brain Res. 1979;177:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">574052</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678833</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, Yu X, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J, Duff K, Przedborski S, Di Monte DA. Lack of nigral pathology in transgenic mice expressing human alpha- synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis. 2001;8:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442360</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol. 1988;62:1963&#x2013;1973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC253280</ArticleId><ArticleId IdType="pubmed">2835501</ArticleId></ArticleIdList></Reference><Reference><Citation>McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2001;2:589&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484002</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992;158:97&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">1316261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B. alpha-Synuclein shares physical and functional homology with 14&#x2013;3-3 proteins. J Neurosci. 1999;19:5782&#x2013;5791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783081</ArticleId><ArticleId IdType="pubmed">10407019</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathke-Hartlieb S, Kahle PJ, Neumann M, Ozmen L, Haid S, Okochi M, Haass C, Schulz JB. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem. 2001;77:1181&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11359883</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard JF, Jr, Smith GK, Nichol CA. A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of 3H2O and adsorption of [3H]-tyrosine by charcoal. Life Sci. 1986;39:2185&#x2013;2189.</Citation><ArticleIdList><ArticleId IdType="pubmed">2878337</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt RH, Ingvar M, Lindvall O, Stenevi U, Bj&#xf6;rklund A. Functional activity of substantia nigra grafts reinnervating the striatum: neurotransmitter metabolism and [14C]2-deoxy-d-glucose autoradiography. J Neurochem. 1982;38:737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">6120214</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25:302&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888878</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 2001;293:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431533</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469&#x2013;6473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet. 2000;9:2683&#x2013;2689.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063727</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol. 1998;152:367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1857971</ArticleId><ArticleId IdType="pubmed">9466562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofaris GK, Layfield R, Spillantini MG. alpha-synuclein metabolism, aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 2001;509:22&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11734199</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J Neurosci. 2000;20:6021&#x2013;6029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772584</ArticleId><ArticleId IdType="pubmed">10934251</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Ponder KP. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther. 2001;12:563&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268288</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990;13:290&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">1695406</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">10455399</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11930016</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.</ArticleTitle><Pagination><StartPage>4703</StartPage><EndPage>4707</EndPage><MedlinePgn>4703-7</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by progressive cerebral atrophy, which may be assessed by using volumetric MRI. We describe a voxel-based analysis of nonlinear-registered serial MRI to demonstrate the most statistically significant (P &lt; 0.001) regions of change at different stages of the disease. We compared presymptomatic (n = 4), mild (n = 10), and moderately affected (n = 12) patients with early- and late-onset AD, with age- and sex-matched controls, and demonstrated increasing global atrophy with advancing disease. Significantly increased rates of hippocampal atrophy were seen in presymptomatic and mildly affected patients. There was a shift in the distribution of temporal lobe atrophy with advancing disease; the inferolateral regions of the temporal lobes showed the most significantly increased rates of atrophy by the time the patients were mildly or moderately affected. Significantly increased rates of medial parietal lobe atrophy were seen at all stages, with frontal lobe involvement occurring later in the disease. Our results suggest that the sites showing the most significant rates of atrophy alter as the disease advances, and that regional atrophy is already occurring before the onset of symptoms. This technique provides insights into the natural history of AD, and may be a valuable tool in assessing the efficacy of disease-modifying treatments, especially if these treatments were to have region-specific effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scahill</LastName><ForeName>Rachael I</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>Dementia Research Group, Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G116/143</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4135-7. doi: 10.1073/pnas.082107399.</RefSource><PMID Version="1">11929987</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11930016</ArticleId><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="doi">10.1073/pnas.052587399</ArticleId><ArticleId IdType="pii">99/7/4703</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Acta Neuropathologica. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox N C, Freeborough P A, Rossor M N. Lancet. 1996;348:94&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly C A, Harvey R J, Cayton H. Br Med J. 1997;314:693&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2126145</ArticleId><ArticleId IdType="pubmed">9116540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C R, Petersen R C, Xu Y C, Waring S C, O'Brien P C, Tangalos E G, Smith G E, Ivnik R J, Kokmen E. Neurology. 1997;49:786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehericy S, Baulac M, Chiras J, Pierot L, Martin N, Pillon B, Deweer B, Dubois B, Marsault C. Am J Neuroradiol. 1994;15:929&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8332162</ArticleId><ArticleId IdType="pubmed">8059663</ArticleId></ArticleIdList></Reference><Reference><Citation>Juottonen K, Laakso M P, Partanen K, Soininen H. Am J Neuroradiol. 1999;20:139&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">9974069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon M J, Wegiel J, Desanti S, Convit A, Saint Louis L A, Rusinek H, Wisniewski H M. Neuroscience. 2000;95:721&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670438</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Jack C R, Jr, O'Brien P C, Kokmen E, Smith G E, Ivnik R J, Boeve B F, Tangalos R G, Petersen R C. Neurology. 2000;54:1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pubmed">10802781</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany R J, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman B T, Albert M S. Ann Neurol. 2000;47:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey K A, Foster N L, Kuhl D E. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E M, Caselli R J, Yun L S, Chen K, Bandy D, Minoshima S, Thibodeau S N, Osborne D. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy A M, Rossor M N, Frackowiak R J S. Alzheimer Dis Assoc Disord. 1995;9:17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605617</ArticleId></ArticleIdList></Reference><Reference><Citation>Small G W, Ercoli L M, Silverman D H, Huang S-C, Komo S, Bookheimer S Y, Lavretsky H, Miller K, Siddarth P, Rasgon N L, et al. Proc Natl Acad Sci USA. 2000;97:6037&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C R, Petersen R C, Xu Y, O'Brien P C, Smith G E, Ivnik R J, Boeve B F, Tangalos E G, Kokmen E. Neurology. 2000;55:484&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724764</ArticleId><ArticleId IdType="pubmed">10953178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox N C, Warrington E K, Freeborough P A, Hartikainen P, Kennedy A M, Stevens J M, Rossor M N. Brain. 1996;119:2001&#x2013;2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C R, Petersen R C, Xu Y C, O'Brien P C, Smith G E, Ivnik R J, Boeve B F, Waring S C, Tangalos E G, Kokmen E. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen G E, Rabbitt R D, Miller M I. IEEE Trans Image Proc. 1996;5:1435&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">18290061</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough P A, Fox N C. J Comput Assist Tomogr. 1998;22:838&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754126</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox N C, Crum W R, Scahill R I, Stevens J M, Janssen J C, Rossor M N. Lancet. 2001;358:201&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476837</ArticleId></ArticleIdList></Reference><Reference><Citation>Crum W R, Scahill R I, Fox N C. Neuroimage. 2001;13:847&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">11304081</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston K J, Holmes A P, Worsley K J, Poline J-P, Frith C D, Frackowiak R S J. Hum Brain Mapp. 1995;2:189&#x2013;210.</Citation></Reference><Reference><Citation>Ashburner J, Friston K J. Neuroimage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron J C, Chetelat G, Desgranges B, Perchey G, Landeau B, De La Sayette V, Eustache F. Neuroimage. 2001;14:298&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467904</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts S A, Barkhof F, Witter M P, Scheltens P. Neurosci Lett. 2000;285:231&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806328</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson P M, Mega M S, Woods R P, Zoumalan C I, Lindshield C J, Blanton R E, Moussai J, Holmes C J, Cummings J L, Toga A W. Cereb Cortex. 2001;11:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113031</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson P M, Vidal C, Giedd J N, Gochman P, Blumenthal J, Nicolson R, Toga A W, Rapoport J L. Proc Natl Acad Sci USA. 2001;98:11650&#x2013;11655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58784</ArticleId><ArticleId IdType="pubmed">11573002</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein S, McHughs P. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E M. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox N C, Warrington E K, Seiffer A S, Agnew S K, Rossor M N. Brain. 1998;121:1631&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762953</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough P A, Fox N C, Kitney R I. Comput Methods Prog Biomed. 1997;53:15&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">9113464</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough P A, Woods R P, Fox N C. J Comput Assist Tomogr. 1996;20:1012&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">8933812</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Stuttgart: Thieme; 1988.</Citation></Reference><Reference><Citation>DeCarli C, Haxby J V, Gillette J A, Teichberg D, Rapoport S I, Schapiro M B. Neurology. 1992;42:2029&#x2013;2036.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407587</ArticleId></ArticleIdList></Reference><Reference><Citation>Shear P K, Sullivan E V, Mathalon D H, Lim K O, Davis L F, Yesavage J A, Tinklenberg J R, Pfefferbaum A. Arch Neurol. 1995;52:392&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">7710375</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox N C, Warrington E K, Rossor M N. Lancet. 1999;353:2125.</Citation><ArticleIdList><ArticleId IdType="pubmed">10382699</ArticleId></ArticleIdList></Reference><Reference><Citation>Linn R T, Wolf P A, Bachman D L, Knoefel J E, Cobb J L, Belanger A J, Kaplan E F, D'Agostino R B. Arch Neurol. 1995;52:485&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">7733843</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause B J, Schmidt D, Mottaghy F M, Taylor J, Halsband U, Herzog H, Tellmann L, Muller-Gartner H W. Brain. 2001;122:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071054</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire E A, Frith C D, Morris R M. Brain. 1999;122:1839&#x2013;1850.</Citation><ArticleIdList><ArticleId IdType="pubmed">10506087</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddock R J, Garrett A S, Buonocore M H. Neuroscience. 2001;104:667&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor M N, Garrett N J, Johnson A L, Mountjoy C Q, Roth M, Iversen L L. Brain. 1982;105:313&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">7082992</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neurobiol Aging. 1997;18:S85&#x2013;S88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11932737</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>416</Volume><Issue>6880</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases.</ArticleTitle><Pagination><StartPage>507</StartPage><EndPage>511</EndPage><MedlinePgn>507-11</MedlinePgn></Pagination><Abstract><AbstractText>A range of human degenerative conditions, including Alzheimer's disease, light-chain amyloidosis and the spongiform encephalopathies, is associated with the deposition in tissue of proteinaceous aggregates known as amyloid fibrils or plaques. It has been shown previously that fibrillar aggregates that are closely similar to those associated with clinical amyloidoses can be formed in vitro from proteins not connected with these diseases, including the SH3 domain from bovine phosphatidyl-inositol-3'-kinase and the amino-terminal domain of the Escherichia coli HypF protein. Here we show that species formed early in the aggregation of these non-disease-associated proteins can be inherently highly cytotoxic. This finding provides added evidence that avoidance of protein aggregation is crucial for the preservation of biological function and suggests common features in the origins of this family of protein deposition diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bucciantini</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Biochimiche, Viale Morgagni 50, Universit&#xe1; degli Studi di Firenze, 50134 Firenze, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannoni</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chiti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Baroni</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Formigli</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zurdo</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Taddei</LastName><ForeName>Niccol&#xf2;</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ramponi</LastName><ForeName>Giampietro</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Stefani</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>453/BI</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant><Grant><GrantID>686</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003603">Cytotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108878">HypF protein, Bacteria</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 Apr 4;416(6880):483-4. doi: 10.1038/416483a.</RefSource><PMID Version="1">11932723</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016475" MajorTopicYN="N">3T3 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005075" MajorTopicYN="N">Biological Evolution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003603" MajorTopicYN="N">Cytotoxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018909" MajorTopicYN="N">src Homology Domains</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId><ArticleId IdType="doi">10.1038/416507a</ArticleId><ArticleId IdType="pii">416507a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11932748</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>416</Volume><Issue>6880</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Changing potency by spontaneous fusion.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>548</EndPage><MedlinePgn>545-8</MedlinePgn></Pagination><Abstract><AbstractText>Recent reports have suggested that mammalian stem cells residing in one tissue may have the capacity to produce differentiated cell types for other tissues and organs 1-9. Here we define a mechanism by which progenitor cells of the central nervous system can give rise to non-neural derivatives. Cells taken from mouse brain were co-cultured with pluripotent embryonic stem cells. Following selection for a transgenic marker carried only by the brain cells, undifferentiated stem cells are recovered in which the brain cell genome has undergone epigenetic reprogramming. However, these cells also carry a transgenic marker and chromosomes derived from the embryonic stem cells. Therefore the altered phenotype does not arise by direct conversion of brain to embryonic stem cell but rather through spontaneous generation of hybrid cells. The tetraploid hybrids exhibit full pluripotent character, including multilineage contribution to chimaeras. We propose that transdetermination consequent to cell fusion 10 could underlie many observations otherwise attributed to an intrinsic plasticity of tissue stem cells 9.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Qi-Long</ForeName><Initials>QL</Initials><AffiliationInfo><Affiliation>Centre for Genome Research, University of Edinburgh, The King's Buildings, West Mains Road, Edinburgh EH9 3JQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Edward P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Austin G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002934">Cinnamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XQ2233B0B</RegistryNumber><NameOfSubstance UI="D006921">Hygromycin B</NameOfSubstance></Chemical><Chemical><RegistryNumber>3YJY415DDI</RegistryNumber><NameOfSubstance UI="C026273">hygromycin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 Apr 4;416(6880):485-7. doi: 10.1038/416485a.</RefSource><PMID Version="1">11932725</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000943" MajorTopicYN="N">Antigens, Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001755" MajorTopicYN="N">Blastocyst</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002459" MajorTopicYN="Y">Cell Fusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002678" MajorTopicYN="N">Chimera</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002934" MajorTopicYN="Y">Cinnamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005314" MajorTopicYN="N">Embryonic and Fetal Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006822" MajorTopicYN="N">Hybrid Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006921" MajorTopicYN="N">Hygromycin B</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11932748</ArticleId><ArticleId IdType="doi">10.1038/nature729</ArticleId><ArticleId IdType="pii">nature729</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11939702</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1355-6177</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of the International Neuropsychological Society : JINS</Title><ISOAbbreviation>J Int Neuropsychol Soc</ISOAbbreviation></Journal><ArticleTitle>What is cognitive reserve? Theory and research application of the reserve concept.</ArticleTitle><Pagination><StartPage>448</StartPage><EndPage>460</EndPage><MedlinePgn>448-60</MedlinePgn></Pagination><Abstract><AbstractText>The idea of reserve against brain damage stems from the repeated observation that there does not appear to be a direct relationship between the degree of brain pathology or brain damage and the clinical manifestation of that damage. This paper attempts to develop a coherent theoretical account of reserve. One convenient subdivision of reserve models revolves around whether they envision reserve as a passive process, such as in brain reserve or threshold, or see the brain as actively attempting to cope with or compensate for pathology, as in cognitive reserve. Cognitive reserve may be based on more efficient utilization of brain networks or of enhanced ability to recruit alternate brain networks as needed. A distinction is suggested between reserve, the ability to optimize or maximize normal performance, and compensation, an attempt to maximize performance in the face of brain damage by using brain structures or networks not engaged when the brain is not damaged. Epidemiologic and imaging data that help to develop and support the concept of reserve are presented.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>G.H. Sergievsky Center, The Taub Institute, Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. ys11@columbia.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG14671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Int Neuropsychol Soc</MedlineTA><NlmUniqueID>9503760</NlmUniqueID><ISSNLinking>1355-6177</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011999" MajorTopicYN="N">Recruitment, Neurophysiological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>81</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>29</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11939702</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11939895</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Independent predictors of cognitive decline in healthy elderly persons.</ArticleTitle><Pagination><StartPage>601</StartPage><EndPage>606</EndPage><MedlinePgn>601-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several studies have shown that individually memory, hippocampal volume, and motor measures presage the onset of dementia. It is unclear if these independently contribute to the prediction of mild cognitive impairment.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the ability of memory, hippocampal volume, and a gait speed to independently predict cognitive decline in healthy elderly persons.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A prospective, longitudinal, observational cohort study with a mean follow-up of 6 years.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">One hundred eight optimally healthy elderly cognitively intact subjects.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Any cognitive impairment noted on the Clinical Dementia Rating Scale (score = 0.5) or persistent or progressive cognitive impairment. Cox modeling determined if time to onset of cognitive impairment was associated with baseline logical memory II test score (a measure of delayed recall), hippocampal volume (magnetic resonance imaging), or gait speed (time to walk 30 ft [9 m]) independent of age, sex, depression, or the allele producing the epsilon4 type of apolipoprotein E (APOE epsilon4).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Questionable dementia occurred in 48 participants in a mean (SD) of 3.7 (2.4) years. This progressed to persistent cognitive impairment in 38 of these participants in a mean (SD) of 4.4 (2.4) years. Logical memory II test performance and hippocampal volume each predicted onset of questionable dementia, independent of age and sex. Time to walk 30 ft additionally contributed independently to the prediction of time to onset of persistent cognitive impairment. Possessing the APOE epsilon4 allele and depression did not enter either model significantly.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Models combining multiple risk factors should refine the prediction of questionable dementia and persistent cognitive impairment, harbingers of dementia. Individuals at risk for cognitive impairment may represent a high-risk group for intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marquis</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Alberta, 2E3.08, 8440 112th St, Edmonton, Alberta, Canada T6G 2B7. richard.camicioli@ualberta.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>M Milar</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Howieson</LastName><ForeName>Diane B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Sexton</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Payami</LastName><ForeName>Haydeh</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Camicioli</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5M01RR0034</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11939895</ArticleId><ArticleId IdType="doi">10.1001/archneur.59.4.601</ArticleId><ArticleId IdType="pii">noc10212</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11941374</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.</ArticleTitle><Pagination><StartPage>452</StartPage><EndPage>457</EndPage><MedlinePgn>452-7</MedlinePgn></Pagination><Abstract><AbstractText>We have previously shown that chronic treatment with the monoclonal antibody m266, which is specific for amyloid beta-peptide (Abeta), increases plasma concentrations of Abeta and reduces Abeta burden in the PDAPP transgenic mouse model of Alzheimer's disease (AD). We now report that administration of m266 to PDAPP mice can rapidly reverse memory deficits in both an object recognition task and a holeboard learning and memory task, but without altering brain Abeta burden. We also found that an Abeta/antibody complex was present in both the plasma and the cerebrospinal fluid of m266-treated mice. Our data indicate that passive immunization with this anti-Abeta monoclonal antibody can very rapidly reverse memory impairment in certain learning and memory tasks in the PDAPP mouse model of AD, owing perhaps to enhanced peripheral clearance and (or) sequestration of a soluble brain Abeta species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dodart</LastName><ForeName>Jean-Cosme</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Gannon</LastName><ForeName>Kimberley S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>DeMattos</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chantal</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>DeLong</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Su</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000936">Antigen-Antibody Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000936" MajorTopicYN="N">Antigen-Antibody Complex</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2002</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>15</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId><ArticleId IdType="doi">10.1038/nn842</ArticleId><ArticleId IdType="pii">nn842</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11949704</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0894-4105</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuropsychology</Title><ISOAbbreviation>Neuropsychology</ISOAbbreviation></Journal><ArticleTitle>Do neuropsychological tests detect preclinical Alzheimer's disease: individual-test versus cognitive-discrepancy score analyses.</ArticleTitle><Pagination><StartPage>132</StartPage><EndPage>139</EndPage><MedlinePgn>132-9</MedlinePgn></Pagination><Abstract><AbstractText>Attempts to identify cognitive markers of a preclinical phase of Alzheimer's disease (AD) have yielded inconsistent findings. The problem may stem in part from methodologies that are insensitive to potential subgroups within the at-risk, preclinical AD population (PCAD). The present study investigated the utility of asymmetric cognitive profiles in identifying individuals at risk for AD. Twenty elderly adults who were later diagnosed with AD (PCAD) and 20 matched control participants were compared on measures of cognitive asymmetry derived from difference scores on tests of verbal and visuospatial ability. Although both groups performed similarly on the individual tests, comparisons using difference scores revealed significantly larger discrepancies between naming and visuoconstruction skills in the PCAD group. The PCAD group also had a higher frequency of asymmetric cognitive profiles relative to a normative group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, San Diego, California 92161, USA. mjacobson@vapop.ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delis</LastName><ForeName>Dean C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Bondi</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12674</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychology</MedlineTA><NlmUniqueID>8904467</NlmUniqueID><ISSNLinking>0894-4105</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014705" MajorTopicYN="N">Verbal Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11949704</ArticleId><ArticleId IdType="doi">10.1037//0894-4105.16.2.132</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11950276</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0969-9961</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>305</StartPage><EndPage>318</EndPage><MedlinePgn>305-18</MedlinePgn></Pagination><Abstract><AbstractText>The epsilon4 allele of apolipoprotein E (apoE) is a risk factor for Alzheimer's disease (AD), perhaps through effects on amyloid-beta (Abeta) metabolism. Detailed analyses of various Abeta parameters in aging APP(V717F+/-) transgenic mice expressing mouse apoE, no apoE, or human apoE2, apoE3, or apoE4 demonstrate that apoE facilitates, but is not required for, Abeta fibril formation in vivo. Human apoE isoforms markedly delayed Abeta deposition relative to mouse apoE, with apoE2 (and apoE3 to a lesser extent) having a prolonged ability to prevent Abeta from converting into fibrillar forms. Isoform-specific effects of human apoE on Abeta levels and neuritic plaque formation mimicked that observed in AD (E4 &gt; E3 &gt; E2). Importantly, observation of an apoE-dependent decrease in percent soluble Abeta and enrichment of Abeta in membrane microdomains prior to Abeta deposition indicates that apoE influences Abeta metabolism early in the amyloidogenic process and provides a possible novel mechanism by which apoE affects AD pathogenesis.</AbstractText><CopyrightInformation>(c) 2002 Elsevier Science (USA).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Center for the Study of Nervous System Injury, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. fagana@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Parsadanian</LastName><ForeName>Maia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00861-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681-16</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId><ArticleId IdType="doi">10.1006/nbdi.2002.0483</ArticleId><ArticleId IdType="pii">S0969996102904833</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11953752</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons.</ArticleTitle><Pagination><StartPage>438</StartPage><EndPage>445</EndPage><MedlinePgn>438-45</MedlinePgn></Pagination><Abstract><AbstractText>Neural stem cells are present both in the developing nervous system and in the adult nervous system of all mammals, including humans. Little is known, however, about the extent to which stem cells in adults can give rise to new neurons. We used immunocytochemistry, electron microscopy, fluorescence microscopy (FM imaging) and electrophysiology to demonstrate that progeny of adult rat neural stem cells, when co-cultured with primary neurons and astrocytes from neonatal hippocampus, develop into electrically active neurons and integrate into neuronal networks with functional synaptic transmission. We also found that functional neurogenesis from adult stem cells is possible in co-culture with astrocytes from neonatal and adult hippocampus. These studies show that neural stem cells derived from adult tissues, like those derived from embryonic tissues, retain the potential to differentiate into functional neurons with essential properties of mature CNS neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Hong-jun</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, Howard Hughes Medical Institute at the Salk Institute, 10010 N. Torrey Pines Road, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2002 May;5(5):392-4. doi: 10.1038/nn0502-392.</RefSource><PMID Version="1">11976698</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000943" MajorTopicYN="N">Antigens, Differentiation</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2001</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2002</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>15</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11953752</ArticleId><ArticleId IdType="doi">10.1038/nn844</ArticleId><ArticleId IdType="pii">nn844</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11959919</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>9</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Tau is essential to beta -amyloid-induced neurotoxicity.</ArticleTitle><Pagination><StartPage>6364</StartPage><EndPage>6369</EndPage><MedlinePgn>6364-9</MedlinePgn></Pagination><Abstract><AbstractText>Senile plaques and neurofibrillary tangles, the two hallmark lesions of Alzheimer's disease, are the results of the pathological deposition of proteins normally present throughout the brain. Senile plaques are extracellular deposits of fibrillar beta-amyloid peptide (Abeta); neurofibrillary tangles represent intracellular bundles of self-assembled hyperphosphorylated tau proteins. Although these two lesions are often present in the same brain areas, a mechanistic link between them has yet to be established. In the present study, we analyzed whether tau plays a key role in fibrillar Abeta-induced neurite degeneration in central neurons. Cultured hippocampal neurons obtained from wild-type, tau knockout, and human tau transgenic mice were treated with fibrillar Abeta. Morphological analysis indicated that neurons expressing either mouse or human tau proteins degenerated in the presence of Abeta. On the other hand, tau-depleted neurons showed no signs of degeneration in the presence of Abeta. These results provide direct evidence supporting a key role for tau in the mechanisms leading to Abeta-induced neurodegeneration in the central nervous system. In addition, the analysis of the composition of the cytoskeleton of tau-depleted neurons suggested that the formation of more dynamic microtubules might confer resistance to Abeta-mediated neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rapoport</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Neuroscience, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Hana N</ForeName><Initials>HN</Initials></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Lester I</ForeName><Initials>LI</Initials></Author><Author ValidYN="Y"><LastName>Vitek</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS039080</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39080</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>12</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11959919</ArticleId><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="doi">10.1073/pnas.092136199</ArticleId><ArticleId IdType="pii">092136199</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glenner G G, Wong C W. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek M P, Rasool C G, de Sauvage F, Vitek S M, Bartus R T, Beer B, Ashton R A, Macq A F, Maloteaux J M, Blume A J. Brain Res. 1988;464:121&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">3064874</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner B A, Mesulam M M. N Engl J Med. 1991;325:1849&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961223</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe D J. Cell. 1993;75:1039&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">8261505</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D J. Annu Rev Cell Biol. 1994;10:373&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888181</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Quinlan M, Tung Y-C, Zaidi M S, Wisniewski H M. J Biol Chem. 1986;261:6084&#x2013;6089.</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo J, Honda T, Mori H, Hamada Y, Miura R, Ogawara M, Ihara Y. Neuron. 1988;1:827&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">2483105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik K S, Joachim C L, Selkoe D J. Proc Natl Acad Sci USA. 1986;83:4044&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Nukina N, Ihara Y. J Biochem. 1986;99:1541&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">2423512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood J G, Mirra S S, Pollock N L, Binder L I. Proc Natl Acad Sci USA. 1986;508:320&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323661</ArticleId><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Noguchi K, Sato K, Hoshimo T, Imahori K. Proc Natl Acad Sci USA. 1993;90:7789&#x2013;7793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47228</ArticleId><ArticleId IdType="pubmed">8356085</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yankner B A. Proc Natl Acad Sci USA. 1994;91:12243&#x2013;12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45413</ArticleId><ArticleId IdType="pubmed">7991613</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Lorenzo A, Yeh J, Yankner B A. Neuron. 1995;14:879&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">7718249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Lu Q, Orecchio L, Kosik K S. Mol Cell Neurosci. 1997;9:220&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">9245504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea T B, Deargay A N, Ekinci F J. Neurosci Res Comm. 1998;22:45&#x2013;49.</Citation></Reference><Reference><Citation>Ekinci F J, Malik K, Shea T B. J Biol Chem. 1999;274:30322&#x2013;30327.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514528</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez A, Toro R, Caceres A, Maccioni R B. FEBS Lett. 1999;459:421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526177</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Ferreira A. J Neurochem. 2000;74:125&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Li L, Chin L S, Greengard P, Kosik K S. Mol Cell Neurosci. 1996;8:286&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">9026316</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson H N, Ferreira A, Eyster M V, Binder L I, Vitek M P. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottenstein J E, Sato G. Proc Natl Acad Sci USA. 1979;76:514&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC382972</ArticleId><ArticleId IdType="pubmed">284369</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti P, Szuchet S, Papasozomenos S C, Zinkowski R P, Binder L I. Proc Natl Acad Sci USA. 1995;92:10369&#x2013;10373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowry O H, Reserbrough N J, Farr A L, Randall R J. J Biol Chem. 1951;193:265&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">14907713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensadoun A, Weinstein R. Anal Biochem. 1976;70:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">1259145</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli U K. Nature (London) 1970;227:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Towbin H, Staehelein T, Gordon J. Proc Natl Acad Sci USA. 1979;76:4354&#x2013;4356.</Citation></Reference><Reference><Citation>Ferreira A, Caceres A. J Neurosci Res. 1992;32:516&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">1527798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Busciglio J, Caceres A. Dev Brain Res. 1989;49:215&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">2509111</ArticleId></ArticleIdList></Reference><Reference><Citation>Piperno G, LeDizet M, Chang X. J Cell Biol. 1987;104:289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114420</ArticleId><ArticleId IdType="pubmed">2879846</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze E, Asai D J, Bulinski J C, Kirschner M. J Cell Biol. 1987;105:2167&#x2013;2177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114866</ArticleId><ArticleId IdType="pubmed">3316248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Kincaid R, Kosik K S. Mol Biol Cell. 1993;4:1225&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275760</ArticleId><ArticleId IdType="pubmed">8167406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V M, Trojanowski J Q. Neuron. 1999;24:507&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595503</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia M L, Cleveland D W. Curr Opin Cell Biol. 2001;13:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E-M, Mandelkow E. J Cell Biol. 1998;143:777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148132</ArticleId><ArticleId IdType="pubmed">9813097</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek B, Ebneth A, Mandelkow E-M, Mandelkow E. J Cell Sci. 1999;112:2355&#x2013;2367.</Citation><ArticleIdList><ArticleId IdType="pubmed">10381391</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreschel D N, Hyman A A, Cobb M H, Kirschner M. Mol Biol Cell. 1992;3:1141&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275678</ArticleId><ArticleId IdType="pubmed">1421571</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson S J, Burgoyne R D. Cell Motil Cytoskel. 1989;12:273&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">2655938</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus A. Curr Opin Cell Biol. 1990;2:10&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">2109620</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus A. J Cell Sci Suppl. 1991;15:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">1824108</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisshaar B, Doll T, Matus A. Development (Cambridge, UK) 1992;116:1151&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">1338311</ArticleId></ArticleIdList></Reference><Reference><Citation>Theiss C, Meller K. Cell Tissue Res. 2000;299:213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">10741462</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Masot X A, Hetman M, Higgins M J, Kobot N, Xia Z. J Neurosci. 2001;21:4657&#x2013;4667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762365</ArticleId><ArticleId IdType="pubmed">11425893</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11967567</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1072-8368</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature structural biology</Title><ISOAbbreviation>Nat Struct Biol</ISOAbbreviation></Journal><ArticleTitle>Mapping the core of the beta(2)-microglobulin amyloid fibril by H/D exchange.</ArticleTitle><Pagination><StartPage>332</StartPage><EndPage>336</EndPage><MedlinePgn>332-6</MedlinePgn></Pagination><Abstract><AbstractText>Despite numerous efforts, the lack of detailed structural information on amyloid fibrils has hindered clarification of the mechanism of their formation. Here, we describe a novel procedure for characterizing the conformational flexibility of beta(2)-microglobulin amyloid fibrils at single-residue resolution that uses H/D exchange of amide protons combined with NMR analysis. The results indicate that most residues in the middle region of the molecule, including the loop regions in the native structure, form a rigid beta-sheet core, whereas the the N- and C-termini are excluded from this core. The extensively hydrogen-bonded beta-sheet core explains the remarkable rigidity and stability of amyloid fibrils. The present method could be used to obtain residue-specific conformational information of various amyloid fibrils, even though it does not provide a high resolution three-dimensional structure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoshino</LastName><ForeName>Masaru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Protein Research, Osaka University, Yamadaoka 3-2, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katou</LastName><ForeName>Hidenori</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hagihara</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Naiki</LastName><ForeName>Hironobu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Biol</MedlineTA><NlmUniqueID>9421566</NlmUniqueID><ISSNLinking>1072-8368</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001613">beta 2-Microglobulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>7YNJ3PO35Z</RegistryNumber><NameOfSubstance UI="D006859">Hydrogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>AR09D82C7G</RegistryNumber><NameOfSubstance UI="D003903">Deuterium</NameOfSubstance></Chemical><Chemical><RegistryNumber>YOW8V9698H</RegistryNumber><NameOfSubstance UI="D004121">Dimethyl Sulfoxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Struct Biol. 2002 May;9(5):323-5. doi: 10.1038/nsb0502-323.</RefSource><PMID Version="1">11976724</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003903" MajorTopicYN="N">Deuterium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004121" MajorTopicYN="N">Dimethyl Sulfoxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006859" MajorTopicYN="N">Hydrogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001613" MajorTopicYN="N">beta 2-Microglobulin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>11</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11967567</ArticleId><ArticleId IdType="doi">10.1038/nsb792</ArticleId><ArticleId IdType="pii">nsb792</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11967566</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1072-8368</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature structural biology</Title><ISOAbbreviation>Nat Struct Biol</ISOAbbreviation></Journal><ArticleTitle>Structural properties of an amyloid precursor of beta(2)-microglobulin.</ArticleTitle><Pagination><StartPage>326</StartPage><EndPage>331</EndPage><MedlinePgn>326-31</MedlinePgn></Pagination><Abstract><AbstractText>The population of one or more partially folded states has been proposed as a critical initial step in amyloid formation for several proteins. Here we use equilibrium denaturation measured by (1)H-(15)N NMR to determine the conformational properties of an amyloidogenic intermediate of human beta(2)-microglobulin (beta(2)m) formed at low pH. The data show that this amyloid precursor is a noncooperatively stabilized ensemble that retains stable structure in five of the seven beta-strands that comprise the native fold. The amyloid precursors of beta(2)m and transthyretin have similar properties despite having structurally unrelated native folds. The data offer a rationale as to why these proteins are both amyloidogenic at low pH and suggest that amyloidosis of these and other proteins may involve ordered assembly from a precursor with similar conformational features.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McParland</LastName><ForeName>Victoria J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>School of Biochemistry and Molecular Biology, University of Leeds, Leeds, LS2 9JT UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalverda</LastName><ForeName>Arnout P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Homans</LastName><ForeName>Steve W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Radford</LastName><ForeName>Sheena E</ForeName><Initials>SE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SF16972</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Biol</MedlineTA><NlmUniqueID>9421566</NlmUniqueID><ISSNLinking>1072-8368</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001613">beta 2-Microglobulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W8T17847W</RegistryNumber><NameOfSubstance UI="D014508">Urea</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Struct Biol. 2002 May;9(5):323-5. doi: 10.1038/nsb0502-323.</RefSource><PMID Version="1">11976724</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011489" MajorTopicYN="N">Protein Denaturation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001613" MajorTopicYN="N">beta 2-Microglobulin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>11</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11967566</ArticleId><ArticleId IdType="doi">10.1038/nsb791</ArticleId><ArticleId IdType="pii">nsb791</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11971084</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1182</StartPage><EndPage>1188</EndPage><MedlinePgn>1182-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychiatric symptoms occur frequently in the course of AD, are a frequent contributor to institutionalization, predict cognitive decline and death, and often require treatment with psychotropic medications. Previous studies investigating the association between APOE genotype and psychiatric symptomatology in AD have reported contradictory results.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether APOE genotype predicts incident psychiatric symptomatology in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighty-seven patients with AD at early stages and no psychiatric history were followed semiannually for up to 9.3 years (mean 5.5 years) for development of delusions, illusions, hallucinations, behavioral symptoms, and depression. Cox proportional hazards models were used to examine the relative risk for incident psychiatric symptomatology (outcome) in relation to APOE genotype (predictor).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The presence of one epsilon4 allele carried a 2.5-fold risk, whereas the presence of two epsilon4 alleles carried a 5.6-fold risk for development of delusions. The associations remained significant even when age, ethnicity, sex, education, duration of disease, and cognitive and functional performance were controlled for. The presence of two epsilon4 alleles was associated with reduced risk for developing hallucinations in the adjusted analysis only. No significant associations were detected between APOE genotype and the incidence of illusions, behavioral symptoms, or depression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The presence of one or more epsilon4 alleles is a significant predictor for the incidence of delusions in the course of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scarmeas</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ciappa</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tycko</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01 RR000645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG007370</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG007370</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR00645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>24</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>24</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11971084</ArticleId><ArticleId IdType="mid">NIHMS262617</ArticleId><ArticleId IdType="pmc">PMC3029097</ArticleId><ArticleId IdType="doi">10.1212/wnl.58.8.1182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos R, Rodriguez B, Carrera C, Beyer K, Lao JI, Sellers MA. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer Dis. 1997;11:S27&#x2013;S34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339270</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147:1049&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982;248:333&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging. 2001;18:45&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11232738</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;277:806&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Mayeux R, Sano M, Hauser WA, Bush T. Predictors of disease course in patients with probable Alzheimer's disease. Neurology. 1987;37:1649&#x2013;1653.</Citation><ArticleIdList><ArticleId IdType="pubmed">3658173</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300&#x2013;2307.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos R, Rodriguez B, Carrera C, et al. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp Clin Pharmacol. 1996;18:693&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">9121226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran G, Marder K, Tang M, et al. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology. 1996;47:256&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710089</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Levy R, McLoughlin DM, Powell JF, Lovestone S. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996;61:580&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486650</ArticleId><ArticleId IdType="pubmed">8971103</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy GM, Taylor J, Tinklenberg JR, Yesavage JA. The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease. Am J Geriatr Psychiatry. 1997;5:88&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">9169250</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Barker WW, Ownby RL, St George-Hyslop P, Duara R. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease. Am J Geriatr Psychiatry. 1999;7:119&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Massey H, Lamb H, Morris C. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1997;63:273.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtovirta M, Soininen H, Helisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology. 1996;46:413&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Alberola R, Gilchirst D, Barker WW, Geroge-Hyslop PS, Duara R. Analysis of phenotype in Alzheimer's disease (AD) associated with apolipoprotein E (APOE) alleles. Neurology. 1994;44(suppl 2):A207.</Citation></Reference><Reference><Citation>Forsell Y, Corder EH, Basun H, Lannfelt L, Viitanen M, Winblad B. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+. Biol Psychiatry. 1997;42:898&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">9359975</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Baker L, Warren A, et al. Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. J Neuropsychiatry Clin Neurosci. 1997;9:64&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9017530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Yasuda M, et al. Factors associated with psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1998;64:648&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170086</ArticleId><ArticleId IdType="pubmed">9598682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology. 1997;49:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305342</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsell Y, Basun H, Corder EH, Lannfelt L, Winblad B. Psychotic symptoms and apolipoprotein E genotypes in an elderly population. Biol Psychiatry. 1998;44:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9646896</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biol Psychiatry. 1999;45:422&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Yasuda M, et al. Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1999;11:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9990558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantillon M, Harwood D, Barker W, et al. No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease. Biol Psychiatry. 1997;41:246&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">9018400</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Vega G, Risser RC, et al. Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. Biol Psychiatry. 1999;45:633&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauricio M, O'Hara R, Yesvage JA, et al. A longitudinal study of apolipoprotein-E genotype and depressive symptoms in community-dwelling older adults. Am J Geriatr Psychiatry. 2000;8:196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10910416</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JY, Stern Y, Sano M, Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol. 1991;48:1141&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">1953398</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Folstein M, Albert M, et al. Multicenter study of predictors of disease course in Alzheimer disease (the &#x201c;Predictors Study&#x201d;). I. Study design, cohort description, and intersite comparisons. Alzheimer Dis. 1993;7:3&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8481224</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M, Folstein M, Albert M, et al. Multicenter study of predictors of disease course in Alzheimer disease (the &#x201c;Predictors Study&#x201d;). II. Neurological, psychiatric, and demographic influences on baseline measures of disease severity. Alzheimer Dis. 1993;7:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8481223</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed. American Psychiatric Press; Washington, DC: 1994. Revised.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology. 1981;31:645&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">7195481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Sano M, Paulson J, Mayeux R. Modified Mini-Mental State Examination: validity and reliability. Neurology. 1987;37(suppl 1):179.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenco GS, Rifai AH, Mulsant BH, Sweet RA, Pasternak RE. Premorbid history of major depression and the depressive syndrome of Alzheimer's disease. Am J Geriatr Psychiatry. 1996;4:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28531059</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Powers PK. Restriction isotyping of human apolipoprotein A-IV: rapid typing of known isoforms and detection of a new isoform that deletes a conserved repeat. J Lipid Res. 1991;32:1529&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pubmed">1684380</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Miller L, Richards M, et al. The Columbia University Scale for Psychopathology in Alzheimer's disease. Arch Neurol. 1992;49:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1558517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawless J. Statistical model and methods for lifetime data. Wiley; New York: 1982.</Citation></Reference><Reference><Citation>Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol. 1996;39:62&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8572669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279:751&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994;271:1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985;35:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">3982631</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol. 1997;41:615&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153523</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology. 1995;45:1323&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">7617191</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333:1242&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566000</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS, Moossy J. Major depression in primary dementia. Clinical and neuropathologic correlates. Arch Neurol. 1988;45:1182&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">3190497</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett. 1995;187:79&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783963</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen HS, Riekkinen PJ., Sr Apolipoprotein E, memory and Alzheimer's disease. Trends Neurosci. 1996;19:224&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">8761956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996;47:876&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">8857712</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstl H, Burns A, Levy R, Cairns N. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry. 1994;165:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">7953058</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkstein SE, Vazquez S, Petracca G, et al. A SPECT study of delusions in Alzheimer's disease. Neurology. 1994;44:2055&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtovirta M, Laakso MP, Soininen H, et al. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience. 1995;67:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtovirta M, Soininen H, Laakso MP, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry. 1996;60:644&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1073948</ArticleId><ArticleId IdType="pubmed">8648331</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry. 1998;155:1512&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812111</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11971085</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>MRI measures of entorhinal cortex vs hippocampus in preclinical AD.</ArticleTitle><Pagination><StartPage>1188</StartPage><EndPage>1196</EndPage><MedlinePgn>1188-96</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MRI measures of the entorhinal cortex and the hippocampus have been used to predict which nondemented individuals with memory problems will progress to meet criteria for AD on follow-up, but their relative accuracy remains controversial.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To compare MRI measures of the entorhinal cortex and the hippocampus for predicting who will develop AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MRI volumes of the entorhinal cortex and the hippocampus were obtained in 137 individuals comprising four groups: 1) individuals with normal cognition both at baseline and after 3 years of follow-up (n = 28), 2) subjects with memory difficulty but not dementia both at baseline and after 3 years of follow-up (n = 73), 3) subjects with memory difficulty at baseline who were diagnosed with probable AD within 3 years of follow-up (n = 21), and 4) patients with mild AD at baseline (n = 16).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Measures of both the entorhinal cortex and the hippocampus were different for each of the pairwise comparisons between the groups (p &lt; 0.001) and were correlated with tests of memory (p &lt; 0.01). However, the volume of the entorhinal cortex differentiated the subjects from those destined to develop dementia with considerable accuracy (84%), whereas the measure of the hippocampus did not.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings are consistent with neuropathologic data showing substantial involvement of the entorhinal cortex in the preclinical phase of AD and suggest that, as the disease spreads, atrophic change develops within the hippocampus, which is measurable on MRI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Killiany</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>M B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Kikinis</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jolesz</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG04953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2002 Nov 12;59(9):1474; author reply 1474-5. doi: 10.1212/wnl.59.9.1474.</RefSource><PMID Version="1">12427916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NASA"><Keyword MajorTopicYN="N">Non-programmatic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>24</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>24</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11971085</ArticleId><ArticleId IdType="doi">10.1212/wnl.58.8.1188</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11986659</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>417</Volume><Issue>6884</Issue><PubDate><Year>2002</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Astroglia induce neurogenesis from adult neural stem cells.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>44</EndPage><MedlinePgn>39-44</MedlinePgn></Pagination><Abstract><AbstractText>During an investigation of the mechanisms through which the local environment controls the fate specification of adult neural stem cells, we discovered that adult astrocytes from hippocampus are capable of regulating neurogenesis by instructing the stem cells to adopt a neuronal fate. This role in fate specification was unexpected because, during development, neurons are generated before most of the astrocytes. Our findings, together with recent reports that astrocytes regulate synapse formation and synaptic transmission, reinforce the emerging view that astrocytes have an active regulatory role--rather than merely supportive roles traditionally assigned to them--in the mature central nervous system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Hongjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, Howard Hughes Medical Institute at the Salk Institute, 10010 North Torrey Pines Road, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016895">Culture Media, Serum-Free</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007797">Laminin</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 May 2;417(6884):29-32. doi: 10.1038/417029a.</RefSource><PMID Version="1">11986650</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016895" MajorTopicYN="N">Culture Media, Serum-Free</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007797" MajorTopicYN="N">Laminin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011916" MajorTopicYN="N">Rats, Inbred F344</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11986659</ArticleId><ArticleId IdType="doi">10.1038/417039a</ArticleId><ArticleId IdType="pii">417039a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11992114</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Sniffing neuropeptides: a transnasal approach to the human brain.</ArticleTitle><Pagination><StartPage>514</StartPage><EndPage>516</EndPage><MedlinePgn>514-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Born</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroendocrinology, University of L&#xfc;beck, Ratzeburger Allee 160, 23538 L&#xfc;beck, Germany. born@kfg.mu-luebeck.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>McGregor</LastName><ForeName>Gerard P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Bickel</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Fehm</LastName><ForeName>Horst L</ForeName><Initials>HL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>11000-17-2</RegistryNumber><NameOfSubstance UI="D014667">Vasopressins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-60-2</RegistryNumber><NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>J48AU3I790</RegistryNumber><NameOfSubstance UI="C011394">ACTH (4-10)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000324" MajorTopicYN="N">Adrenocorticotropic Hormone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009994" MajorTopicYN="N">Osmolar Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014667" MajorTopicYN="N">Vasopressins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11992114</ArticleId><ArticleId IdType="doi">10.1038/nn849</ArticleId><ArticleId IdType="pii">nn849</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12015594</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>417</Volume><Issue>6886</Issue><PubDate><Year>2002</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.</ArticleTitle><Pagination><StartPage>254</StartPage><EndPage>259</EndPage><MedlinePgn>254-9</MedlinePgn></Pagination><Abstract><AbstractText>The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process we have developed a drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid, that is a competitive inhibitor of SAP binding to amyloid fibrils. This palindromic compound also crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP. This mechanism of drug action potently removes SAP from human amyloid deposits in the tissues and may provide a new therapeutic approach to both systemic amyloidosis and diseases associated with local amyloid, including Alzheimer's disease and type 2 diabetes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pepys</LastName><ForeName>M B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, London NW3 2PF, UK. m.pepys@rfc.ucl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herbert</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hutchinson</LastName><ForeName>W L</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Tennent</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Lachmann</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Gallimore</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Lovat</LastName><ForeName>L B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Bartfai</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Alanine</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hertel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Jakob-Roetne</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Norcross</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Kemp</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Yamamura</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Purvis</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kolstoe</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>P N</ForeName><Initials>PN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002264">Carboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003432">Cross-Linking Reagents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C455899">R-1-(6-(R-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000683">Serum Amyloid P-Component</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 May 16;417(6886):231-3. doi: 10.1038/417231a.</RefSource><PMID Version="1">12015581</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002264" MajorTopicYN="N">Carboxylic Acids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003432" MajorTopicYN="N">Cross-Linking Reagents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000683" MajorTopicYN="N">Serum Amyloid P-Component</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>11</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12015594</ArticleId><ArticleId IdType="doi">10.1038/417254a</ArticleId><ArticleId IdType="pii">417254a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1202204</PMID><DateCompleted><Year>1976</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>1975</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.</ArticleTitle><Pagination><StartPage>189</StartPage><EndPage>198</EndPage><MedlinePgn>189-98</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Folstein</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Folstein</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006259" MajorTopicYN="N">Craniocerebral Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="Y">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008659" MajorTopicYN="N">Metabolic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009497" MajorTopicYN="N">Neurotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1975</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1975</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1975</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pii">0022-3956(75)90026-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12032347</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>11</Issue><PubDate><Year>2002</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice.</ArticleTitle><Pagination><StartPage>7705</StartPage><EndPage>7710</EndPage><MedlinePgn>7705-10</MedlinePgn></Pagination><Abstract><AbstractText>Endogenous metals may contribute to the accumulation of amyloid plaques in Alzheimer's disease. To specifically examine the role of synaptic zinc in the plaque accumulation, Tg2576 (also called APP2576) transgenic mice (hAPP(+)) expressing cerebral amyloid plaque pathology were crossed with mice lacking zinc transporter 3 (ZnT3(-/-)), which is required for zinc transport into synaptic vesicles. With aging, female hAPP(+):ZnT3(+/+) mice manifested higher levels of synaptic zinc, insoluble amyloid beta, and plaques than males; these sex differences disappeared in hAPP(+):ZnT3(-/-) mice. Both sexes of hAPP(+):ZnT3(-/-) mice had markedly reduced plaque load and less insoluble amyloid beta compared with hAPP(+):ZnT3(+/+) mice. Hence, of endogenous metals, synaptic zinc contributes predominantly to amyloid deposition in hAPP(+) mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joo-Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>National Creative Research Initiative Center for the Study of Central Nervous System Zinc and Department of Neurology, University of Ulsan College of Medicine, Seoul 138-736, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Toby B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Palmiter</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Sang Won</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Jae-Young</ForeName><Initials>JY</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DK-53013</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2002 May 28;99(11):7317-9. doi: 10.1073/pnas.122249699.</RefSource><PMID Version="1">12032279</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>2</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12032347</ArticleId><ArticleId IdType="pmc">PMC124328</ArticleId><ArticleId IdType="doi">10.1073/pnas.092034699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price D L, Sisoda S S. Annu Rev Neurosci. 1998;21:479&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D J. Nature (London) 1999;399:A23&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters C L, Simms G, Weinman N A, Multhaup G, McDonald B L, Beyreuther K. Proc Natl Acad Sci USA. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lemaire H G, Unterbeck A, Salbaum J M, Masters C L, Grzeschik K H, Multhaup G, Beyreuther K, Muller-Hill B. Nature (London) 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush A I, Pettingell W H, Multhaup G, de Paradis M, Vonsattel J P, Gusella J F, Beyreuther K, Masters C L, Tanzi R E. Science. 1994;265:1464&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">8073293</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura T, Suzuki K, Kohata N, Takeuchi H. Biochemistry. 2000;39:7024&#x2013;7031.</Citation><ArticleIdList><ArticleId IdType="pubmed">10841784</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Atwood C S, Moir R D, Hartshorn M A, Vonsattel J P, Tanzi R E, Bush A I. J Biol Chem. 1997;272:26464&#x2013;26470.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D S, McLaurin J, Qin K, Westaway D, Fraser P E. Eur J Biochem. 2000;267:6692&#x2013;6698.</Citation><ArticleIdList><ArticleId IdType="pubmed">11054124</ArticleId></ArticleIdList></Reference><Reference><Citation>Deibel M A, Ehmann W D, Markesbery W R. J Neurol Sci. 1996;143:137&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981312</ArticleId></ArticleIdList></Reference><Reference><Citation>Danscher G, Jensen K B, Frederickson C J, Kemp K, Andreasen A, Juhl S, Stoltenberg M, Ravid R. J Neurosci Methods. 1997;76:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334939</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell M A, Robertson J D, Teesdale W J, Campbell J L, Markesbery W R. J Neurol Sci. 1998;158:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9667777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny R A, Legg J T, McLean C A, Fairlie D P, Huang X, Atwood C S, Beyreuther K, Tanzi R E, Masters C L, Bush A I. J Biol Chem. 1999;274:23223&#x2013;23228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny R A, Atwood C S, Xilinas M E, Gray D N, Jones W D, McLean C A, Barnham K J, Volitakis I, Fraser F W, Kim Y, et al. Neuron. 2001;30:665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430801</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh S W, Jensen K B, Jensen M S, Silva D S, Kesslak P J, Danscher G, Frederickson C J. Brain Res. 2000;852:274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J Y, Mook-Jung I, Koh J Y. J Neurosci. 1999;19:RC10. (1&#x2013;5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782620</ArticleId><ArticleId IdType="pubmed">10341271</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Clausell J. J Chem Neuroanat. 1996;11:99&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">8877598</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederickson C J, Suh S W, Silva D, Frederickson C J, Thompson R B. J Nutr. 2000;130:1471S&#x2013;1483S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801962</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S M, Won M H, Cole T B, Jensen M S, Palmiter R D, Danscher G. Brain Res. 2000;865:227&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821925</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature (London) 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan S S, Veerhuis R, Kamphorst W, Eikelenboom P. Neurodegeneration. 1995;4:291&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">8581561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim C L, Morris J H, Selkoe D J. Am J Pathol. 1989;135:309&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879919</ArticleId><ArticleId IdType="pubmed">2675616</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren S D, Kamboh M I, DeKosky S T. J Comp Neurol. 1998;396:511&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651008</ArticleId></ArticleIdList></Reference><Reference><Citation>Assaf S Y, Chung S H. Nature (London) 1984;308:734&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">6717566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel H J, Cole T B, Born D E, Schwartzkroin P A, Palmiter R D. Proc Natl Acad Sci USA. 1997;94:12676&#x2013;12681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25081</ArticleId><ArticleId IdType="pubmed">9356509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole T B, Wenzel H J, Kafer K E, Schwartzkroin P A, Palmiter R D. Proc Natl Acad Sci USA. 1999;96:1716&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15571</ArticleId><ArticleId IdType="pubmed">9990090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K K, Borchelt D R, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole T B, Robbins C A, Wenzel H J, Schwartzkroin P A, Palmiter R D. Epilepsy Res. 2000;39:153&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">10759303</ArticleId></ArticleIdList></Reference><Reference><Citation>Budde T, Minta A, White J A, Kay A R. Neuroscience. 1997;79:347&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">9200720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J Y, Cole T B, Palmiter R D, Koh J Y. J Neurosci. 2000;20:RC79. (1&#x2013;5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772632</ArticleId><ArticleId IdType="pubmed">10807937</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan M J, Lipinski W J, Bian F, Durham R A, Pack A, Walker L C. Am J Pathol. 2001;158:1173&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell G A, Welch M G, Frederickson C J. Nature (London) 1984;308:736&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">6717567</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Aronson M, Fuld P, Kawas C, Brown T, Morgenstern H, Frishman W, Gidez L, Eder H, Ooi W L. Ann Neurol. 1989;25:317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">2712531</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallee B L, Coleman J E, Auld D S. Proc Natl Acad Sci USA. 1991;88:999&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50942</ArticleId><ArticleId IdType="pubmed">1846973</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallee B L, Falchuk K H. Physiol Rev. 1993;73:79&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">8419966</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood C S, Moir R D, Huang X, Scarpa R C, Bacarra N M E, Romano D M, Hartshorn M A, Tanzi R E, Bush A I. J Biol Chem. 1998;273:12817&#x2013;12826.</Citation><ArticleIdList><ArticleId IdType="pubmed">9582309</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C. Mol Med Today. 1999;5:343&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431167</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Citron M. Neuron. 2000;27:419&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055423</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Kaether C, Steiner H, Haass C. Curr Opin Neurobiol. 2001;11:585&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">11595492</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Nature (London) 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews P M, Jiang Y, Schmidt S D, Chishti M A, Horne P, Heslin D, French J, et al. Nature (London) 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond D M, Gottschall P E, Ugen K E, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. Nature (London) 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12036342</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-2623</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>12</Issue><PubDate><Year>2002</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>A new type of prodrug of catecholamines: an opportunity to improve the treatment of Parkinson's disease.</ArticleTitle><Pagination><StartPage>2349</StartPage><EndPage>2351</EndPage><MedlinePgn>2349-51</MedlinePgn></Pagination><Abstract><AbstractText>After decades of research around dopamine agonists, we have found a promising compound in S-PD148903 that represents a new type of prodrug, which in the rat is bioactivated to the catecholamine S-5,6-diOH-DPAT, known to display mixed dopamine D(1)/D(2) receptor agonist properties just like apomorphine. This prodrug has an enone structure which by an oxidative bioactivation mechanism is converted to the corresponding catechol and is delivered enantioselectively into the CNS. This novel concept has the potential to revolutionize the treatment of Parkinson's disease by competing with L-DOPA, the current treatment of choice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Venhuis</LastName><ForeName>Bastiaan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University Centre for Pharmacy, University of Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodenhuis</LastName><ForeName>Nienke</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wikstr&#xf6;m</LastName><ForeName>H&#xe5;kan V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Wustrow</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Meltzer</LastName><ForeName>Leonard T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Wise</LastName><ForeName>Lawrence D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Pugsley</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Sundell</LastName><ForeName>Staffan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dijkstra</LastName><ForeName>Durk</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C457999">PD 148903</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>64309-39-3</RegistryNumber><NameOfSubstance UI="C015842">2-(N,N-dipropyl)amino-5,6-dihydroxytetralin</NameOfSubstance></Chemical><Chemical><RegistryNumber>CKR7XL41N4</RegistryNumber><NameOfSubstance UI="D015081">2-Naphthylamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Med Chem 2002 Aug 29;45(18):4056</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015081" MajorTopicYN="N">2-Naphthylamine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011355" MajorTopicYN="N">Prodrugs</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013237" MajorTopicYN="N">Stereoisomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12036342</ArticleId><ArticleId IdType="doi">10.1021/jm025508m</ArticleId><ArticleId IdType="pii">jm025508m</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12042777</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>siRNA-directed inhibition of HIV-1 infection.</ArticleTitle><Pagination><StartPage>681</StartPage><EndPage>686</EndPage><MedlinePgn>681-6</MedlinePgn></Pagination><Abstract><AbstractText>RNA interference silences gene expression through short interfering 21 23-mer double-strand RNA segments that guide mRNA degradation in a sequence-specific fashion. Here we report that siRNAs inhibit virus production by targeting the mRNAs for either the HIV-1 cellular receptor CD4, the viral structural Gag protein or green fluorescence protein substituted for the Nef regulatory protein. siRNAs effectively inhibit pre- and/or post-integration infection events in the HIV-1 life cycle. Thus, siRNAs may have potential for therapeutic intervention in HIV-1 and other viral infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Novina</LastName><ForeName>Carl D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Dykxhoorn</LastName><ForeName>Derek M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Beresford</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Riess</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Kyung</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Collman</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Judy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Premlata</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Phillip A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI 35502</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI45306</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32AI10523</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-CA42063</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-CA14051</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37-GM34277</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-GM07748</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015704">CD4 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022661">RNA, Untranslated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2002 Jul;8(7):659-60. doi: 10.1038/nm0702-659.</RefSource><PMID Version="1">12091895</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015704" MajorTopicYN="N">CD4 Antigens</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020868" MajorTopicYN="Y">Gene Silencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022661" MajorTopicYN="N">RNA, Untranslated</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019713" MajorTopicYN="N">Receptors, CCR5</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016662" MajorTopicYN="N">Virus Integration</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12042777</ArticleId><ArticleId IdType="doi">10.1038/nm725</ArticleId><ArticleId IdType="pii">nm725</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12042811</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.</ArticleTitle><Pagination><StartPage>600</StartPage><EndPage>606</EndPage><MedlinePgn>600-6</MedlinePgn></Pagination><Abstract><AbstractText>The mechanism by which dopaminergic neurons are selectively lost in Parkinson disease (PD) is unknown. Here we show that accumulation of alpha-synuclein in cultured human dopaminergic neurons results in apoptosis that requires endogenous dopamine production and is mediated by reactive oxygen species. In contrast, alpha-synuclein is not toxic in non-dopaminergic human cortical neurons, but rather exhibits neuroprotective activity. Dopamine-dependent neurotoxicity is mediated by 54 83-kD soluble protein complexes that contain alpha-synuclein and 14-3-3 protein, which are elevated selectively in the substantia nigra in PD. Thus, accumulation of soluble alpha-synuclein protein complexes can render endogenous dopamine toxic, suggesting a potential mechanism for the selectivity of neuronal loss in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School and Division of Neuroscience,The Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Shyan-Yuan</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Frank J S</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Weihong</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG17573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS03352</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048948">14-3-3 Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2002 Jun;8(6):564-5. doi: 10.1038/nm0602-564.</RefSource><PMID Version="1">12042803</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048948" MajorTopicYN="N">14-3-3 Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>27</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12042811</ArticleId><ArticleId IdType="doi">10.1038/nm0602-600</ArticleId><ArticleId IdType="pii">nm0602-600</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>